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Diabetes and obesity are twin epidemics that are closely linked to each 
other. In the United States, diabetes currently affects approximately 29.1 million 
adults and children. The estimated economic cost of treating diabetic patients and 
their related complications reached $245 billion in the US in 2012.  Additionally, 
the prevalence of obesity is increasing during the recent decades. The National 
Health and Nutrition Examination Survey 2011-2012 reported that more than two-
thirds of US adults (68.5%) are overweight, and more than one-third (34.9%) were 
obese. 
Both diabetes and obesity are currently considered diseases. Although 
they cannot be completely cured, diabetes and obesity can sometimes be 
prevented by increasing physical activity and eating healthy foods. Producing 
healthy foods or healthy agro-produced supplements would be the first line of 
defense against such diseases. In search of plant products that can be used for 
preventative medicine, we recently discovered that grape pomace, the by-product 
from the waste of the wine and juice industries, has great potential to prevent 
diabetes and obesity. The fundamental goal of this research is to elucidate the 
molecular mechanism(s) of the grape pomace extract’s (GPE) preventive 
functions on diabetes and obesity, and to provide scientific evidence to guide its 
use in developing functional foods for diabetes and obesity prevention. We 
hypothesize that GPE may prevent diabetes and obesity through altering the 
expression of genes on the signaling or metabolic pathways that lead to diabetes 
and obesity manifestation. This research project targeted on 4 specific objectives: 
1) to characterize the action of GPE in reducing postprandial hyperglycemia 
through inhibition of alpha-glucosidase; 2) to understand the mode of molecular 
action of GPE in control of diabetes; 3) to understand the mode of molecular 
action of GPE in control of obesity; 4) to examine the effects of GPE on diabetes 
and obesity at genome wide. 
Throughout these research activities, we provided molecular evidence 
toward understanding the mode action of GPE in preventing diabetes and obesity. 
Such knowledge will provide guidance for future studies in developing GPE as 
an alternative therapeutic for the control of diabetes and obesity. Moreover this 
study may also lead to food industry applications in producing functional foods 
for diabetic and obese populations.  
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The metabolic syndrome refers to a cluster of risk factors leading to an 
increased risk of heart disease and other health problems. High blood glucose 
(diabetes) and obesity are two of the major factors used as diagnostics of metabolic 
syndrome. In fact, diabetes and obesity are considered twin epidemics, closely linked 
to each other. In the United States, diabetes currently affects approximately 29.1 
million adults and children. The estimated economic cost for treating diabetic 
patients and their related complications reached $245 billion in the U.S. in 2012.  The 
prevalence of obesity has also dramatically increased during recent decades. The 
National Health and Nutrition Examination Survey 2011-2012 reported that more 
than two-thirds of U.S. adults (68.5%) are overweight, and more than one-third 
(34.9%) are obese. Both diabetes and obesity are currently considered diseases. 
Although they cannot be completely cured, diabetes and obesity can both be 
prevented by increasing physical activity and eating healthy foods. Therefore, 
producing healthy foods or healthy agro-produced supplements would be the first 
line of defense in preventing such diseases.  
The grape, Vitis vinifera, is one of civilization’s oldest domesticated fruit 
crops and has become one of the most economically important crops adopted by 
many cultures. Health benefits of grapes and grape products, such as wine, are well 
documented in the literature. In recent research, grape pomace, the by-products of 
the waste of the wine and juice industries, was discovered to have great potential to 
prevent diabetes and obesity. The fundamental goal of this research is to elucidate 
the molecular mechanism(s) of grape pomace extract (GPE) in preventing against 
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diabetes and obesity and to provide scientific evidence to guide its use in developing 
functional foods for the prevention of diabetes and obesity. We hypothesize that GPE 
may help to prevent diabetes and obesity through altering the expression of genes, 
either known or novel, in the signaling or metabolic pathways leading to the 
manifestation of diabetes and obesity. The specific objectives for the current study 
were: 1) to characterize the action of GPE in reducing postprandial hyperglycemia 
through the inhibition of alpha-glucosidase; 2) to understand the mode of molecular 
action of GPE in the control of diabetes; 3) to understand the mode of molecular 
action of GPE in the control of obesity; 4) to examine the effects of GPE on genome-
wide transcriptome expression using the RNA-sequencing approach.  
Throughout these designated research activities, we provided molecular 
evidence toward understanding the mode action of GPE in preventing diabetes and 
obesity. Such knowledge could provide guidance for future studies in developing 
GPE as an alternative therapeutic for the control of diabetes and obesity. Moreover 
this study may also lead to food industry applications in producing functional foods 
for diabetic and obese populations.   
Detailed outlines for each specific objective, including methods and 
anticipated findings, were described as follow. 
 
Specific Objective 1: to characterize the action of GPE in reducing 
postprandial hyperglycemia through inhibition of alpha-glucosidase. 
In this objective, GPE was extracted from grape pomace and used in an in-
vitro yeast alpha-glucosidase inhibition assay to understand the kinetics of GPE-
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affected alpha-glucosidase inhibition. Additionally, the extracted GPEs were also 
gavaged to STZ-induced diabetic mice for 2h OGTT tests to examine the acute effects 
of GPE on the control of blood glucose. 
Through these experiments, we hypothesized that GPE could inhibit yeast 
alpha-glucosidase activity in vitro. This inhibition is dosage-dependent and through 
competing the active reaction site(s) with substrates. We also hope to demonstrate 
that GPE can reduce acute blood glucose level in mice when it is consumed with 
starch. 
Specific Objective 2: to understand the mode of molecular action of GPE in 
control of diabetes. 
Long term effects of GPE on treatment and prevention of diabetes were 
examined using a mouse model. For diabetes treatment experiments, mice were first 
STZ treated to induce diabetes. For the diabetes prevention experiment, mice were 
fed a high fat diet (HFD).  
All mice, including STZ treated or non-STZ-treated mice, were fed with 
HFD supplemented with (GPE treatment) or without (control) GPE for 12 weeks. 
Body weight, food intake, and blood glucose were monitored weekly. After the 
feeding experiment, blood and other tissues (pancreas, intestine, and liver) were 
collected and subjected to various examinations, including HbA1c and peptide 
hormones using ELISA and gene expression changes at RNA level using real time 
RT-PCR. 
No significant effects of GPE were found in STZ-induced diabetic mice, 
indicating that GPE may not be used for diabetic treatment. However, GPE can 
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significantly reduce blood glucose in non-STZ-treated mice with decreasing 
accumulation of GHbA1c. Glucose homeostasis-related peptide hormones such as 
GLP-1, glucagon, DPP-4, and insulin were significantly altered by GPE. 
Furthermore, GPE significantly downregulated the expression of insulin, glucagon 
and several gut hormones, as well as those regulating systemic inflammation. These 
results provide insights into the molecular mechanisms directing the effects of GPE 
in the prevention of diabetes. 
Specific Objective 3: to understand the mode of molecular action of GPE in 
control of obesity. 
To understand the role of GPE in the control of obesity, we first examined 
the effects of GPE on adipose cell differentiation using 3T3-L1 cell line.  Adipocyte 
differentiation and lipid accumulation was monitored and quantified by Oil-Red-O 
staining. Gene expression changes related to adipocyte differentiation were 
monitored using the RT-PCR approach. To further examine the role of GPE in obesity 
prevention, we then designed a long term feeding experiment using mouse model. 
All mice were fed with HFD supplemented with or without GPE for 12 weeks. Body 
weight, food intake, and fasting glucose were monitored weekly. After the mice were 
sacrificed, animal adipocytes was analyzed using the histo-chemistry approach. 
Tissues of liver, heart, kidney, pancreas and white adipose were collected for RNA 
expression analysis. The ARC and LHA regions of the hypothalamus tissue were also 
dissected and used to examine the expression of genes related to food intake. 
GPE significantly affected adipogenesis in 3T3-L1 cells, as indicated by 
decreased oil accumulation. GPE also altered gene expression patterns involved in 
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the adipogenesis transcriptional cascade in 3T3-L1 cells.  GPE reduced body weight 
and inhibited adiposity process in the mouse feeding experiment. Although no 
significant changes in gene expressions related to food intake in ARC and LHA 
regions were observed, GPE did attenuate the expressions of CEBPα, SREBF1 and 
PPARγ. GPE also significantly reduced systematic inflammation through the 
inhibition of PAI-1 and the increasing expression of adiponectin. 
Specific Objective 4: to examine the effects of GPE on genome-wide 
transcriptome expression using the RNA-sequencing approach.  
GPE plays important roles in prevention of diabetes and obesity. Several key 
genes regulating the secretion of peptide hormones related to glucose homeostasis 
and those to adipocyte differentiation were significantly altered by GPE. However, it 
is not clear how GPE affects gene expression changes on a genome-wide scale. Using 
the RNA-seq approach, in this objective, we intended to examine the role of GPE in 
tuning genome-wide gene expressions which lead to prevention against diabetes and 
obesity. Total RNAs were isolated from the livers of mice treated or untreated with 
GPE and subjected to high throughput transcriptome sequencing using RNA-seq 
techniques. Data were bioinformatically analyzed to identify those that are up- or 
down-regulated by GPE. 
Overall, more than 36 million clean reads were obtained from each sample, 
and approximately 95% of reads were mapped to the mouse reference genome. Over 
15,000 genes were identified that were expressed in the mouse. Only 181 genes were 
identified with altered expression by GPE. Most of the GPE upregulated genes were 
involved in the metabolism process to accelerate energy expenditure and solute 
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transport. However, GPE significantly downregulated a large number of genes 
related to immune responses, oxidative stress responses, and inflammation 
biomarkers. 
Finally, due to limited resources at VSU, all animal feeding experiments 
were conducted through collaborations or paid service at the University of Georgia 
(Dr. Tai L. Guo’s research group) or the China Agriculture University (Dr. 
Xiangdong Li’s research group), respectively.  The project was approved by the 
respective IACUCs of their institutions. Animal care, handling, feeding, and animal 
sacrifice were handled by staff in their research teams.  At no time was any animal 
handled by the author of this dissertation. However, all molecular experiments 
conducted after sacrifice of the mice used for these experiments and those not 
involving animal feedings were conducted by the author alone. 
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Chapter 1: Literature Review 
 
1.1 Metabolic syndrome and its prevention 
 
Metabolic syndrome is a cluster of risk factors that includes obesity; high 
triglycerides, blood pressure, and blood glucose and low high-density cholesterol. It 
increases the risk for heart disease and other health problems. Metabolic syndrome 
is caused by the imbalance of energy utilization and storage and can increase the risk 
of development of coronary heart disease, predominantly heart attack, stroke, kidney 
failure, gout, cancer, amputations and blindness (Eckel et al., 2005; Isaacs & 
Vagnini, 2006), and it is associated with morbidity and all-cause mortality (Malik et 
al., 2004; Lakka et al., 2002; Hu et al., 2005). The prevalence of metabolic syndrome 
has been increasing worldwide in recent decades. According to the 2003-2006 
National Health and Nutrition Examination Survey, in the United States, the 
prevalence of metabolic syndrome is approximately 34% of the adult population 
(Ford et al., 2005; Ford et al., 2010).   
Among the factors that can cause metabolic syndrome, genetics play a key 
role in controlling its development. People who have inherited the genetic tendency 
towards insulin resistance are candidates to develop metabolic syndrome. On the 
other hand, increased consumption of a high calorie diets and decreased physical 
activity have accelerated the prevalence of metabolic syndrome. Clinical and 
epidemiological evidence suggests that lifestyle factors, especially diet, are essential 
in controlling metabolic syndrome (Grundy et al., 2005).  Therapies adopting a 
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healthy lifestyle approach become the first-line of intervention on its prevention. A 
healthy lifestyle includes a balanced variety of foods and daily exercise. Consuming 
a healthy diet rich in fruits and vegetables is highly recommended, and it may reduce 
the risk of cancer and other chronic diseases (CDC State Indicator Report on Fruits 
and Vegetables 2013). Maintaining a healthy weight, waist measurement and body 
mass index (BMI) by increasing physical activity is another important lifestyle 
choice. Research has highlighted the potential therapeutic effects and nutraceutical 
properties found in natural products. Positive effects were revealed from food-based 
nutritional compounds for maintaining healthy body weight, lowering blood glucose, 
correcting lipid panels and decreasing the blood pressure (Ford et al., 2003). The 
anti-inflammatory and antioxidant effects of nutraceuticals have specific applications 
in preventing oxidative stress, which may play a role in the pathophysiology of 
diabetes, obesity and cardiovascular disease (Oberly, 1988; Rao, 2002). In a word, 




Diabetes mellitus is a group of metabolic syndromes with a hallmark of 
hyperglycemia- increased blood glucose levels. It is caused by 1) interruption of the 
homeostasis of carbohydrate, protein and lipid metabolism, 2) lack of insulin 
secretion, or 3) increase of insulin resistance. Diabetes mellitus currently affects 200 
million people globally, approximately 5 % of the adult population. Diabetes is 
ranked as the 6th leading cause of death in the U.S. Diabetes effects young people as 
well as aging people. About 215,000 people younger than 20 years had diabetes (type 
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1 or type 2) in the U.S. in 2010. Approximately 25.8 million adults and children in 
the U.S. suffer from diabetes according to CDC’s National Diabetes Fact Sheet 2012. 
This number is expected to be over 40 million (Stephens et al., 2006) or more by 
2025, given that more than 86 million American adults were diagnosed as pre-
diabetes in 2012 (National Diabetes Statistics Report, 2014).  
The number of diabetic patients has dramatically increased in recent decades; 
the prevalence of diabetes was boosted by the increased consumption of refined sugar 
and processed foods with high calories, along with decreased physical activity 
(Stephens et al., 2006). The prevalence of diabetes is increasing dramatically 
worldwide. Growth is expected to occur in developing countries along with the 
consequences of population ageing, increasing urbanization, unhealthy diets, obesity 
and sedentary lifestyles. 
 
Insulin is a principal peptide hormone, produced by beta cells of the pancreas, 
that regulates the uptake of glucose from the blood. Based on the insulin secretion 
and response to insulin, diabetes has been classified into three categories: Type 1 
Diabetes: the failure of sufficient insulin production from β cells of pancreas causes 
of high blood sugar. It is an insulin-dependent diabetes, also called juvenile diabetes 
with early onset. Type 2 diabetes mellitus or "adult-onset diabetes" results from 
insulin resistance, a condition in which cells fail to use insulin properly, referred to 
as non-insulin-dependent diabetes, which is more than ninety percent of all cases of 
diabetes. The third type of diabetes is gestational diabetes caused by the hormonal 
changes (Biessels et al., 2004) during pregnancy, which lead to insulin insufficiency 
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or insulin resistance. Deficiency of insulin or the insensitivity of its receptors plays 
a critical role in all forms of diabetes mellitus (Bell et al., 1980). 
The serious long-term complications from diabetes are the major cause of 
hospitalization and death. Diabetes can cause retinopathy, cardiomyopathy, renal 
failure, altered immune functions, peripheral neuropathy, and intestinal dysfunction 
(Biessels et al., 2004; Martinez-Tellez et al., 2005). The economic cost of treating 
diabetic patients, and their related complications, reached $245 billion in 2012.  
Although long-term complications of diabetes develop gradually, untreated diabetes 
can cause many complications, even disability and death. Acute complications were 
common in Type I diabetes patients, including symptoms such as diabetic 
ketoacidosis and nonketotic hyperosmolar coma. Type 2 diabetes is the most 
common form of diabetes, affecting 90% to 95% of diabetes patients. Improperly 
treated diabetes can cause serious long-term complications. Over time, the high 
glucose levels in the blood can damage the nerves and small blood vessels of the 
eyes, kidneys, and heart.  Complications include diabetic retinopathy, nerve damage, 
stroke, cardiovascular disease, blindness, kidney failure, and macro and micro-
vascular damage, nephropathy, impaired immune functions, and lower limb 
amputation. (Martinez-Tellez et al., 2005). 
 
1.2.1 Diabetes treatment 
Diabetes is treatable and preventable. Conventional anti-diabetic drugs play 
a key role in diabetes treatment. However, side effects from these drugs can be 
problematic. Side effects include: 1) unwanted weight gain; 2) acidosis, caused by 
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buildup of acidic metformin byproducts in the blood stream; 3) several dangerous 
and life threatening symptoms such as malaise, fatigue, nausea and weakness; and 4) 
some anti-diabetes drugs, such as acarbose, sulfonylureas, metformin or 
thiazolidinediones, can cause gastrointestinal disturbances, upset stomach, nausea, 
diarrhea, constipation and increased flatulence.  
Fortunately, diabetes is preventable. Many plant species have shown 
promising effects in the management of diabetes. Medicinal plants, as well as 
agricultural by-products, are inherently safe because of their natural origin, and many 
have been traditionally used since ancient times by physicians to treat a great variety 
of human diseases.  
The existing conventional diabetes drugs, along with their molecular targets 
and sites of action, have been extensively studied (Prabhakar et al., 2011). Different 
diabetes drugs target different organs, such as liver, pancreas, small intestine, adipose 
tissue and muscle (Eurich et al., 2007). Based on each drug’s mode of action, they 
can be divided into two groups: 1) Insulin secretagogues (sulfonylureas, 
meglitinides, phenylalanine derivatives insulin) which stimulate insulin release by 
pancreatic beta cells; and 2) Insulin sensitizers (biguanides, metformin, 
thiazolidinediones) that reduce insulin resistance by activating PPAR-γ in fat and 
muscle to increase the peripheral glucose uptake and act on liver to decrease glucose 
production (Prabhakar et al., 2011).  
 
1.2.2. Carbohydrate metabolism and Alpha-glucosidase inhibitors  
Diabetes is, in part, related to the amount of carbohydrates in the diet. 
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Complex carbohydrates are digested primarily in the lumen of the small intestine by 
α-amylase to yield linear oligosaccharides and branched isomaltose 
oligosaccharides. Both of these can be further subjected to hydrolysis to release 
glucose and fructose by α-glucosidase and be absorbed into the bloodstream 
(Casirola et al., 2006). Alpha-glucosidase is a key membrane-bound intestinal 
enzyme presented in the brush-border of the small intestine mucosa. It inhibits 
glucoside hydrolase activity by controlling the delay of the carbohydrate absorption 
and lowering the postprandial glycaemia. α-glucosidase has been used widely as a 
target by the commercial antidiabetic medicines (for example acarbose, miglitol, and 
voglibose) in the regulation of blood glucose levels and treatment of type 2 diabetes 
(Yamazaki et al., 2007; Van et al., 2006; Casirola et al., 2006; Van et al., 2005; 
Nakamura et al., 2005; Fujisawa et al., 2005). Studies of the anti-hyperglycemic 
effects of α-glucosidase inhibitors have demonstrated its efficacy in reducing 
postprandial blood glucose levels, improving glycated haemoglobin (HbA1c) levels, 
and attenuating pancreatic islet damage (Negishi et al., 1996; Yamazaki et al., 2007). 
It attenuates postprandial hyperinsulinemia, increases the sensitivity of insulin 
receptor thus improve insulin sensitivity (Yamazaki et al., 2007), stimulating 
secretion and prolonging the effect of the key incretin hormone glucagon-like 
peptide-1 (GLP-1) (Yusuke et al., 2009), and it can delay or prevent the long-term 
complications of the type 2 diabetes (Lee et al., 1982). The effect of chronic alpha-
glycosidase inhibition on diabetic nephropathy in the db/db mouse is well 
established. Alpha-glucosidase inhibitors like acarbose can be used as a monotherapy 
and in combination therapy with other commercial diabetes drugs. Synergistic effects 
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have been reported with the combination of acarbose and DPP-4 inhibitors 
(inhibitors of dipeptidyl peptidase 4 reduce glucagon and blood glucose levels) (Aoki 
et al., 2012; Narita et al., 2012; Qualmann et al., 1995). Even though glucose 
lowering drugs were effectively used to manage blood glucose levels under normal 
range, it is very challenging to find a medicine that has no side effects. Side effects 
and other disadvantages of conventional antidiabetic drugs are very common. 
Gastrointestinal disturbances, upset stomach, nausea, diarrhea, constipation and 
increased flatulence caused by commercial α-glucosidase inhibitors have been 
reported (Prabhakar et al., 2011), as well as stomach pain and bloating, liver 
problems, skin reactions, and swelling due to fluid build-up  
 
1.2.3. Medicinal Plants: An Alternative Tool to Manage Diabetes 
An alternative to these synthetic conventional diabetes drugs is the use of 
many plant species that have shown promising effects in the management of diabetes. 
Medicinal plants have been traditionally used since ancient times by physicians to 
treat a great variety of human diseases. Currently, over 800 different natural 
medicines are widely used in several traditional medical systems to prevent diabetes 
(Casirola et al., 2006). Oriental countries such as China, Korea and India have long 
histories of using medicinal plants for the management of diabetes. Several medicinal 
plants have been investigated for their beneficial effects in the treatment of different 
types of diabetes. In addition, thousands of herb formulas and dietary supplements 
are available on the market for diabetic patients to use (Prabhakar et al., 2011). 
Dietary phytochemicals work through various metabolic pathways to reduce 
postprandial hyperglycemia. Plants with hypoglycemic activity have been the subject 
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of numerous studies; many of these natural medicines regulate blood sugar levels 
through a variety of mechanisms. In some cases, their effects are similar to 
conventional medicines. Multiple beneficial activities include regulating 
carbohydrate metabolism, preventing ß-cells apoptosis (which is one of the key point 
on triggering diabetes), increasing insulin releasing activity, and improving glucose 
uptake and utilization. 
 
1.3 Obesity 
Obesity is another complex disorder involving an excess of body fat 
accumulation. Obesity is defined by BMI (Body Mass Index), which is a 
measurement obtained by dividing a person's weight by the square of the person's 
height, by the World Health Organization 2006 Classification. People are classified 
as obese when their BMI exceeds 30 kg/m2. Obesity is a complex medical condition 
with a negative impact on health, leading to reduced mortality and mobility and 
augmented health problems (Haslam and James, 2005). The prevalence of obesity 
has been increasing during the recent decades. Obesity rates have more than doubled 
in adults and children since the 1970’s (National Center for Health Statistics, 2009). 
The National Health and Nutrition Examination Survey 2011-2012, reported that 
more than two-thirds of U.S. adults (68.5%) are overweight, and over one-third 
(34.9%) of adults were obese (Ogden et al., 2014). The trend for increased prevalence 
of obesity has persisted, particularly for adolescents and men (Ogden et al., 2004). 
The onset of obesity is happening earlier with 31.8% of children and adolescents 
being overweight or obese in the U.S. (Ogden et al., 2013).  
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Obesity, particularly excessive abdominal obesity, plays a key role in 
developing metabolic syndrome. It increases the risk of many common health 
problems. Numerous complications associated with obesity include the dramatic 
increase of diabetes mellitus (Colditz et al., 1995; Chan et al., 1994) , hypertension 
(Sjostrom et al., 2004; Huang et al., 1998), cardiovascular disorders (Suk et al., 2003; 
Millionis et al., 2004; Song et al., 2004), cancers (Calle et al., 2003; Danaei et al., 
2005),  dyslipidaemia (Datillo and Kris-Etherton, 1992),  non-alcoholic fatty liver 
disease (NAFLD) (Malnick et al., 2003; Hamaguchi et al., 2005), osteoarthritis (Hart 
et al., 1993; Cicuttini et al., 1996) and psychological disorders (Gortmaker et al., 
1993). The predominant treatment for obesity is lifestyle modification, increasing 
physical activity and improving lifestyle choices to maintain a healthy body weight 
and waist measurement. For certain patients, drugs or bariatric (weight-loss) surgery 
are recommended. The total medical cost related to managing obesity and related 
health problems is a burden on the public health system. The financial cost of 
combatting the current prevalence of obesity in the U.S. has increased annually. 
Based on the current trends in the growth of obesity, total healthcare costs 
attributable to obesity and obesity-related diseases will increase by as much as $66 
billion annually. By the year 2030, this annual cost will reach $861 to $957 billion, 
and will account for 16% to 18% of U.S. health expenditures (F as in Fat: How 
Obesity Threatens America's Future 2012). 
 
1.4 Close link between diabetes and obesity 
There has been a rapid increase in obesity prevalence worldwide during the 
past decades. The number of diabetes patients has increased by 40%, particularly the 
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number of individuals diagnosed with obesity and developing diabetes later. 
Diabetes and obesity have become major public health problems, with serious 
implications in industrialized countries as well as in developing nations. Smyth and 
Heron (2005) have reported that there is increased interest among researchers in the 
link between diabetes and obesity, the twin epidemics. A connection between obesity 
and diabetes was investigated and discovered that obese individuals had more than a 
10-fold increase in chances of developing type 2 diabetes compared to normal weight 
individuals (Must et al., 1999; Field et al., 2001). Obesity-derived cytokines and 
insulin resistance are the main factors involved in the development of type 2 diabetes. 
Several other factors, including glucose toxicity, lipotoxicity and beta cell failure 
(Stumvoll et al., 2005) also contribute to the development of type 2 diabetes. 
Numerous studies have revealed that insulin resistance plays a key role between 
obesity and diabetes (Jung and Choi, 2014) Obesity is characterized by increased 
storage of fatty acids in an expanded adipose tissue mass. It is closely associated with 
the development of insulin resistance. Individuals with insulin resistance are not 
sensitive to insulin, and cells in the body are unable to use insulin effectively. With 
the reduced response to insulin, pancreatic cells increase their production of insulin 
to combat the increased levels of blood glucose (Shanik et al., 2008). Meanwhile, 
insulin-resistance stimulates pancreatic β-cells proliferation, which leads to 
pancreatic β-cell deterioration and apoptosis, decreased insulin secretion and 
eventually to the development of diabetes (Dandona et al., 2005; Chetboun et al., 
2012; Butler et al., 2003). 
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 1.5 Chronic inflammation, obesity and insulin resistance 
 
1.5.1. Adipose tissue is an endocrine organ 
During the past two decades, the complex nature of adipose tissue stands out 
and has become an area of intense investigation. Fat tissue, or adipose, was formerly 
considered a passive energy storage element and related to lipid metabolism. For 
many years, it was believed that the main function of adipose was thought to store 
energy in the form of triglycerides during energy consumption, releasing fatty acids 
when energy expenditure exceeds energy intake. Another biological function of fat 
tissue was considered to act as a cushion and insulate the body to prevent heat lost.  
However, in 1994 with the identification and characterization of leptin, a 16-kDa 
polypeptide with structural homology to cytokine, adipose tissue was consequently 
confirmed to be a complex and highly active metabolic and endocrine organ 
(Kershaw and Filer, 2004; Zhang et al., 1994; Ahima et al., 2000; Fruhbeck et al., 
2001). Adipose tissue secretes numerous peptide hormones and receptors which have 
neuroendocrine functions, including effectively communicating with the brain and 
peripheral tissues to modulate glucose homeostasis, influencing energy metabolism, 
regulating appetite and insulin resistance and controlling immune function 
(Matsuzawa et al., 1999; Funahashi et al., 1999).  When immune cells, such as 
macrophages (Bornstein et al., 2000; Xu et al., 2003; Weisburg et al., 2003) and T 
lymphocytes (Kintscher et al., 2008; Rausch et al., 2007; Wu et al., 2007), infiltrate 
into adipose tissue in obese mice and humans, the infiltrated adipose tissue immune 
cells trigger insulin resistance by promoting a proinflammatory environment within 
the adipose tissue. This discovery has led to the second revolution in the field of 
18  
adipose tissue biology (Bonnie 2008). Inflammation and insulin resistance presented 
in adipose tissue link obesity and diabetes together. 
 
1.5.2. Adipose-derived hormones -- adipokines 
Adipose tissue contains numerous cell types such as adipocytes, immune 
cells, endothelia cells and fibroblasts. Abundant peptide hormones that are involved 
in signaling transduction pathways, are secreted and released into systemic 
circulation by adipose tissue. These adipocyte-specific proteins are known as 
adipokines (Kwon and Pessin, 2013). Functioning as classic circulating hormones, 
they have been shown to have a variety of local, peripheral, and central effects and 
to play a primary role in communication with other organs including liver, muscle, 
brain, intestine and immune system (Kwon and Pessin, 2013). Over the last two 
decades several research teams have explored the linkage of adipokines with obesity, 
type 2 diabetes and cardiovascular disease. Increased risk of developing diabetes has 
been observed in obese individuals (BMI≥30 kg/m2), compared to those with normal 
body weight (BMI<25 kg/m2) (Luft et al., 2013), even though the molecular 
mechanisms of the association of obesity and type 2 diabetes are still unclear.  
Inflammatory responses in adipose tissue have been shown to be a major factor 
explaining the mechanism of obesity-associated type 2 diabetes. Human and rodent 
animal models have been used to investigate how this low-grade chronic systemic 
inflammation contributes to the association between obesity and diabetes. Mild 
obesity-induced inflammation has been reported  in liver and muscle, and significant 
immune cells infiltration and inflammation has been observed in adipose tissue 
(Kwon and Pessin, 2013; Duncan et al., 2003; Hotamisligil, 2006; Luft  et al., 2013; 
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Shoelson et al., 2006; Schenk et al., 2008; Ouchi et al., 2011). Based on these studies, 
metabolism and immunity are undistinguishably linked to each other (Odegaard and 
Chawla, 2013). 
Adipose tissue secreted adipokines play important roles in regulating a 
variety of complex processes, including fat metabolism, feeding behavior, energy 
and glucose homeostasis, vascular tone and insulin sensitivity (Rondinone 2006). 
Chronic low‐grade inflammation is a key feature of obesity that is correlated with 
insulin resistance and type 2 diabetes (Kim et al., 2009). The inflammatory function 
of adipokines plays a crucial role in mediating obesity-induced insulin resistance. 
Adipose-derived hormones include tumor necrosis factor (TNF)-alpha, 
resistin, IL-6, IL-8, acylation-stimulating protein (ASP), angiotensinogen, 
plasminogen activator inhibitor-1 (PAI-1), leptin and adiponectin. Adipokines have 
been categorized into two groups: pro- and anti-inflammatory adipokines. 
 
1.5.3. Pro-inflammatory adipokines 
In 1994, Friedman et al. reported a novel gene called leptin (Lepob). Leptin 
was the first adipocyte-derived hormone to be discovered. Leptin receptor (Leprdb) 
was reported in 1995 and 1996; the db gene encodes the leptin receptor and is 
expressed in the hypothalamus, where it helps to regulate hunger and body weight 
gain (Tartaglia et al., 1995; Chan et al., 1994; Hua et al., 1996). Leptin regulates food 
intake and energy expenditure predominantly through hypothalamic pathways by 
acting on receptors in the hypothalamus (Williams et al., 2009). Leptin was named 
from the Greek “lepto” meaning “thin”. It was initially thought to be as a signal to 
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the brain to decrease food intake and lower body weight (Zhang, 1994). Humans and 
rodents that are leptin deficient Lepob/ Lepob and leptin receptor deficient 
Leprdb/Leprdb express the lack of a functional leptin or leptin receptor and exhibit 
a remarkable hyperphagia, obesity and insulin resistance. In Lepob/ Lepob mice, 
obesity was reduced and insulin sensitivity was restored by exogenous administration 
of leptin (Kwon and Pessin, 2013). However, the concept of leptin as an anti-obesity 
hormone has been questioned due to the phenomenon that the circulating levels of 
leptin and leptin resistance were increased in obese rodents and humans. The 
relationship between plasma leptin and adiposity in normal weight and overweight 
women were reported by Havel et al. Leptin concentration is directly associated with 
adiposity, and  plasma leptin levels increased with weight gain and decreased with 
weight loss (Havel et al., 1996), while adipocytes secreted leptin in a positive linear 
correlation to total body adipose tissue mass.  Thus, leptin is now viewed as signal 
of energy deficiency rather than a weight loss hormone.  
In addition to its effects on energy homeostasis, the biological function of 
leptin is to regulate neuroendocrine function (Galic et al., 2010; Howard et al., 2004; 
Ahima and Flier, 2000; Friedman and Halaas, 1998).  Blüher and Mantzoros reported 
that certain leptin levels are required to activate the hypothalamic-pituitary-gonadal 
and hypothalamic-pituitary-thyroid axes in men (Blüher and Mantzoros, 2004). 
Several other important endocrine effects of leptin were reported, including 
regulation of immune function by changing the cytokine production by immune cells, 
modulation of fetal and maternal metabolism, stimulation of endothelial cell growth, 
and the acceleration of beta islet cells proliferation. On the other hand, leptin interacts 
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with other hormones and energy regulators, such as insulin, glucagon, insulin-like 
growth factor, growth hormone, glucocorticoids and cytokines, which are also 
involved in numerous biological metabolisms (Kershaw and Flier, 2004; Margetic et 
al., 2002). 
Numerous adipose‐secreted factors have recently been described as potential 
mediators that link obesity‐derived chronic inflammation with insulin resistance 
(Figure 1-1). One such adipokine is inflammatory regulator interleukin‐6 (IL‐6) 
(Kim et al., 2009). IL-6 is a cytokine secreted by abundant cell types including 
adipocytes, adipose stromal cells and muscle cells (Kern et al., 2001; Crichton et al., 
1996). Approximate 1/3 of the IL-6 was produced by adipose tissue, and circulation 
of IL-6 concentrations was positively correlated with obesity. IL-6 impaired glucose 
tolerance and insulin resistance (Fernandez-Real and Recart, 2003), and decreased 
expression and circulating concentrations of IL-6 were detected with weight loss in 
obese and diabetes individuals (Kramer et al., 2006; Hotamisligil et al., 1995; Kern 
et al., 2001; Lazar, 2005). IL-6 appears to play a central role in regulating adipocytes 
and hepatocytes in the insulin signaling pathway. Senn et al., 2003 reported that IL-
6 is the key pro-inflammatory cytokines. By inducing SOCS3, a suppressor of 
cytokine signaling and a negative regulator of insulin signaling, the cascade genes 
expression including insulin-induced insulin receptor, IRS-1 tyrosine 
phosphorylation, p85 binding and down-stream PKB/Akt phosphorylation was 
impaired in liver cells (Galic et al., 2010; Senn et al., 2003). On the other hand, 
Matthews et al (2010) conducted a test to determine whether complete deletion of 
IL-6 in mice, an IL-6(-/-), results in induced obesity, hepatosteatosis, inflammation 
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and insulin resistance. IL-6 deficient mice displayed mature-onset obesity, 
hepatosteatosis, liver inflammation and insulin resistance when compared with 
control mice on a standard chow diet. A process related to defects in mitochondrial 
metabolism was found in IL-6 deficient mice; IL-6 deficiency exacerbates high fat 
diet-induced hepatic insulin resistance and inflammation (Matthews et al., 2010). To 
investigate the possible mechanism of the anti-obesity effect of IL-6, Wallenius et 
al., 2002) injected rats centrally and peripherally with IL-6 at low doses. IL-6 
treatment increased energy expenditure and reversed insulin resistance, indicating 
that IL-6 exerts anti-obesity effects in rodents (Wallenius et al., 2002). Furthermore, 
IL-6 was reported to promote fatty acids oxidation and glucose uptake in skeletal 
muscle (Galic et al 2010; Carey et al., 2006; Kelly et al., 2004). These discoveries 
shed a different light on the role of IL-6 in obesity and insulin resistance.    
Another adipocyte secretory protein involved in insulin resistance is Tumor 
Necrosis Factor α (TNFα), which was the first adipose derived factor associated in 
the induction of insulin resistance in obesity and type 2 diabetes. TNFα is a 
paracrine/autocrine factor highly expressed in adipose tissues that is associated with 
obesity, chronic inflammation and type 2 diabetes. The direct effects of TNFα on the 
functions of adipose tissue have been studied (Ruan and Lodish 2013).  The 
expression levels of TNFα were increased in both obese animals and human subjects. 
A positive association between adiposity and insulin resistance was reported. A 
number of studies have demonstrated that TNFα is implicated in the pathogenesis of 
obesity and in alterations in gene expression in metabolically important tissues such 
as adipocyte and liver (Ruan and Lodish 2013; Ruan et al., 2002). TNFα induces 
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genes implicated in inflammatory responses such as chemokines, cytokines, and their 
receptors in adipose tissue. It represses genes involved in glucose uptake and fatty 
acid metabolism in liver, increases plasma concentrations of free fatty acids and 
exhibits repressive effects on gene expression in skeletal muscle. TNFα also inhibits 
insulin signaling and attenuates insulin sensitivity in adipocytes (Hotamisligil 2003; 
Fernandez-Real and Ricart 2003). Over-expression of TNFα in adipose tissue will 
affect several downstream mediators in insulin signaling pathways. These include 
the increase of activation of serine kinase, which in turn increases serine 
phosphorylation of IRS1 and 2 (Insulin receptor Substrate 1 and 2), decreases the 
sensitivity of insulin receptors, thus leading to a critical decrease in insulin 
sensitivity. 
More recently, the finding of other adipocyte-specific factors was reported, 
such as resistin, CCL2, chemokine (C-C motif) ligand 2 which has also been referred 
to as monocyte chemotactic protein 1 (MCP1), plasminogen-activator inhibitor type 
1 (PAI-1), angiopoietin-like protein 2 and chemerin. Diet-induced obesity triggered 
immune cell infiltration into adipose tissue, and pro-inflammatory adipokines were 
secreted, circulating adipokines, leading to inflammation and prompting the 
development of insulin resistance and type 2 diabetes. 
 
1.5.4. Anti-inflammatory adipokines- adiponectin 
Adipose tissue is an active endocrine organ that secretes numerous 
adipokines, the majority of which are pro-inflammatory factors that lead to the 
development of insulin resistance and type 2 diabetes. However, the discovery of 
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adiponectin, the 247 amino acids peptide produced by adipose most abundant gene 
transcript 1 (apM1), shed light on the anti-inflamatory function of the adipokines 
(Maeda et al., 1996). Adiponectin was induced in differentiation from pre-adipocytes 
to adipocytes. It is entirely synthesized in white adipose tissue and secreted into the 
bloodstream. The circulating concentration is relatively high at approximately 0.01% 
of all plasma protein (about 5-10 μg/mL). Chandran et al. have demonstrated that 
plasma adiponectin levels have a strong and consistent inverse association with both 
insulin resistance and inflammatory states.  Adiponectin plays an important role in 
the regulation of glucose metabolism in human and animal models (Chandran et al., 
2003). Adiponectin levels were increased with the administration of insulin-
sensitizing drugs (Kershaw and Filer 2004; Chandran et al., 2003; Diez et al., 2003). 
Adiponectin has potent anti-inflammatory properties, and levels of adiponectin are 
decreased in patients with obesity, type 2 diabetes and atherosclerosis. Furthermore, 
circulating levels of adiponectin were significantly increased with weight loss 
(Vázquez-Vela 2008; Coppola et al., 2008; Yatagai et al., 2003).   
The mechanisms for adiponectin’s metabolic effects have been fully 
described in various organs, in both rodent and human models. The administration 
of adiponectin has been shown to regulate insulin signaling by increasing insulin-
induced tyrosine phosphorylation of the insulin receptor in skeletal muscle and 
improving whole-body insulin sensitivity (Yamauchi et al., 2001; Stefan et al., 2002). 
In the liver, adiponectin enhances insulin sensitivity by increasing tissue fat oxidation 
and reducing circulating fatty acid levels and intracellular triglyceride contents. Also, 
inhibited gluconeogenesis and increased glucose uptake were observed in liver.  In 
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vascular endothelial cells, adiponectin suppresses monocyte adhesion by inhibiting 
the expression of adhesion molecules, thereby reducing cytokine production from 
macrophages so as to decrease the inflammatory environments occuring during the 
early phases of atherosclerosis (Diez et al., 2003; Chandran et al., 2003). Taken 
together, adiponectin is a unique adipokine positively linking insulin resistance with 
obesity and diabetes. 
Understanding the mechanism of signaling pathways by which adipokines 
are controlled in target tissues such as skeletal muscle and liver may also expose 




Figure 1- 1 Sexretion of inflammatory adipokines from adipose tissue in obese state. 
In obese state, the enlarged adipose tissue leads to dysregulated secretion of adipokines 
and increased release of free fatty acids. The free fatty acids and pro-inflammatory 
adipokines get to metabolic tissues, including skeletal muscle and liver, and modify 
inflammatory responses as well as glucose and lipid metabolism, thereby contributing 
to metabolic syndrome. In addition, obesity induces a phenotypic switch in adipose 
tissue from anti-inflammatory (M2) to pro-inflammatory (M1) macrophages. On the 
other hand, the adipose production of insulin-sensitizing adipokines with anti-
inflammatory properties, such as adiponectin, is decreased in the obese state. - See 
more at: http://www.mdpi.com/1422-0067/15/4/6184/htm#sthash.0787EcKY.dpuf  
 
1.6 Network connection of multiple peripheral gastrointestinal hormones and 
hypothalamic central neuron peptide hormones to control energy balancing  
 
Obesity is a complex disorder involving an excess of body fat accumulation. 
It has been officially recognized as a chronic disease by the American Medical 
Association (AMA).  
When energy intake exceeds energy expenditure, obesity will develop. Food 
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intake and energy expenditure are the key factors contributing to adiposity and 
obesity. Maintenance of energy homeostasis and body weight involves the regulation 
of the coordinated network of peripheral gastrointestinal hormones and hypothalamic 
neuropeptides. During the past two decades, the complex nature of adipose tissue has 
become an area of intense investigation. The discovery of leptin, a 16-kDa 
polypeptide with structural homology to cytokine, has led to the redefinition of 
adipose tissue as a complex and highly active metabolic and endocrine organ 
(Kershaw and Filer, 2004; Zhang et al., 1994; Ahima et al., 2000; Fruhbeck et al., 
2001). Numerous studies have indicated that leptin has an anorexigenic effect and 
informs the brain of energy status (Aydin et al., 2008). Energy homeostasis is 
controlled by a complex neuroendocrine system consisting of peripheral signals 
(such as leptin), and central signals, in particular, neuropeptides. Several 
neuropeptides with anorexigenic (POMC, CART, and CRH) as well as orexigenic 
(NPY, AgRP, and MCH) actions are involved in this complex controlling system 
(Hillebrand et al., 2002).  
 
The hypothalamus and its circuits that play a central role in controlling 
feeding behavior and regulating short-term and long-term food intake behavior 
(Clifford et al., 2002; Williams et al., 2001) are shown in Figure 1-2. Numerous 
neuropeptides produced by the hypothalamic arcuate nucleus (ARC), particularly 
neuropeptide Y (NPY) and agouti-related protein (AgRP), are involved in 
maintaining food intake and body weight control. NPY is a central stimulator of food 
intake (Chamorro et al., 2002). Ninety per cent of NPY neurons co-express with 
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AgRP (Schwartz et al., 2000). Leptin and insulin inhibit food intake and increase 
energy expenditure through inhibition of orexigenic NPY/AgRP neurons and 
stimulation of anorexigenic pro-opiomelanocortin (POMC)/cocaine- and 
amphetamine-regulated transcript (CART) neurons in the ARC. NPY/AgRP neurons 
simultaneously activate an anabolic pathway and inactivate a catabolic pathway (Shi 
et al., 2009; Baskin et al., 1999; Kristensen et al., 1998; Cowley et al., 2001). 
Control of food intake involves not only the hypothalamus in the central 
nervous system (CNS), but also the gastrointestinal (GI) tract signaling system, 
pancreas and liver (Figure 2-2). Numerous peripheral peptide hormones play a key 
role in regulating food intake and energy homeostasis (Naslund et al., 2007). Many 
of the peptides involved in controlling food intake and satiety signals in the 
hypothalamus are also present in the enteroendocrine cells of the mucosa of GI tract; 
neuropeptides in the CNS that influence food intake are influenced by peptide signals 
from the gut.  In the neuronal network, satiety signals from the gut were closely 
linked with hypothalamic centers for controlling food intake and eating behavior. 
Multiple gastrointestinal peptides that influence food intake are connected to the 
central neuron system controlling food intake. Ghrelin, secreted by endocrine cells 
in the stomach, is an orexigenic hormone that stimulates growth hormone release and 
enhances feeding and weight gain to regulate energy homeostasis (Tschöp et al., 
2000). Ghrelin acts on the hypothalamus to stimulate feeding. It was considered an 
appetite-stimulating hormone and was implicated in both short- and long-term 
appetite and body weight regulation. When acting as an orexigenic peptide, ghrelin 
stimulates food intake by activating NPY/AgRP neurons and balancing inhibitory 
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signals received from insulin, leptin and peptide YY (Hillebrand et al., 2002; Kojima 
et al., 1999; Tschöp et al., 1999; Wren et al., 2001).  In addition, high-fat diet (HFD) 
feeding caused ghrelin resistance in arcuate neuropeptide Y (NPY)/Agouti related 
peptide neurons (Briggs, 2011), and the hypothalamic circuitry became resistant to 
ghrelin. Anorexic peripheral peptides also play important roles in regulating food 
intake and energy homeostasis.  Cholecystokinin (CCK) is the most studied gut 
peptide regulating food intake (Ritter, 1999). It is secreted by cells in the duodenum 
and jejunum when they are exposed to food, and it induces satiety in the CNS. 
Glucagon-like peptides (GLP-1 and GLP-2) are peptide hormones that stimulate the 
secretion of insulin. GLP is released from the lower gastrointestinal tract following 
food intake and plays dual roles in the regulation of blood glucose concentrations 
through its concurrent insulin tropic and glucagonostatic actions (glucose-lowering 
effect) (Näslund et al., 1999; Ørskov, 1999). Numerous anorexic peripheral peptides 
such as Peptide YY, amylin, insulin, bombesin, glucagon, and GIP, are all known to 
be anorexigenic and are recognized as physiologic regulators of food intake 
contributing to the control of obesity (Arora 2006). This multiple-hormone-
controlled energy homeostasis has become a central target for the design of 






Figure 1- 2 Control of energy homeostasis by arcuate nucleus neurons.There are two 
sets of neurons in the arcuate nucleus — Agrp/Npy and Pomc/Cart neurons — that are 
regulated by circulating hormones. Agrp (agouti-related protein) and Npy 
(neuropeptide Y) are neuropeptides that stimulate food intake and decrease energy 
expenditure, whereas the alpha-melanocyte stimulating hormone (a post-translational 
derivative of proopiomelanocortin, Pomc) and Cart (cocaine- and amphetamine-
regulated transcript) are neuropeptides that inhibit food intake and increase energy 
expenditure. Insulin and leptin are hormones that circulate in proportion to body 
adipose stores; they inhibit Agrp/Npy neurons and stimulate adjacent Pomc/Cart 
neurons. Lower insulin and leptin levels are therefore predicted to activate Agrp/Npy 
neurons, while inhibiting Pomc/Cart neurons. Ghrelin is a circulating peptide secreted 
from the stomach that can activate Agrp/Npy neurons, thereby stimulating food intake; 
this provides a potential molecular mechanism for integrating long-term energy balance 
signals with short-term meal pattern signals. Ghsr, growth hormone secretagogue 
receptor; Lepr, leptin receptor; Mc3r/Mc4r, melanocortin 3/4 receptor; Y1r, 
neuropeptide Y1 receptor. Adopt from Nature Reviews Genetics 3, 589-600.  
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1.7 Adipogenesis, a highly orchestrated multistep process of the transcriptional 
network 
Adipogenesis is the process of the differentiation of fibroblast like pre-
adipocytes into the well-established matured spherical adipocytes which contains 
lipids (Lefterova and Lazar, 2009). Take the advantage of the in vitro model of 3T3-
L1 and 3T3-F442A, the pre-adipocyte cell lines, the adipogenesis has been precisely 
illustrated (Rosen et al., 2000; Gregoire, 2001). A highly orchestrated multistep 
process of the transcriptional network was involved in adipogenesis (Ali et al., 2013). 
Several transcription factors are sequentially activated in adipogenesis transcriptional 
cascade. Remarkably CCAAT/enhancer binding proteins (C/EBPβ, C/EBPδ and 
C/EBPα) gene family, peroxisome proliferator activated receptor-γ (PPAR-γ) and 
Sterol regulatory element-binding transcription factor 1 (SREBF1), have been shown 
to have significant roles in promoting adipogenesis (White and Stephens, 2009). These 
factors are essential to promote the terminal or mature adipocyte phenotype. 
Differentiation of pre-adipocyte cells into adipocytes involves a series of events 
including growth-arrest, mitotic clonal expansion, and terminal differentiation and 
mature adipocytes (Sun et al., 2009; Lefterova and Lazar, 2009). In response to 
hormonal stimuli such as cortisol and insulin, C/EBPβ and C/EBPδ are induced 
immediately which in turn activate PPARγ and C/EBPα (Farmer, 2006). PPARγ and 
C/EBPα form a positive feedback loop to induce the expression of each other and 
regulate the adipocyte differentiation (Rosen et al., 2002). PPARγ and C/EBPα in turn 
to induce the expression of genes that are necessary for regulating fatty acid storage 
and glucose metabolism (Rosen, E.D. and MacDougald, 2006). They are highly 
expressed in adipose tissue and are key factors controlling the down-stream adipocyte 
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differentiation and adipocyte-specific gene expression (Lefterova et al., 2008), such 
as lipoprotein lipase (LPL), which is considered as the early stage marker for the 
adipocyte differentiation, and  adipocyte fatty acid–binding protein (aP2), which is an 
intermediate sign of adipocyte differentiation (Rosen and Spiegelman , 2000; 
(Bernlohr et al., 1984; Katz et al., 1999; Spiegelman et al., 1983; MacDougald et al., 
1995). Sterol regulatory element-binding proteins (SREBPs) are also involved in 
adipocyte differentiation. SREBPs are a family of transcription factors that regulate 
lipid homeostasis.  SREBPs are induced very early during adipocyte differentiation 
and stimulate the expression of PPARγ, and induce the fundamental coordinator of 
the adipocyte differentiation process (Eberlé et al., 2004; Shao and Espenshade, 2012; 
Saladin et al., 1999).  
 
Figure 1- 3 Transcriptional events in adipocyte differentiation. A summary (present 
view) of the molecular processes of adipocyte differentiation, focusing only on 
transcriptional events. Direct or indirect transcriptional events are indicated by solid 
lines. Broken lines represent interactions that are less well understood. Specific 
transcription factors are denoted with square boxes; unknown factors are indicated with 
question marks. Abbreviations: ADD1, adipocyte determination- and differentiation-
dependent factor 1; C-EBPalpha, CCAAT-enhancer binding protein-alpha; RXR, 
retinoid X receptor; SREBP, sterol regulatory element binding proteins; STAT, signal 
transducers and activators of transcription. Adapted from Morrison and Farmer. Picture 
was adopted from International Journal of Obesity (2003) 27, 147–161.  
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1.8 Health benefits of grape  
 
1.8.1 Grape and grape pomace 
The grape (Vitis vinifera) is one of the oldest fruit crops domesticated. 
Cultivation of grapes began 6,000–8,000 years ago in the Near East, and is one of 
the most economically important plants adopted by all cultures. Several phenolic 
compounds that can improve the human health are found in grapes. The well-known 
“French Paradox” identifies the fact that the epidemiological observation of despite 
high intake of dietary cholesterol and saturated fat, but low incidence of coronary 
heart disease (CHD) death rates are present in the Mediterranean region (Renaud et 
al., 1992). The routine consumption of red wine was considered as the factor 
lowering the development of coronary heart disease. This attracted more attention of 
scientists to define the chemical composition in grapes. A large number of different 
natural grape products are widely used in the nutritional products market, and the 
beneficial effects of using flavonoids and poly-phenolic compounds from grape and 
grape-derived products have been well studied.  The bioactivities of grape 
polyphenols and the health promoting effects of different varieties of grape have been 
documented. 
 
1.8.2. Bioactivites of phenolic compounds in grape products. 
Numerous phytochemicals are found in grapes. Among these, phenolic 
compounds are the most abundant and widely studied.  Different phenolic 
compounds are present in grape skin, seeds, fruit stems, as well as juice and wine 
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product. The phenolic compounds mainly include anthocyanins, flavanols, 
resveratrol and phenolic acids (Xia et al., 2010; Dopico-Garcia et al., 2008; Novaka 
et al., 2008; Spacil et al., 2008). Anthocyanins are pigments that mainly exist in grape 
skins. Red grape skin has more total polyphenols compared to white grape due to the 
lack of anthocyanins in white grape varieties. Flavan-3-ols are more abundant in 
white varieties. Flavonoids are widely distributed in grapes, especially in seeds and 
stems. Georgiev et al summarized the most common flavonoids found in grapes: they 
are anthocyanins (3-O-monoglucosides or 3,5-O-diglucosides of malvidin, cyanidin, 
peonidin, delphinidin, pelargonidin and petunidin, as well as their acetyl-, p-
coumaroyl- and/or caffeoyl-esters), flavonols (3-O-glycosides of quercetin, 
kaempferol, myricetin, laricitrin, isorhamnetin and syringetin), flavanols [(+)-
catechin, (−)-epicatechin, (−)-epicatechin-3-O-gallate], dihydroflavonols (astilbin 
and engeletin) and proanthocyanidins [principally contain (+)-catechins, (−)-
epicatechin and procyanidin polymers] (Georgiev et al., 2014; Chacona  et al., 2009; 
Bagchi  et al., 2000; Cantos et al., 2002). There are different phenolic compounds in 
different parts of the grape. The distribution and occurrence of polyphenols in grape 
are different.  
During 2014, more than 7.8 million tons of grapes were grown commercially 
in the U.S. (http://www.agmrc.org/commodities__products/fruits/grapes-profile/), 
and more than 60% of these were used to make wine or juice. Grape pomace is the 
main byproduct of wine and juice production and is primarily composed of skin, 
seed, pericarp, and fruit-stem; it comprises approximately 25% of grape weight 
during grape processing.  Grape pomace is currently used as fodder or fertilizer, or it 
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may be thrown away at a cost. The complex phytochemicals especially polyphenols 
in the seed and skin of grape pomace attracted more scientists to study the potential 
of turning the by-product waste to nutraceuticals and value adding products. On the 
other hand, grape pomace contains mixtures of flavonoid structures; different 
degrees of polymerization will occur during its secondary metabolism. This makes it 
difficult to establish which of the molecules are active. Furthermore, it is likely that 
the beneficial effects on human health may not be due to one molecule but a 
combination of effects of different phytochemicals (Pedrielli et al., 2002; Montagut 
et al., 2010). 
 
1.8.3. Antioxidants of grapes 
Numerous studies have shown that phenolic compounds from grape exerts 
positive benefits on human health; many of these compounds have been shown to 
have potent antioxidant activities. Significant antioxidant activity has been observed 
from pomace and seed flour extract of grapes (Ruberto et al., 2007; Parry et al., 
2006). Grape seed extract may be useful for the prevention of certain metabolic 
syndromes and cardiovascular disease. Grape and grape products also possess other 
important properties including anti-radiation, anti-mutagenic, anti-inflammatory, 
anti-bacterial, and other beneficial effects (Bagchi et al., 2003; Halliwel et al., 1992; 
Belleville, 2002; Sun et al., 2002). 
 
1.8.4. Protect against cardiovascular disease  
Grape derived products (especially grape seed extract) are commercially 
available as over counter medicine from many pharmacies and grocery stores. 
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Abundant animal model and preclinical evidence suggests that grape seed extract has 
beneficial effects on the cardiovascular system. The polyphenol resveratrol is found 
in grape seed. Resveratrol has been identified as the potential cause of beneficial 
properties in red wine (Tomé-Carneiro et al., 2012; Bertelli et al., 1998). The 
beneficial effects of resveratrol were also reported as decreasing insulin resistance, 
reducing ischemic heart disease, preventing heart failure and avoiding hypertension 
(Petrovski et al., 2011; Bertelli et al., 1998). The polyphenols in grapes can reduce 
phosphodiesterase-5 activity, decrease the risk of cardiovascular disease (Dell et al., 
2005), reduce platelet adhesion and aggregation and generate superoxide anion 
(Olaset al., 2008). 
 
1.8.5. Protect against metabolic syndrome: Diabetes and obesity 
Metabolic syndrome, especially diabetes and obesity are the most prevalent 
health problem affecting one third of U.S. population. Numerous flavonoid 
polyphenolics, including catechin, anthocyanin, isoflavones, quercetin, rutin are 
presented in grapes extracts. The mixture of these flavonoids structures in grape 
extracts were reported to have anti hyperglycemic effects. Abundant evidences 
suggest that flavonoids found in grapes play a key role in preventing the development 
of diabetes and obesity by acting as multi-target modulators with reducing the 
oxidative stress and lower the degree of systematic inflammation (Tsuda et al., 2012; 
Chuang et al., 2011), and improve the insulin resistance. Chuang et al (2012) 
screened different varieties of red, green, and blue-purple seeded and seedless 
California grapes to test the effects of freeze-dried grape powder and grape powder 
extracts on glucose tolerance and inflammation in obese mice, and found that grape 
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powder acutely improves glucose tolerance and chronically reduces inflammation in 
obese mice.  The polyphenols in the grape have demonstrated dramatic inhibitory 
effects in streptozotocin-induced diabetic rat models (Al-Awwadi et al., 2004; Al-
Awwadi and Bornet, 2004); reducing body growth, food intake and hyperglycemia, 
and increasing insulin sensitivity. Procyanidin, quercetin, resveratrol and 
proanthocyanidin derived from grape products have been widely studied. The benefit 
efficacy of stimulating glucose uptake in adipocyte cells, decreasing lipid 
peroxidation, increasing pancreatic glutathione levels, protecting pancreas β-cell 
function and protecting against β-cell loss,  have been fully reported (El-Alfy et al., 
2005; Baur et al., 2006; Lagouge et al., 2006).  Studies on Carols Muscadine also 
demonstrated the inhibitory and anti-diabetic effects of the extracts on α-glucosidase 
and pancreatic lipase were investigated (You et al., 2011; Montaguta et al., 2010; 
Moreno et al., 2003). Muscadine possessed the strongest anti-diabetic activity in the 
EtOH fractions. Competitive mode of action was shown in their enzymatic 
inhibitions.  
Diabetes and obesity could be manageable through a combination of diet, 
exercise and appropriate medications to lower adipogenesis. Many plant-based 
products show promising effects on the management and prevention of diabetes and 
obesity. Therefore, producing healthy foods or healthy agro-produced supplements 
would be the first line of defense against such metabolic syndrome.  In search of such 
products, we recently discovered that grape pomace has great potential to prevent 
diabetes and obesity. Water extracts of grape pomace (GPE) significantly reduced 
blood glucose levels and decreased body weight when fed to mice. However, neither 
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the long term effects of GPE on diabetes and obesity control nor the molecular 
mechanisms involved has yet been fully elucidated. Such information is critical for 
its practical use in prevention and management of diabetes and obesity. 
Understanding the molecular mechanism(s) underlying GPE’s role in preventing 
diabetes and obesity is important to guide its use in developing functional foods. The 
research plan proposed here is to define the long term effect(s) of GPE in preventing 
diabetes and obesity and unveil the possible molecular mechanism(s) of such 
prevention properties, focusing on different hormone peptides and the 
interrelationship among the central and peripheral neuropeptides. 
  
 1.9 Summary and hypothesis 
Grape pomace, the by-product from the wine and juice industry, may have 
great potential beneficial health effects in preventing diabetes and obesity. However, 
the molecular mechanisms of such preventative properties are largely unknown. This 
research project was designed to elucidate such mechanisms at the physiological and 
molecular levels to provide evidence on grape pomace’s roles in preventing diabetes 
and obesity. The designated research activities will target four specific objectives: 1) 
to characterize the action of grape pomace extract (GPE) in reducing postprandial 
hyperglycemia through inhibition of alpha-glucosidase; 2) to understand the mode 
of molecular action of GPE in control of diabetes; 3) using a 3T3-L1 pre-adipocyte 
cells and mouse model to examine the effects of long term GPE administration on 
reducing obesity through regulation of adipogenesis; and 4) to examine the effects 
of GPE on blood glucose and body weight control in genome wide with RNA-seq, 
whole transcriptome shotgun sequencing technology. Throughout these designated 
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research activities, we will provide molecular evidence toward understanding the 
mode action of GPE in preventing diabetes and obesity. Such knowledge will provide 
guidance for future studies in identifying bio-activate compounds from GPE to 
develop alternative medicines for the control of diabetes and obesity. More 
importantly, this study may lead to food industry applications in producing functional 
foods for diabetes and obesity populations. 
 The fundamental goal of this research is to begin to elucidate the molecular 
mechanism(s) of the GPE’s preventive functions on the metabolic syndrome, diabetes 
and obesity, and to provide scientific evidence to guide its application for the use as 
functional food or alternative medicine. We hypothesize that GPE may prevent 
metabolic syndrome including diabetes and obesity through alternating the expression 
of genes, known or novel, on the signaling or metabolic pathways that lead to 
reduction of diabetes and obesity. The project focused on examining such molecular 
mechanism(s) and hypothesis that support the incorporation of GPE as an alternative 
therapy for controlling postprandial blood sugar, regulate insulin resistance and 
preventing diabetes and obesity. Four specific objectives, as described following, will 
be addressed for this rpoject. 
Specific Objective 1: To characterize the action of GPE in reducing 
postprandial hyperglycemia through inhibition of alpha-glucosidase. GPE is rich in 
phytochemicals which could lower the blood glucose; however the fundamental 
mechanism remains unclear.  Grape products may lower blood glucose through α-
Glucosidase activity inhibition. This hypothesis will be tested using both an in vitro 
α-Glucosidase activity assay and an in vivo induced diabetes mouse model. Yeast α-
40  
Glucosidase will be used to monitor GPE’s inhibitory effects and the inhibitory 
kinetic assays will be conducted to determine the inhibition mode of GPE against a- 
glucosidase activity.  For the in vivo assay, the STZ-induced diabetes mice will be 
orally administrated starches with or without GPE supplementation at 400 mg/kg 
body weight. Postprandial blood glucose will be monitored to determine the effects 
of GPE on suppression of postprandial hyperglycemia.  
Specific Objective 2: To understand the mode of molecular action of GPE in 
control of diabetes.  
It is well known that diabetes occurrence is due to the disturbance of glucose 
metabolism and homeostasis. Peptide hormones play important roles in regulating 
glucose metabolism and homeostasis. However, how the GPE will affect these 
regulatory systems is currently unknown. This objective will examine the effects of 
GPE in regulating these key processes using mouse model. Our hypothesis is that the 
prolonged oral administration of GPE will regulate glucose homeostasis in small 
intestine and pancreas in mouse.  Mouse glycated hemoglobin (HbA1C) and 
molecular markers involved in peptide hormones (Ins, Lep, Adipo, Gip, Glp-1, Gcg, 
PAI-1 and Resis) will be analyzed at the transcriptional level to decode the effects of 
GPE in regulating these pathways. In addition, a shorter list of these markers (insulin, 
leptin, and adiponectin, ghrelin, GIP, GLP-1, glucagon, PAI-1, Resis) will also be 
tested in plasma at the protein level using ELISA assays. The results will be compared 
to elucidate the GPE’s regulation mechanisms at both transcriptional and translational 
levels. 
Specific Objective 3: To understand the mode of molecular action of GPE in 
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control of obesity. Consumption of a high fat diet can lead to obesity and insulin 
resistance (Qatanani and Lazar, 2007). Our current study approved that oral 
administration of GPE can alleviate obesity resulting from prolonged consumption of 
western-style diet. However, the mechanism(s) of this effect remain(s) unknown. In 
this objective, we will first focus on: 1) using adipocyte precursor cell model 3T3-L1, 
we will also examine the role of GPE in regulating genes expression involved in 
adipocyte differentiation, a major process to induce full maturation into adipocytes 
and generate fat mass; 2) the possible roles of GPE in regulating inflammation using 
a mouse model. The genes examined will include Adipoq, Cebpa, Pparg, Ppargc1a, 
(PGC-1a), Cebpα, Cebpβ, aP2, FAS, SREBP-1c, LPL, PGC-1α and PGC-1β; and 3) 
to examine the long term effects of GPE administration in reducing obesity through 
regulation of central neuropeptides.  
Energy homeostasis is controlled by a complex neuroendocrine system 
consisting of peripheral signals, such as leptin and CCK, and central signals, in 
particular, neuropeptides. Several neuropeptides with anorexigenic (POMC, CART, 
and CRH) and orexigenic (NPY, AgRP, and MCH) actions are involved in this 
complex controlling system (Hillebrand et al., 2002). NPY/AgRP neurons exist as 
neuronal targets of leptin in the ARC where they are concentrated in the ventromedial 
ARC and regulate food intake. This objective will focus on investigating the 
expression of these hypothalamic neuropeptide to test if GPE can alter their 
expression and hence regulate energy homeostasis.  
To test the hypothesis that GPE can regulate energy balancing, reduce body 
weight and acute blood glucose levels through controlling the central neuron system, 
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a 12-week mouse feeding experiment will be conducted to investigate GPE’s long 
term effect(s) on food intake, blood glucose control, as well as lipid accumulation.  
Specific Objective 4: By taking advantage of high throughput RNA 
sequencing technology, we will elucidate gene expression profiles at a genomic level 
caused by GPE treatment under high fat diet condition. Our specific focus will be on 
glucose and lipid metabolisms and their related signal transduction pathways.  
 
 1.10 Significant of research 
Grape products have been known to be abundant in various bioactive 
compounds. Known beneficial effects of bioactive compounds from grape products 
include: functional foods (dietary fiber + polyphenols), food processing 
(biosurfactants), cosmetics (grapeseed oil + antioxidants), pharmaceutical/biomedical 
(pullulan) and supplements (grape pomace powder) (Dwywe et al., 2014). The annual 
production of grape pomace (along with its multitude of applications) create an 
opportunity to discover an unexploited market with great commercial potential in the 




Chapter 2: Grape Pomace Aqueous Extract Inhibits α-
Glucosidase in vitro and Suppresses Postprandial 





Diabetes is a group of metabolic diseases, the serious long-term complications 
of which are a major cause of hospitalization and death. Postprandial hyperglycemia 
is a direct and independent risk factor for type 2 diabetes. Intestinal α-glucosidases 
are key enzymes in controlling carbohydrate digestion and glucose absorption. 
Recently, there has been growing interests in using food-based α-glucosidase 
inhibitors as alternative treatment for improving postprandial hyperglycemia and 
controlling blood glucose.   
A specific grape pomace (Cabernet Franc), the by-product from wine and 
juice manufacturing was prepared in water.  An in vitro yeast α-glucosidase inhibition 
assay, as well as the measurement of the kinetics of GPE-affected yeast α-
glucosidases inhibition were conducted. Total carbohydrates were evaluated by 
HPLC. Mice were treated with streptozocin to induce diabetes. Oral GPE treatment 
and starch challenge were performed on STZ-induced diabetic mice to determine 
whether the administration of GPE can moderate postprandial hyperglycemia through 
the inhibition of intestinal a-glucosidases. 
Grape pomace water extract (GPE) caused a dose-dependent reduction of 
yeast α-glucosidase activity with an IC50 value of 508.4μg equivalents/mL. Yeast α-
glucosidase activity was reduced by 87.1% when treated with 1mg equivalent/mL 
GPE for 30 min. The enzyme kinetic study revealed that the GPE was a competitive 
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inhibitor of α-glucosidase.  When consumed, GPE significantly decreased blood 
glucose by 43.6±7.5% in diabetic mice.  
The results in this current study strongly support the potential use of GPE as 
an alternative to commercial α-glucosidase inhibitors used in diabetes prevention and 
treatment. 
 
 2.2 Introduction 
Diabetes mellitus is a group of metabolic syndromes with a hallmark 
characteristic of hyperglycemia - increased blood glucose. The prevalence of diabetes 
is increasing dramatically worldwide, boosted by the increased consumption of refined 
sugar and processed foods with high calories, as well as by decreased physical activity 
(Stephens et al., 2006). Diabetes affects young as well as aging people. Based on the 
National Diabetes Statistics Report, 2014, approximately 29.1 million adults and 
children in the U.S. suffer from diabetes. This number is expected to rise to over 40 
million (Stephens et al., 2006; National Diabetes Statistics Report, 2014). The serious 
long-term complications from diabetes are major causes of hospitalization and death. 
The economic cost of treating diabetes and its related complications reached $245 
billion in 2012.  Although long-term complications of diabetes develop gradually, 
untreated diabetes can cause many complications and disabilities, even death. Over time, 
hyperglycemia can damage the nerves and small blood vessels of the eyes, kidneys, and 
heart. Furthermore, improperly treated diabetes can cause serious long-term 
complications, including diabetic retinopathy, nerve damage, stroke, cardiovascular 
disease, blindness, kidney failure, and macro and micro-vascular damage, nephropathy, 
impaired immune functions, and lower limb amputation (Biessels et al., 2004; Martinez-
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Tellez et al., 2005). 
 Diabetes is sometimes treatable and preventable. Conventional anti-diabetic 
drugs play a key role in diabetes treatment. However, side effects and other 
disadvantages of conventional anti-diabetic drugs are very common. These include 
unwanted weight gain (Prabhakar et al., 2011), stomach pain and bloating, liver 
problems, skin reactions, and swelling due to fluid build-up. Other symptoms such as 
malaise, fatigue, nausea, and weakness have also been reported. Medicinal plants, as 
well as agricultural by-products, have shown promising effects in the management of 
diabetes. Many have been traditionally used since ancient times to treat a great variety 
of human diseases. Several medicinal plants have been investigated for their beneficial 
effects in the treatment of different types of diabetes (Prabhakar et al., 2011). Bitter 
melon (Mormodicacharantia) has long been used in China and India as a vegetable and 
is reported to help control blood glucose levels. Hypoglycemic effects of bitter melon 
have been demonstrated in cell culture, animal models and human clinical studies. It’s 
powerful insulin lowering properties are currently being considered as an effective 
treatment for diabetes (McCarty, 2004; Krawinkel and Keding 2006). Panax Ginseng 
was used as a holly panacea in oriental cultures for thousands of years, especially for its 
healthy glucose level maintenance property. Chinese or Korean ginseng has the highest 
therapeutic potency among all ginseng varieties. Several studies have found that Korean 
red ginseng significantly stimulates insulin release from isolated rat pancreatic islets, 
decreases serum levels of glucose, and glycosylates hemoglobin A1c (HbA1c) in 
streptozotocin (STZ)-induced diabetic rats in a dosage-dependent manner (Kim 2008; 
Anoja et al., 2002; Hui et al., 2009). 
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    Diabetes is, in part, related to the amount of carbohydrate in the diet. 
Complex carbohydrates are digested primarily in the lumen of the small intestine by 
α-amylase to yield linear oligosaccharides and branched isomaltose. These are then 
further hydrolyzed by α-glucosidase to release glucose and fructose which will be 
absorbed into the bloodstream (Casirola et al., 2006). Alpha-glucosidase is a key 
intestinal enzyme presented in the brush-border of the small intestine mucosa. It 
controls the rate of carbohydrate absorption and adjusts postprandial glycaemia. 
Alpha-glucosidase has been used widely as a target by several commercial 
antidiabetic medicines (for example acarbose, miglitol, and voglibose) in the 
regulation of blood glucose and treatment of type 2 diabetes (Yamazaki et al., 2007; 
Van et al., 2006; Casirola et al., 2006; Van et al., 2005; Nakamura et al., 2005; 
Fujisawa et al., 2005, Yamamoto and Otsuki 2006; Chiasson et al., 2004).  
Studies of the anti-hyperglycemic effects of α-glucosidase inhibitors have 
demonstrated its efficacy in reducing postprandial blood glucose, improving glycated 
haemoglobin (HbA1c), and attenuating pancreatic islet damage (Negishi et al., 1996; 
Yamazaki et al., 2007). Alpha-glucosidase inhibitors diminish postprandial 
hyperinsulinemia and improve insulin sensitivity through increasing insulin receptor 
sensitivity (Yamazaki et al., 2007). α-glucosidase inhibitors stimulate insulin 
secretion by prolonging the effect of the key incretin hormone glucagon-like peptide-
1 (GLP-1) (Yusuke et al., 2009), and by preventing the long-term complications of  
type 2 diabetes (Lee et al., 1982). The alpha-glucosidase inhibitor acarbose can be 
used as a monotherapy. It also works well in combination therapy with other 
commercially available anti-diabetic drugs. Synergistic effects have been reported 
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with the combination of acarbose and DPP-4 inhibitors (inhibitors of dipeptidyl 
peptidase 4 reduce glucagon and blood glucose levels) (Aoki et al., 2012; Narita et 
al., 2012; Qualmann et al., 1995). Even though glucose lowering drugs were 
effectively used to manage blood glucose, it is very challenging to find a medicine 
that has no side effects.  
    Cultivation of grapes began 6,000 to 8,000 years ago in the Near East. It is 
one of the oldest fruit crops that has been domesticated and adopted by all cultures. 
Several phenolic compounds that can improve human health are found in grapes. The 
well-known “French Paradox” refers to the epidemiological observation of the high 
intake of dietary cholesterol and saturated fat and the low incidence of coronary heart 
disease (CHD) and related deaths present in the Mediterranean region (Renaud et al., 
1992). The routine consumption of red wine is considered to be the factor lowering 
the development of coronary heart disease. This attracted more attention from 
scientists seeking to define the chemical composition of grapes. A large number of 
different natural grape products are widely accepted in the nutritional products 
market. The beneficial effects of using flavonoids and poly-phenolic compounds from 
grape and grape-derived products have been well studied (Quiñones et al., 2013, Kim 
et al., 2014). Different phenolic compounds are present in grape skin, seeds, and fruit 
stems, as well as juice and wine products. The phenolic compounds mainly include 
anthocyanins, flavanols, resveratrol, and phenolic acids (Xia et al., 2010; Dopico-
Garcia et al., 2008; Novaka et al., 2008; Spacil et al., 2008; Montaguta et al., 2010; 
Al-Awwadi et al., 2004). Anthocyanins are pigments that mainly exist in grape skins. 
Red grape has more total polyphenols compared to white grape due to the lack of 
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anthocyanins in white grape varieties. On the other hand, flavan-3-ols are more 
abundant in white varieties. 
    During 2012, more than 7.3 million tons of grapes were grown 
commercially in the U.S. (http://www.agmrc.org/commodities products/fruits/grapes-
profile/), and over 60% of these were used to make wine or juice. Grape pomace is 
the main byproduct of wine and juice production and is primarily composed of skin, 
seed, pericarp, and fruit-stem; it comprises approximately 25% of grape weight during 
grape processing.  Grape pomace is currently used as either fodder or fertilizer, or it 
may be discarded at a cost. The complex phytochemicals, especially polyphenols, in 
the seed and skin of grape pomace have promoted the study of the potential of turning 
this waste by-product into nutraceuticals and value-added products. Grape pomace 
contains mixtures of flavonoid structures, and different degrees of polymerization will 
occur during its secondary metabolism. This makes it difficult to establish which of 
the molecules are active. Furthermore, it is likely that the beneficial effects on human 
health may not be due to one molecule but a combination of effects of different 
phytochemicals (Pedrielli et al., 2002; Montagut et al., 2010). 
    Grape pomace may have great potential health benefits in preventing 
diabetes. However, the molecular mechanisms of such preventative properties are 
largely unknown. In our previous study (Parry et al., 2011), grape pomace from 
variety Tinta Cao was investigated. High antioxidant activities, inhibition of the 
proliferation of HT-29 and Caco-2 colon cancer cells through the triggering of 
apoptosis pathway, and phytochemical compositions have been reported. In our 
current study, the anti-diabetic properties of grape pomaces were investigated. The in 
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vitro action of GPE in reducing postprandial hyperglycemia through inhibition of 
alpha-glucosidase was examined. In vivo studies of both diabetic mice and healthy 
human subjects were conducted. GPE’s inhibitory effect on postprandial 
hyperglycemia and the effects of GPE on acute insulin secretion and effects on lipid 
metabolism in human pilot trials were observed. 
 
2.3 Materials and methods 
 
Cabernet Franc grape pomace samples (fermented for 2 weeks) were obtained 
from Chrysalis Vineyards, Virginia in 2011.  Dulbecco's Modified Eagle's Medium 
(DMEM), antibiotic/ antimycotic, fetal bovine serum (FBS), and 0.25% trypsin with 
0.9 mM EDTA were purchased from Invitrogen (Carlsbad, CA). IEC-6 cell lines were 
purchased from American Type Culture Collection (Rockville, MD). Acarbose and 
p-Nitrophenyl- β- D-glucopyranoside (pNPG) were purchased from Sigma-Aldrich 
Co. LLC (St. Louis, MO). 
 
Sample preparation and extractions 
Grape pomace samples were air dried under low pressure. Dried pomace was 
milled to 40 mesh size using a Scienceware Bel Art Micromill, (Pequannock, NJ). 
The milled grape pomace was then extracted with water (1:10 m/v) by shaking for 2 
hours at ambient temperature. Following extraction, the mixture was centrifuged at 
4,000 rpm at 20oC for 30min. Supernatants were collected and freeze dried in the 
bench top freeze drier (AdVantage 2.0 BenchTop Freeze Dryer / Lyophilizer, SP 
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Scientific) to obtain GPE. 
 
In vitro yeast α-glucosidase inhibition assay  
Yeast α-glucosidase (Sigma Aldrich Chemical Co, USA) was dissolved in 
phosphate buffer (pH 6.8) at a concentration of (1 U/mL). p-Nitrophenyl- β- D-
glucopyranoside (pNPG) (Sigma Aldrich Chemical Co., U.S.A.) was used as the 
substrate for the yeast α-glucosidase activity assay. An inhibition assay was conducted 
according to the protocol described by Hogan et al, (2010) with a minor modification. 
In brief, the mixture of 80μl sample solution with 20μl enzyme solution (1 U/mL) was 
first incubated for 3 minutes at 37oC. After incubation, 100μl of 4 mM p-nitrophenyl-
α-d-glucopyranoside (pNPG) solution in phosphate buffer (pH 6.8) was added to the 
reaction and then incubated for additional 30 minutes at 37oC.  The α-glucosidase 
activity was quantified by measuring the p-nitrophenol release from pNPG at 405 nm 
wave-length. The phosphate buffer (pH 6.8) was used as control.  All measurements 
were taken in triplicate. The inhibition of Alpha-glucosidase activity was expressed 
as percentage of the control using the following formula: 
% Inhibition= [Abs (Control)-Abs (Sample)]/Abs (Control) X100 
                            
Kinetics of GPE-affected yeast α-glucosidases inhibition 
To further determine the time and dose effects of GPE on yeast a-glucosidase 
inhibition, a series of enzymatic reactions with different dosages of GPE (from 0 to 
1000 μg/ml) were conducted in a 96-well plate. Reactions were dynamically 
measured at 405 nm for 75 min with a 5-minute interval. The combinations of 
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different concentrations of substrate pNPG (0.4, 0.5, 1, 2 mM) and different 
concentrations of the GPE (0, 100, 200, 300, 400, and 500 μg/ml) were tested. The 
double reciprocal Lineweaver–Burke plots were prepared to illustrate the inhibition 
pattern. The IC50 value is defined as the concentration of an inhibitor required to 
inhibit 50% of the α-glucosidase activity, which is a measure of the inhibitor’s relative 
effectiveness.  Acarbose was used as a positive control. 
 
Determination of total carbohydrate  
Total carbohydrate was determined by the Phenol-Sulfuric Acid Method 
described by Nielson (Nielson et al., 2010). Trehalose was used for standardization. 
Individual sugar content was measured using HPLC according to Bogdanov 
(Bogdanov, et al., 1997) on a high-pressure SHIMADZU liquid chromatograph 
equipped with LC-10ATVP liquid chromatograph pumps, DGU-14A degasser, CTO-
10AVP column thermostat, RID-10A refractometric detector, POL-LAB CHROMA 
2001 software and SUPELCOSIL LC-NH2), 25 cm x 4.6 mm, 5 μm chromatograph 
column. 20 μl samples were injected onto the column and separation was conducted 
at 30°C with the mobile phase made up of acetonitrile: water (8:2) at a flow rate of 
1.3 ml/min. The identification of sugars in GPE was conducted by comparing 
retention times of individual sugars in the reference vs. tested solution. The 
quantitative assays were made of the following carbohydrates: fructose, glucose, 
sucrose, turanose, maltose, isomaltose, and trehalose.  
STZ induction of diabetic mice 
Six-week old male C57BL/6NCr mice, (National Cancer Institute, Frederick, 
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MD, USA) were housed in clean cages at 12-hour light dark cycle at 20°C to 22°C 
with 2 mice/cage with food access ad libitum. The animals were used after a 2-week 
acclimatization period before starting the experiment. The mice were maintained on 
rodent feed (Harlan Tekland Global Diets 2018 rodent diet containing 60% of calories 
from carbohydrate, 23% of calories from protein, and 17% of calories from fat; 
digestible energy of 3.4 Kcal/g, Madison WI, USA) with continuous access to tap 
water for the duration of the experiment. Animal husbandry, care, and experimental 
procedures were approved by the Institutional Animal Care and Use Committee of 
the University of Georgia. Streptozotocin was dissolved in ice-cold 100mM sodium 
citrate buffer (pH 4.5) and injected intraperitoneally immediately at a dose of 
150mg/kg body weight. Fasting blood glucose (FBG) was monitored on day 7 post 
injection. Values higher than 126 mg/dL were considered to be diabetic as previously 
described by Hogan (Hagon et al., 2010) and assigned to one of 3 groups (n = 10).  
Oral GPE treatment and starch challenge  
Diabetic mice were fasted for 14-hours in freshly cleaned cages with free 
access to water before the experiment. Basic Corn Starch, (Cargill incorporated, 
Cargill Gel # 03420) was suspended in 0.1 M sodium citrate buffer (pH 4.5) with 25 
mg/ml and vortexed vigorously. GPE was dissolved in starch-sodium citrate solution 
(250 mg/ml). Mice in the control group were given 0.2 mL of starch sodium citrate 
solution by oral gavage while the GPE treatment group mice were administered with 
the mixture of GPE and starch suspension 0.2 ml. Acarbose (Sigma Aldrich Chemical 
Co, USA) was suspended in the same starch solution and fed by oral gavage at 75 
mg/kg BW in the positive control group. 
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Samples of approximately 5 μL of whole blood were collected from the tail 
vein of each mouse at 7 time points 0, 15, 30, 45, 60, 90, and 120 minutes after 
treatment. Blood glucose was measured with a blood glucometer and accompanying 
test strips (ACCU-CHEK Meter®, Roche Diagnostics, Kalamazoo, MI). The area 
under the glucose tolerance curve (AUC0-120 min) was calculated using SPSS 
software. The total anti-hyperglycemic response (AUC0-120 min) was expressed as 
percentage of inhibition compared with the control group. 
Statistical Analysis 
Tests were conducted in triplicate with data reported as mean ± standard 
deviation. Analysis of variance (ANOVA) and Tukey’s post hoc analyses were used 
to determine differences among group means. Pearson Correlation Coefficients were 
used to determine correlations among means. Statistical significance was defined as 
P value less than 0.05. 
 
 2.5 Results 
 
In vitro yeast α-Glucosidase inhibition by GPE 
To examine whether GPE can inhibit α-glucosidase activity, enzymatic 
inhibitory assays were performed. The inhibitory effects of GPE on yeast α-
glucosidase activity at different concentrations were observed at different reaction 
times (Fig. 2-1). A dose-dependent pattern of the α-glucosidase inhibition was 
found (Fig. 2-1a). Inhibitory action of GPE against yeast α-glucosidase started to 
show when the enzymatic reaction was treated with 200μg/ml GPE, and at 
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400μg/ml GPE level, 37.9±8.1% of the α-glucosidase activity was inhibited.  An 
IC50 value of 508.4μg/mL was calculated. Yeast α-glucosidase activity was 
reduced by 87.1±1.0% after 30 min reaction at 1mg mL. Furthermore, GPE 
produced a dose-dependent pattern of yeast α- glucosidase inhibition (Fig. 2-1a). 
To determine the GPE’s mode action on α-glucosidase, a Lineweaver-Burk plot 
was performed. A strong competitive inhibition was observed indicating that GPE 
inhibits α-glucosidase through binding to the active site on the enzyme and 
preventing further substrate binding.  
    Enzymatic inhibition of α-Glucosidase was used for screening the 
potential capacity of GPE on controlling blood glucose through down regulation of 
carbohydrate digestion. To determine the GPE’s mode action towards α-
glucosidase, a Lineweaver-Burk double reciprocal plot was performed (Fig. 2-1c). 
The maximum velocity (Vmax) of the reaction was unchanged, and this was 
confirmed by the intersecting point for different doses of GPE occurring on the 1/v 
axis (1/vmax). The enzyme kinetic study revealed that GPE contains active 
compounds that bind to the catalytic site of the enzyme α-glucosidase and prevent 
further binding of the substrate to the enzyme.  
Determination of total carbohydrates  
The phenol-sulfuric acid method was used to determine total carbohydrate 
in GPE. This colorimetric method detected virtually all classes of carbohydrates in 
a sample, including mono-, di-, oligo-, and polysaccharides.  48.3± 0.5 mg/g of total 
carbohydrate were detected. Individual sugar content assayed by HPLC identified 
17.5 mg/g glucose, 21.0 mg/g fructose, 1.5 mg/g sucrose, 8.0 mg/g trehalose, and 
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0.17 mg/g rafinose. These results indicated that GPE contained very little 
carbohydrate and would not be expected to affect postprandial blood glucose 
significantly. 
Effects of the grape pomace treatment on postprandial blood glucose by oral 
administration of GPE in STZ-treated mice. 
Changes in postprandial blood glucose were measured after carbohydrate 
load to the fasted diabetic mice with or without co-administration of GPE. The 
commercial anti-diabetic drug acarbose was used as positive control. Blood glucose 
increased by 49.6±7.1 mg/dl after 30 min administration of corn starch to the 
control group. Only a 29.3±6.2 mg/dl blood glucose increase was observed in corn 
starch with 250 mg/kg bw GPE group. The highest inhibitory effect was observed 
at the 60-min time point with 53.1% of inhibition by GPE compared to the control 
group (Fig. 2-2a). A similar result was observed in the group of mice gavaged with 
corn starch and acarbose (75 mg/kg bw). GPE also exerted a significant decrease 
(p<0.05) of the increment in blood glucose; AUC0-120 min (Area Under the Curve 
for 120 min) (Fig. 2-2b). When corn starch was loaded, blood glucose AUC0-120 
min in the GPE and acarbose groups was reduced 47.7% and 43.4% respectively.  
No significant difference between GPE and acarbose tested groups was observed.  
 
 2.6 Discussion 
 
In the present study we examined the properties of GPE on α-glucosidase 
activity inhibition. Yeast α-glucosidase was used as a model for investigating the 
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potential capacities of GPE on α-glucosidase activity in vitro. GPE also exhibited 
inhibitory effects on mammalian α-glucosidase activity and suppressed postprandial 
hyperglycemia in STZ-induced diabetic mice in vivo. Similar results were reported 
by Hogan (Hogan et al. 2010). This prompted us to investigate whether grape pomace 
can be used to prevent diabetes through α-glucosidase inhibition in humans by 
lowering plasma glucose, prolonging glucose absorption, and suppressing peak 
levels of postprandial blood glucose for the future study.  
Complex carbohydrates cannot be absorbed in the small intestinal lumen and 
transported into blood circulation until the polysaccharides are digested and broken 
down into monosaccharides. Small intestinal alpha-glucosidase plays a key role in 
carbohydrate metabolism. Alpha-glucosidase inhibition has been used widely as a 
good model for investigating the effects of antidiabetic compunds. Alpha-glucosidase 
inhibition can delay the carbohydrate digestion and glucose absorption, eventually 
lowering postprandial hyperglycemia.  Pre-diabetes occurs when a patient’s blood 
glucose is higher than normal but not yet high enough to be diagnosed as diabetes 
(between 100 and 125 mg/dL). Pre-diabetes leads to a higher risk for developing type 
2 diabetes. 15% to 30% of people with pre-diabetes will develop type 2 diabetes within 
five years without lifestyle changes to improve their health. Recently, there has been 
a growing interest in food based α-glucosidase inhibitors, which provide a potential 
therapeutic approach in the prevention of diabetes among healthy people and in the 
management of pre-diabetic patients and type 2 diabetes. Our results suggest that 
grape pomace, a food based byproduct, could be an excellent candidate as an anti-
diabetic treatment. Few publications report the bioactive compounds in different grape 
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varieties, and the phenolic contents are the major contributors for the natural α-
glucosidase inhibitors (Horgan et al., 2010).  In our previous study with Tinta Cao 
pomace extract (Parry et al., 2011), high antioxidant activities were determined using 
an oxygen radical absorption capacity (ORAC) assay along with DPPH• and ABTS•+ 
scavenging capacities. Phytochemical compositions including total phenolic content 
(TPC); individual phenolic acids were also studied, and the results demonstrated that 
grape pomace extract has the potential to be a bioactive food ingredient. Similar results 
were reported with grape products (Gonzalez-Paramas, et al., 2004; Zhang et al., 
2011). Catechin, quercetin and ellagic acid were reported to exhibit very strong anti-
diabetic activities in muscadine against α-glucosidase (Yu et al., 2012).  
  The goal of controlling diabetes is to manage blood glucose so that it stays 
within healthy levels. Dietary change is recommended to control type 2 diabetes in 
patients with or without insulin intervention.  Numerous studies using cultured cell 
lines and rodents have been reported for the potential diabetic-prevention effects of 
grapes, grape skin, grape seeds, and grape polyphenol extracts. However, clinical 
trials addressing the effect of grape pomace on regulating blood glucose are limited. 
The effects of grape pomace water extract on improvement of postprandial 
hyperglycemia in vivo with human subjects will be tested. Alpha-glucosidase 
inhibitors such as Acarbose and Miglitol were widely used for managing diabetes; 
however, there were strong side effects associated with taking these drugs (Fujisawa 
et al., 2005). Alternative to these synthetic conventional diabetes medicines, natural 
products have shown promising effects on diabetes management. Thousands of herb 
formulas and dietary supplements are available on the market for diabetic patients 
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(Prabhakar et al., 2011; Casirola et al., 2006). Dietary phytochemicals work through 
various metabolic pathways to reduce postprandial hyperglycemia. Plant products 
with hypoglycemic activity have been the subject of numerous studies. These natural 
medicines regulate blood sugar through a variety of mechanisms including 
carbohydrate metabolism alternation, ß-cells apoptosis prevention (which is one of 
the key points in triggering diabetes), insulin releasing activity growth, and glucose 
uptake improvement and utilization. Understanding the long term effects of grape 
pomace on regulating carbohydrate metabolism and the molecular mechanism(s) 
involved is an important aspect and should be the focus of future studies.  
 
 2.6 Conclusion 
Grape pomace suppressed postprandial hyperglycemia through inhibitory 
effects on α-glucosidase activity. GPE also reduced acute blood glucose in vivo in 
STZ induced-diabetic mice. This study provides basic knowledge and information 
on the potential use of GPE in functional foods for preventing diabetes and possibly 
obesity as well. The long term effects of GPE on control of blood glucose and lipid 
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Figure 2- 1 Kinetics studies of Cabernet Franc pomace extract on yeast α-glucosidase 
inhibition at different concentrations.a. Cabernet Franc pomace extract exerted a dose-
dependent pattern on yeast α-glucosidase inhibition at 37oC for 30 min. b. Time course 
responses during 66 minutes of different concentration of the pomace extracts on the 
enzyme activity; GPE exhibits a consentration-dependent manner on yeast α-
glucosidase inhibition. c. Lineweaver-Burk plots of kinetic analysis of yeast α-
glucosidase inhibition at different concentration of substrate pNPG (0.4, 0.5, 1, 2 mM)) 
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Figure 2- 2 Changes in postprandial blood glucose level (incremental AUC0-120 min) 
affected by administration of GPE in STZ-induced diabetic mice. a. Modified 2h OGTT 
(Oral Glucose Tolerant Test) shows the glycemic response curve in diabetic mice after 
corn starch challenge. b. Increment of the blood glucose AUC0-120 min (Area Under the 
Curve for 120 min) after administration of GPE. Results are expressed as Mean± SEM. 
*: p < 0.05 (n = 10)  
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Chapter 3: Grape Pomace Aqueous Extract (GPE) Prevents 
Western High Fat Diet-induced Diabetes and Attenuates 
Systemic Inflammation 
 
3.1 Abstract  
 
Diabetes mellitus is a group of metabolic syndromes with a hallmark of hyperglycemia. 
Serious long-term complications from diabetes are a major cause of hospitalization and 
death. We recently discovered that grape pomace, the by-product from the waste of the 
wine and juice industries, has great potential to prevent diabetes. In this study, we 
examined the potential use of grape pomace in controlling high blood glucose in 
response to Cabernet Franc Grape pomace aqueous extract (GPE). Both streptozotocin 
(STZ)-induced diabetic mice and non-STZ treated mice were fed with high fat diet that 
was supplemented with 2.4 g/kg GPE for 12 weeks. GPE had no significant effect on 
STZ-induced diabetic mice. However, GPE significantly reduced blood glucose by 
16.1% (p<0.05%) in non-STZ treated HFD-fed mice following a 10-week feeding 
period when compared with high fat diet controls. GPE reduction of hyperglycemia 
also promoted a significant reduction of GHbA1c accumulation. Circulating peptide 
hormones related to glucose homeostasis, including GLP-1, glucagon, DPP-4 and 
insulin, were drastically altered by GPE. Moreover, GPE attenuated the expressions of 
insulin, glucagon, and several gut hormones at the mRNA level. In addition, GPE 
significantly down regulated 5 biomarker genes for systematic inflammation. Taken 
together, our results highlight a role of GPE as a potential alternative approach to 




Grape pomace is the main by-product of wine and juice production. It is 
primarily composed of skin, seed, pericarp, and fruit-stem; and it comprises 
approximately 25% of grape weight during grape processing.  The complex 
phytochemicals (especially polyphenols) in grape pomace have attracted many 
scientists to study the potential of turning the by-product waste to a nutraceutical and 
value added product. Numerous phenolic compounds, especially flavonoids, are widely 
distributed in grapes. Many of these have been shown to have beneficial health effects. 
The most common phenolic compounds found in grapes with bioactivities are 
anthocyanins, flavonols, flavanols, dihydroflavonols and proanthocyanidins (Georgiev 
et al., 2014; Chacona et al., 2009; Bagchi et al., 2000; Cantos et al., 2002). Grape 
derived products are commercially available as over-the-counter medicines from many 
pharmacies and grocery stores. Animal and preclinical studies suggest that grape seed 
extract has preventive effects on certain metabolic syndromes and protects the 
cardiovascular system (Georgiev et al., 2014). Furthermore, resveratrol is a major 
polyphenol that is thought to be a potential contributor of several beneficial properties 
of red wine (Tomé-Carneiro et al., 2012; Bertelli et al., 1998). Resveratrol decreases 
insulin resistance, prevents heart failure, and prevents hypertension (Petrovski et al., 
2011; Bertelli et al., 1998). It decreases the risk of cardiovascular disease (Dell et al., 
2005), and reduces platelet adhesion, aggregation and generation of superoxide anion 
(Olaset al., 2008). 
Diabetes is a group of metabolic syndromes with a hallmark of hyperglycemia. 
It is caused by an interruption in carbohydrate, protein and lipid metabolism. Lack of 
insulin secretion and increase of insulin resistance (Stumvoll et al., 2005). The network 
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of insulin, glucagon and multiple gastrointestinal hormones play key roles in the 
regulation of blood glucose homeostasis (Aronoff et al., 2004). Glucagon-like peptides 
(GLP-1 and GLP-2) and glucose-dependent insulinotropic peptide (GIP) are the major 
incretins that stimulate the secretion of insulin (Zunz and La Barre, 1929). GLPs are 
released from the lower gastrointestinal tract following food intake and play dual roles 
in the regulation of blood glucose concentrations through their concurrent insulin tropic 
and glucagonostatic actions (glucose-lowering effect) (Näslund et al., 1999; Ørskov, 
1999). GIP is recognized as a physiologic regulator of food intake contributing to the 
control of obesity (Arora, 2006). Energy balance and glucose homeostasis have become 
central targets for the design of pharmacological agents needed to prevent and treat 
diabetes. 
Abundant evidence suggest that  grape flavonoids play a key role in preventing 
the development of diabetes by acting as multi-target modulators that reduce oxidative 
stress, lower the degree of systematic inflammation (Tsuda et al., 2012; Chuang et al., 
2011), and improve insulin resistance and anti-hyperglycemic effects. In obese mice, 
grape powder has been shown to acutely improve glucose tolerance and chronically 
reduce inflammation (Chuang et al., 2012). In streptozotocin (STZ)-induced diabetic 
rat models (Al-Awwadi et al., 2004; Al-Awwadi and Bornet, 2004), polyphenols in the 
grape could reduce body weight, food intake and hyperglycemia, and increase insulin 
sensitivity. Grape pomace byproducts from the Norton grape have been reported to 
contain significant amount of antioxidants (Hogan et al., 2010), and consumption of 
Norton grape pomace for 3 months exerted an anti-inflammatory effect in a diet 
induced mouse obesity model (Hogan et al., 2011). 
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Diabetes can be manageable through a combination of diet, exercise and 
appropriate medications. Many plant-based products show promising effects on the 
management and prevention of diabetes. Producing healthy foods or healthy agro-
produced supplements could be a first line of defense against diabetes. However, the 
molecular mechanisms of such preventative properties are largely unknown. In our 
previous study (Parry et al., 2011), the grape pomace from the variety Tinta Cao was 
investigated. High antioxidant activities, and inhibition of the proliferation of HT-29 
and Caco-2 colon cancer cells through triggering apoptosis were demonstrated. The in 
vitro action of grape pomace aqueous extract (GPE) in reducing postprandial 
hyperglycemia through inhibition of alpha-glucosidase was also demonstrated. In 
addition, in vivo studies with diabetic mice and healthy human subjects revealed GPE’s 
effect on postprandial hyperglycemia, acute insulin secretion and lipid metabolism (Li 
et al., Submitted). However, neither the long-term effects of GPE on diabetes nor the 
molecular mechanisms involved have yet been fully elucidated. Such information is 
critical for its practical use in the prevention and management of diabetes. In our current 
study, the anti-diabetic properties of grape pomaces were investigated.  
 
3.3. Materials and Methods  
 
Sample Preparation and Extractions  
Cabernet Franc grape pomace samples (fermented for 2 weeks) were obtained 
from Chrysalis Vineyards, Virginia in 2011. Grape pomace was air dried under low 
pressure and milled to 40 mesh size using a Scienceware Bel Art Micromill 
(Pequannock, NJ). The milled grape pomace was then extracted with water (1:10 m/v) 
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with shaking for 2 hours at ambient temperature. Following extraction, the mixture was 
centrifuged at 4,000 rpm at 20oC for 30 min. Supernatants were collected and freeze 
dried in the bench top freeze drier (AdVantage 2.0 BenchTop Freeze Dryer / 
Lyophilizer, SP Scientific) to obtain GPE. 
 
STZ and High Fat Diet (HFD)-induction of Hyperglycemia in Mice 
Approximately sixteen-week old male C57BL/6NCr mice (National Cancer 
Institute, Frederick, MD, USA) were housed in clean cages at 12-hour light dark cycle 
at 20°C to 22°C with 5 mice/cage. Animal husbandry, care, and experimental 
procedures were approved by the Institutional Animal Care and Use Committee at 
University of Georgia. Streptozotocin was dissolved in ice-cold 100 mM sodium citrate 
buffer (pH 4.5) and injected intraperitoneally at a dose of 150 mg/kg body weight. A 
total of 24 STZ-induced diabetic mice with fasting blood glucose higher than 120 
mg/dL were used. 12 mice without STZ induction served as STZ treatment control. All 
36 mice were maintained on rodent chow (8728C Teklad Certified Rodent Diet, Harlan 
Laboratories, Inc, Frederick, MD) until the experiment started. Two groups of STZ-
induced mice (n=12 in each group) and non-STZ mice (n=6 in each group) were fed 
with either 1) high fat diet (D04011601), or 2) high fat diet mixed with GPE at 2.4 g/kg 
diet (D12121001). The composition of the animal diet is summarized in Table 3-1. 
Mice were fed with their respective diets for 12 weeks with water available ad libitum. 
Approximately 5 μL of whole blood was collected from the tail vein of each mouse 
once a week. Blood glucose was measured with a blood glucometer and accompanying 
test strips (ACCU-CHEK Meter®, Roche Diagnostics, Kalamazoo, MI). Body weight 
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was measured weekly. 
 
Animals and Tissue Collection 
At the end of the feeding study, diet was removed 12 h prior to sacrifice. Mice 
were anesthetized with CO2, and blood was collected by cardiac puncture into glass 
tubes for serum isolation. Seperate plastic vials that had been previously rinsed with 
potassium EDTA solution were used for HbA1c measuraments. The serum was 
separated after centrifugation at 1,000x g for 15 min at 4°C and stored for later use. 
Small intestine and pancreas were collected, immediately frozen in liquid nitrogen and 
stored in -80oC for analysis.  
 
Mouse Glycated Hemoglobin (HbA1C) Determination 
Glycosylated (or glycated) hemoglobin (hemoglobin A1c, Hb1c, or HbA1c, 
A1C) is a form of hemoglobin used primarily to identify the average plasma glucose 
concentration over prolonged periods of time. It is commonly used as a golden rule for 
measurement of blood glucose management in type 2 diabetes.  HbA1c was measured 
with a mouse glycated hemoglobin A1c (GHbA1c) ELISA Kit (Biotrend, CA, USA). 
Briefly, the microtiter plate was pre-coated with an antibody specific to GHbA1c. 
Standards or samples were then added to the appropriate microtiter plate wells with a 
biotin-conjugated polyclonal antibody preparation specific for GHbA1c and Avidin 
conjugated to Horse-radish Peroxidase (HRP), and incubated for 60 minutes. The TMB 
(3,3'5, 5' tetramethyl-benzidine) substrate solution was then added to each well 
following several washes. The enzyme-substrate reaction was terminated by the 
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addition of a sulphuric acid solution and the color change was measured at a 
wavelength of 450 nm ± 2 nm using a spectrophotometer. The concentration of 
GHbA1c in the samples was then determined by comparing the O.D. of the samples to 
the standard curve. 
 
RNA Isolation and Gene Expression Analysis 
Total RNA was extracted from small intestine and pancreas with RNeasy Plus 
Universal Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The concentration and purity of RNA were determined by measuring the 
absorbance in a Nano drop spectrophotometer.  Total RNA was treated with DNase I 
at room temperature for 15 min to remove genomic DNA contamination. RT2 First 
Strand Kit from Qiagen (Qiagen, Hilden, Germany) was used to synthesize first strand 
complementary DNA (cDNA). The gene expression levels were analyzed by 
Quantitative real-time RT-PCR conducted on the Bio-Rad CFX-96 Real-Time PCR 
System using RT2 SYBR Green Master mix (Bio-Rad Laboratories, Hercules, CA). 
The customized Mouse Diabetes RT² Profiler™ PCR Array containing 84 genes related 
to the onset, development, and progression of diabetes was used to examine the 
expression patterns of the selected genes. The marker genes for diabetes and glucose 
homeostasis, inflammatory mediators tested are listed in Table 3-2. Hot-Start DNA Taq 
Polymerase was activated by heating at 95°C for 10 min and real time PCR was 
conducted for 40 cycles (15 s for 95°C, 1 min for 60°C). All results were obtained from 
at least three independent biological repeats. Data were analyzed using the ΔΔCT 
method. Actin gene was used as the house-keeping gene for expression calculation.  
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Gene Expression Analysis at Protein Levels  
To further verify the expression changes at mRNA level, Bio-Plex Pro Diabetes 
Assays were conducted to get insight for the selected genes’ expressions at the 
translational level using a Mouse Diabetes Multiplex magnetic bead–based multiplex 
assay kit by following the manufacturer’s instruction (Bio-Rad, Hercules, CA). Plates 
were run on a Bio-Plex MAGPIX™ Multiplex Reader with Bio-Plex Manager™ MP 
Software (Luminex, Austin, TX). Each biomarker concentration was calculated as 
pg/ml. The levels of sensitivity in this panel were 0.64, 4.31, 0.59, 0.5, 68.29, 5.07, 
2.98 and 184.89 pg/ml for ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1 and 
resistin, respectively.  
 
Statistical analysis 
All data collected, including blood glucose, ELISA and HbA1c, were expressed 
as mean ± SE, and analyzed using one-way ANOVA followed by Bonferroni’s multiple 
comparison post-hoc tests. Statistical significance was defined as p ≤ 0.05. 
 
3.4. Results 
Effect of Different Dietary Treatments on Blood Glucose and Body Weight 
STZ-induced diabetic mice and non-STZ treated mice were used to examine the 
efficacy of GPE on diabetes treatment and prevention. Figure 3-1 shows the effects of 
long-term consumption of GPE incorporated in a high fat diet on blood glucose. In STZ 
treated groups, there was no significant difference on blood glucose between the HFD 
fed and HFD+GPE fed mice. In non-STZ treated groups, at early treatment stages (first 
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4 weeks), there was no significant difference on blood glucose between HFD and 
HFD+GPE fed mice. However, after week 10, hyperglycemia was successfully induced 
by consumption of HFD diet with average blood glucose higher than 180 mg/dl. 
Importantly, consumption of GPE significantly inhibited such blood glucose increase 
induced by HFD. The blood glucose in HFD+GPE treatment group was 12.6%, 15.1% 
and 10.1% lower than that of HFD fed alone at week 8, 10 and 12 respectively (p=0.07, 
p< 0.01, p< 0.05, respectively). Furthermore, blood glucose of the HFD+GPE group 
did not differ actoss the 12-week experimental period. For body weight, no significant 
difference was observed among all groups during the 12-week feeding period (data not 
shown).  
 
Effect of Different Dietary Treatments on Glycated Hemoglobin, HbA1C 
HbA1C was measured at the end of the experiment (Figure 3-2).  We observed 
a significant decrease (32.8% at p< 0.05) in non-STZ treated mice fed with HFD+GPE 
compared to those fed with HFD only. No significant difference was observed between 
STZ-induced diabetic groups. As the level of plasma glucose increased, the fraction of 
glycated hemoglobin also increased.  
Effect of GPE on peptide hormones related to glucose homeostasis  
Circulating peptide hormones such as glucagon, insulin, PAI-1 and resistin are 
important biomarkers for glucose homeostasis. We quantitatively examined the amount 
of these hormones in serum using the Bio-Plex Pro Diabetes Assay. GPE consumption 
did not affect these peptide hormone levels in STZ-induced mice. No significant 
differences were observed between STZ-induced diabetic mice fed with HFD and those 
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fed with HFD+GPE. However, between non-STZ treated mouse groups, GPE 
significantly reduced serum levels of glucagon, PAI-1, insulin and resistin (Figure 3-
3). 
 
RNA expression profile of the peptide hormones regulating glucose homeostasis  
The mRNA expression profiles of the peptide hormones which potentially 
regulate glucose metabolism were also examined in non-STZ treated groups. These 
genes encoded peptide hormones, including glucagon, insulin, PAI-1, 
dipeptidylpeptidase-4 (DPP-4), GLP-1 and GIP. The expressions of glucagon, insulin 
and resistin were examined using pancreas RNA while PAI-1, DPP-4, GLP-1 and GIP 
were examined using small intestine RNA. As shown in Figure 3-4, long-term 
consumption of GPE downregulated the expression of glucagon (39.1%, P<0.05) and 
insulin (53.5% at P=0.07 level) in pancreas. GPE also downregulated PAI-1 (71.6%, 
P<0.05) and DPP-4 (46.7%, p<0.01) in small intestine. DPP-4 promotes the 
degradation of GLP-1 and GIP and enhances the release of glucagon (Kim and Egan, 
2008). Consistently, GLP-1 expression in small intestine was increased 44.7% (P<0.05) 
following consumption of GPE (Figure 3-4), while no significant change was observed 
for GIP expression (data not shown).  
 
GPE reduced inflammation cytokines expression  
Obesity is often considered as a systematic inflammation. During obesity 
development and its progression to hyperglycemia, various inflammation cytokines are 
expressed. To investigate the effect of GPE on systematic inflammation, we examined 
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the expression changes of several inflammation mediators in the small intestine (Figure 
3-5). Real-time RT-PCR showed that dietary GPE supplementation significantly 
suppressed the expression of inflammation cytokines TNF-α, INF-γ and IL-12β (Fig. 
3-6) by 63.3%, 38.4% and 64.8% respectively (P<0.05). Resistin was 31.7% down, 
(P<0.05) in pancreas. PAI-1 was also significantly downregulated (71.6% down, 
P<0.01) by GPE consumption. No significant changes in IL-6 were observed.  
3.5. Discussion 
A growing body of evidence suggests that the consumption of grapes and/or 
grape derived food products rich in polyphenols promotes a variety of health effects. 
Grape products show beneficial effects in preventing the development of metabolic 
syndromes, particularly diabetes, obesity and heart disease (El-Alfy et al., 2005; Kim 
et al., 2014; Kim et al., 2015; Pezzuto 2008; Seeram 2008).  In our previous studies (Li 
et al, submitted), grape pomace water extract showed a dose-dependent inhibition of α-
glucosidase activity and significantly decreased blood glucose in diabetic mice and 
normal human subjects within 3 hours of GPE consumption. In addition, GPE delayed 
carbohydrate digestion, absorption and transportat to the blood stream. These results 
prompted us to examine the long-term effects of GPE in regulating carbohydrate 
metabolism and to elucidate the molecular mechanism(s) involved.  
 
In this study, we found that GPE did not play a critical role on STZ-induced 
diabetic mice during the 12-week feeding period, although there was a slight reduction 
in blood glucose at week 8. In our previous studies using a modified 2h Oral glucose 
Tolerant Test, STZ-induced diabetic mice gavaged with GPE-corn starch suspension 
resulted in a significant decrease in postprandial blood glucose compared with the STZ-
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induced mice only gavaged with corn starch (Li et al., submitted). Taken together, our 
results suggest that GPE could suppress acute blood glucose but long-term 
consumption of GPE would not help treat diabetes. Interestingly, when we fed GPE to 
non-STZ treated mice supplied with HFD, we found that GPE had significant effects 
on preventing HFD-induced hyperglycemia. Circulating peptide hormones in the blood 
and HbA1c were also dramatically altered by GPE. Further, RNA expression of several 
peptide hormones related to glucose homeostasis were significantly changed by GPE. 
In addition, biomarker genes for systematic inflammation were also altered by GPE. 
These results suggest that daily consumption of GPE might prevent hyperglycemia 
caused by high fat diet.  Similar evidence was obtained by Laight et al., (2009) who 
reported that consumption of grape seed extract for 4 weeks significantly improved 
markers of inflammation and glycaemia in obese Type 2 diabetic subjects with 32 
patients involved in a double blind randomized placebo controlled trial. 
To elucidate the molecular mechanisms involved in blood glucose lowering 
properties of the GPE, we further evaluated the effects of GPE on the glucose 
homeostasis. Glucose homeostasis was primarily governed by the two counteracting 
hormones: the glucose-elevating hormone glucagon and the glucose-lowering hormone 
insulin (Aronoff et al., 2004). Disruption of the equilibration by augmented secretion 
of glucagon and decreased secretion of insulin typically promotes commenced 
postprandial hyperglycemia (Yabe et al., 2015; Unger & Cherrington, 2012). Incretins, 
such as GLP-1, GIP and DPP-4, stimulate insulin secretion from pancreatic β cells 
(Yabe et al., 2015; Drucker, 2013; Holst, 2007; Seino & Yabe, 2013); GLP-1 inhibits 
glucagon release from the alpha cells of the islets of Langerhans, while GIP enhances 
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glucagon secretion (Yabe et al., 2015; Christensen et al., 2014; Christensen et al., 2011; 
Drucker, 2013; Holst, 2007; Mentis et al., 2011; Seino & Yabe, 2013; Taminato et al., 
1977). Both GLP-1 and GIP are rapidly degraded by the enzyme DPP-4 (McIntosh et 
al., 2005; Behme et al., 1995; Dupre et al., 1995). Mice fed diet that was supplemented 
with GPE significantly decreased glucagon expression in this study. On the other hand, 
GLP-1 expression was significantly increased, which is consistent with the observation 
that DPP-4 expression was significantly decreased by GPE consumption. Numerous 
studies are in agreement with these findings. It has been reported that grape seed extract 
enriched in procyanidins (GSPE) improves glycemia by affecting the insulin release 
and decreasing glucose levels in Wistar female rats, increasing the active form of GLP-
1 and inhibiting intestinal DPP-4 activity (González-Abuín et al., 2014; González-
Abuín et al., 2014; González-Abuín et al., 2012).  
Accumulating evidence indicates that grape polyphenols work in many 
different ways to decrease blood glucose (Zhang et al., 2011), improve insulin 
resistance (Baur et al., 2006; Sun et al., 2007; Lagouge et al., 2006), suppress 
hyperinsulinemia (Hokayem et al, 2013), and reduce blood pressure and lipid 
concentration (Perez-Jimenez et al., 2008; Vislocky et al., 2010; Schini-Kerth et al., 
2010; Barona et al., 2012). Consistently, our results showed that the plasma glucose 
and insulin mRNA expression was significantly decreased in the non-STZ treated mice 
fed with GPE. Consumption of a high fat diet can increase body fat deposition, diminish 
glucose uptake and consumption in skeletal muscle, and consequently increase insulin 
resistance (Lovejoy et al., 2001; Mayer-Davis et al., 1997; Flanagan et al., 2008; 
Tanaka et al., 2007). Adipose tissue also increases the amount of adipocytes and 
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produces several hormones and cytokines that affect glucose homeostasis and fat 
metabolism (Ahima & Flier, 2000; Trujillo & Scherer, 2006). For example, resistin, a 
cysteine-rich adipose-derived peptide hormone, potentially links obesity and insulin 
resistance (Barnes & Miner, 2009). In rodents, exposure to resistin results in decreased 
response to insulin (Rangwala et al., 2004). Conversely, acute administration of resistin 
impairs glucose tolerance and insulin action (Kim et al., 2001). Our study demonstrated 
that GPE had a decreasing effect on circulating and mRNA expression level of resistin. 
This might contribute to an improvement of glucose metabolism and insulin resistance. 
Additional evidence indicate that excessive fatty acid consumption in high fat 
diets results in excessive lipid accumulation in adipose and peripheral tissues, and 
subsequent chronic low-grade systemic inflammation (Ouchi et al., 2011). Chuang et 
al. (2011) reported that grape powder extract rich in phenolic phytochemicals possess 
anti-oxidant and anti-inflammatory properties. It attenuated TNFα-mediated 
inflammation through inhibiting the expression of IL-6, IL-1β, IL-8, MCP-1, COX-2 
and TLR-2 and improves insulin resistance in primary cultures of newly differentiated 
human adipocytes. Increased expression of TNF-α mRNA in white adipose tissue in 
obese humans has a strong positive correlation with the level of hyperinsulinemia and 
can lead to insulin resistance (Hotamisligil et al., 1995; Hotamisligil et al., 1993). In 
our study, the mRNA expression levels of inflammation cytokine/ adipokines genes 
including PAI-1, TNF-α, INF-γ and IL-12β in small intestine were significantly 
suppressed by GPE consumption while IL-6 showed no significant difference. Similar 
to our findings, HFD-induced obese mice supplemented with the Norton grape pomace 
(250mg/kg body weight for 12 weeks) exhibited less oxidative stress (Hogan et al., 
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2010), and that one-year consumption of grape extract downregulated the expression 
of key pro-inflammatory cytokines (Tome-Carneiro et al., 2013).  
 
3.6. Conclusion 
Our main goal was to investigate the effects of a dietary grape pomace extract 
supplement on the prevention of hyperglycemia and diabetes. This study provides 
important evidence that long-term consumption of GPE can: 1) lower the blood glucose 
and improved HbA1c. 2) down-regulate the expression of several cytokines involved 
in chronic low-grade inflammation triggered by high fat diet, and 3) attenuate insulin 
resistance in HFD-induced diabetes mice, but not in STZ-induced diabetic mice. It is 
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Figure 3- 1 Effect of two different dietary treatments (with or without GPE) on blood 
glucose in STZ-treated and non-STZ mice. Blood glucose was expressed as the mean 
± SE (n=6-20). Means of blood glucose at each time point with asterisk indicated 
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Figure 3- 2 Effect of two different dietary treatments (with or without GPE) on glycated 
hemoglobin, HbA1C in STZ-treated and non-STZ mice. Glycated hemoglobin A1C 
was expressed as the mean ± SE (n=6-20). Mean HbA1C for each group with * 
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Figure 3- 3 Effect of GPE on serum levels of insulin, glucagon, PAI1, resistin. Results 
were expressed as relative expression levels (mean ± SEM, n=6-12). Significant 
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(C)                (D) 
Figure 3- 4 GPE affected peptide hormones which regulate blood glucose homeostasis 
in non-diabetic mice.A-D: GLP-1, glucagon, DPP-4 and insulin gene. Pancreas and 
small intestine were harvested from animals on different diets, total mRNA was 
extracted, and the mRNA level was determined using real-time PCR. Results are 
expressed as relative expression levels (mean ± SEM, n = 6) to control. Columns 
marked with * are significantly different from each other at p ≤ 0.05.   
 
82  













































(A)             (B) 














































     
(C)                                                         (D) 























      (E) 
83  
Figure 3- 5 Effects of GPE on inflammatory mediator genes in small intestine and 
pancreas.Pancreas and small intestine were harvested from animals on different diets, 
total mRNA was extracted, and the mRNA level was determined using real-time PCR. 
Results are expressed as relative expression levels (mean ± SEM, n = 6) to control. 




Table 3-1. Macronutrient and micronutrient content of the mouse diets. 
 
 HFD HFD+GPE 
Product # D04011601 D12121001 
% gm kcal gm kcal 
Protein 24 20 24 20 
Carbohydrate 41 35 41 35 
Fat 24 45 24 45 
Total  100  100 
kcal/gm 4.7  4.7  
     
Ingredient gm kcal gm kcal 
Casein, 80 Mesh 200 800 200 800 
L-Cystine 3 12 3 12 
     
Corn Starch 0 0 0 0 






     
Cellulose, BW200 50 0 50 0 
     






     
Mineral Mix S10026 10 0 10 0 
Mineral Mix S10026B 0 0 0 0 
DiCalcium Phosphate 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 
Potassium Citrate, 1 H2O 16.5 0 16.5 0 
     
Vitamin Mix V10001 10 40 10 40 
Choline Bitartrate 2 0 2 0 
     
Grape Extract 0 0 2.07 0 
     
FD&C Yellow Dye #5 0.05 0 0 0 
FD&C Red Dye #40 0 0 0 0 
FD&C Blue Dye #1 0 0 0.05 0 






     




Table 3-2. List of genes encoding different peptide hormones related to glucose 
homeostasis and inflammatory cytokines. 
Peptide hormones related to glucose homeostasis: GLP-1, glucagon, 
insulin, GLP-1, DPP-4, GIP 





Chapter 4: Anti-obesity Activity of Grape Pomace Aqueous 
Extract on Suppressing Adipogenesis in Murine 3T3-L1 





Obesity is a key factor leading to metabolic syndromes that are characterized by an 
increase in body fat accumulation. We have recently reported that grape pomace extract 
can prevent obesity. In this study, we examined the potential role of grape pomace 
extract in controlling adipogenesis and body weight. Cabernet Franc Grape pomace 
aqueous extract (GPE) was used in the experiments. 3T3-L1 pre-adipocyte cells were 
induced into adipocyte in culture medium with or without GPE. GPE significantly 
affected adipogenesis in 3T3-L1 cells supported by decreased oil accumulation and 
changes in gene expression patterns involved in the adipogenesis transcriptional 
cascade. In a second experiment, C57BLK/6J mice were fed a high fat diet 
supplemented with or without 2.4g/kg GPE for 12 weeks. GPE reduced body weight 
compared to the control group, and inhibited adiposity by promoting a significant 
reduction in abdominal fat accumulation. In addition, GPE attenuated the expression 
of CEBPα, SREBF1 and PPARγ and reduced systematic inflammation through 
inhibition of PAI-1 expression and increase of the anti-inflammatory adipokine 
adiponectin. Our results highlight the role of GPE as an alternative approach to 








Obesity significantly increases the risk of several life-threatening diseases, 
such as heart disease, type 2 diabetes and cancer. In 2013, the American Medical 
Association officially classified obesity as a disease (http://www.ama-assn.org). 
Obesity is dramatically increasing globally, with more than 1.9 billion adults (39%) 
overweight. Of these, over 600 million (13%) people worldwide are suffering from 
obesity according to World Health Organization (WHO report 2014, 
http://www.who.int/mediacentre/factsheets /fs311/en/). In the United States, based on 
published data by CDC, more than one-third of adults (34.9% or 78.6 million) are 
obese (Ogden et al., 2014).  
Overweight and obesity are defined as excessive fat accumulation in the body. 
It is caused by the interruption of the equilibrium of energy intake and expenditure 
(Spiegelman and Flier, 2001; Panico and Iannuzzi, 2004; Kopelman, 2000). Obesity 
is a major factor associated with serious health disorders such as type 2 diabetes. The 
infiltration of inflammatory cells into adipose tissue triggers a low-grade systematic 
inflammation and eventually impairs insulin sensitivity and develops into type 2 
diabetes (Hotamisligil and Erbay, 2008; Nath et al., 2006; Mokdad et al., 2003). 
Obesity has also been associated with several other disorders, such as hypertension 
(Dorresteijn et al., 2012), atherosclerosis (Ouimet 2013), and cardiovascular disease 
(Must 1999). In addition, obesity is closely associated with cancers of the colon, 
breast, endometrium, kidney, and esophagus (adenocarcinoma) (Calle and Thun, 
2004).  
 
Adipose tissue, until recently has been considered as an inactive reservoir for 
88 
 
energy storage. With the discovery and characterization of leptin, the 16-kDa 
polypeptide with structural homology to cytokine, adipose tissue was re-discovered 
and consequently recognized as a complex and highly active metabolic and endocrine 
organ (Kershaw and Filer, 2004; Zhang et al., 1994; Ahima et al., 2000; Fruhbeck et 
al., 2001). Adipose tissue plays an important role in the regulation of whole body fatty 
acid homeostasis (Galic et al., 2010) by secreting numerous bioactive peptide 
hormones, named “adipokines”. Adipokines, such as leptin, adiponectin, plasminogen 
activator inhibitor-1 (PAI-1) and resistin regulate metabolism from both the local 
(autocrine/paracrine) and systemic (endocrine) level (Kershaw and Filer, 2004). 
Adipose tissue expresses numerous receptors for traditional endocrine hormones, 
nuclear hormone receptors, cytokine receptors and catecholamine receptors. Those 
receptors connect the response of the traditional hormone system to the network of 
the central neuron system (Kershaw and Filer, 2004). The hormones and receptors 
secreted by adipose tissue effectively communicate with the brain and peripheral 
tissues to modulate glucose homeostasis, influence energy metabolism, regulate 
appetite, adjust insulin resistance and control immune function (Matsuzawa et al., 
1999; Funahashi et al., 1999).  
Adipogenesis is the process where fibroblasts like pre-adipocytes differentiate 
into the well-established matured spherical adipocytes, which contain lipids 
(Lefterova and Lazar, 2009). An in vitro model of 3T3-L1 and 3T3-F442A, the pre-
adipocyte cell lines, has been developed to study adipogenesis (Rosen et al., 2000; 
Gregoire, 2001). A highly orchestrated multistep process of the transcriptional 
network is involved in adipogenesis (Ali et al., 2013). Several transcription factors are 
sequentially activated in adipogenesis transcriptional cascade. Remarkably 
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CCAAT/enhancer binding proteins (C/EBPβ, C/EBPδ and C/EBPα) gene family, 
peroxisome proliferator activated receptor-γ (PPAR-γ) and Sterol regulatory element-
binding transcription factor 1 (SREBF1), have been shown to have significant roles 
in promoting adipogenesis (White and Stephens, 2009). These factors are essential in 
promoting the terminal or mature adipocyte phenotype. Differentiation of pre-
adipocyte cells into adipocytes involves a series of events including growth-arrest, 
mitotic clonal expansion, and terminal differentiation and mature adipocytes (Sun et 
al., 2009; Lefterova and Lazar, 2009). In response to hormonal stimuli such as cortisol 
and insulin, C/EBPβ and C/EBPδ are induced immediately which in turn activate 
PPARγ and C/EBPα (Farmer, 2006). PPARγ and C/EBPα form a positive feedback 
loop to induce the expression of each other and regulate the adipocyte differentiation 
(Rosen et al., 2002). PPARγ and C/EBPα in turn induce the expression of genes that 
are necessary for regulating fatty acid storage and glucose metabolism (Rosen, E.D. 
and MacDougald, 2006). They are highly expressed in adipose tissue and are key 
factors controlling the down-stream adipocyte differentiation and adipocyte-specific 
gene expression (Lefterova et al., 2008), such as lipoprotein lipase (LPL), which is 
considered as the early stage marker for the adipocyte differentiation, and  adipocyte 
fatty acid–binding protein (aP2), which is an intermediate sign of adipocyte 
differentiation (Rosen and Spiegelman , 2000; (Bernlohr et al., 1984; Katz et al., 1999; 
Spiegelman et al., 1983; MacDougald et al., 1995). Sterol regulatory element-binding 
proteins (SREBPs) are also involved in adipocyte differentiation. SREBPs are a 
family of transcription factors that regulate lipid homeostasis.  SREBPs are induced 
very early during adipocyte differentiation and stimulate the expression of PPARγ, 
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and induce the fundamental coordinator of the adipocyte differentiation process 
(Eberlé et al., 2004; Shao and Espenshade, 2012; Saladin et al., 1999).  
The prevalence of obesity has increased worldwide and negatively impacted 
human health. Systemic chronic inflammation due to adipogenesis is major factor for 
obesity.  The main causes of obesity are thought to be related to diet (high fat 
consumption) and lifestyle (lack of physical activities). The existing literatures 
indicated that prolonged consumption of a high fat diet can lead to obesity and insulin 
resistance. Thus, understanding adipogenesis has been a major focus of researchers. 
New therapeutic intervention strategies to combat obesity involve identifying factors 
that control fat accumulation. Bioactive food components have been well studied in 
their ability to prevent obesity. The grape (Vitis vinifera) is one of the world’s oldest 
domesticated fruit crops, as well as one of the most economically important fruit 
plants worldwide. A large variety of natural grape products are widely used as 
nutritional products. The bioactivities of grape polyphenols and the health promoting 
effects of different varieties of grape have been documented. Numerous bioactivities 
of phenolic compounds in grape products, especially flavonoids are widely distributed 
in grapes. Many of these have potent positive effects modulating human health 
(Georgiev et al., 2014; Chacona et al., 2009; Bagchi et al., 2000; Cantos et al., 2002). 
Flavonoids, for example, anthocyanins, flavonols, flavanols, dihydroflavonols and 
proanthocyanidins are the most common phenolic compounds found in grapes. 
Phenolic compounds from grapes also exert positive benefits on human health. Some 
of the more important benefits reported include anti-radiation, anti-mutagenic, anti-
inflammatory and anti-bacterial effects (Bagchi et al., 2003; Halliwel et al., 1992; 
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Belleville, 2002; Sun et al., 2002). These beneficial effects have also been 
pharmacologically documented as decreasing insulin resistance, reducing ischemic 
heart disease, preventing heart failure and avoiding hypertension (Petrovski et al., 
2011; Bertelli et al., 1998).  
Grape pomace, the by-product from the wine and juice industry, may have 
potential beneficial effects in preventing diabetes and obesity. In our previous studies, 
we have reported that oral administration of Grape Pomace Aqueous Extract (GPE) 
can attenuate diabetes through inhibiting small intestine α-glucosidase activity and 
decreasing post-prandial hyperglycemia resulted from the prolonged consumption of 
western-style diet. However, the mechanism(s) of the effect of GPE on adipogenesis 
and obesity remains unknown. In the present study, using adipocyte precursor cell 
model 3T3-L1, we examined the role of GPE in regulating expression of genes that 
are involved in adipocyte differentiation. In a second study, we investigated the 
possible roles of GPE in regulating obesity, inflammation and insulin resistance in a 
high-fat-diet fed mouse model.  
 
4.3 Materials and methods 
 
Materials 
Cabernet Franc grape pomace samples (fermented for 2 weeks) were obtained 
from Chrysalis Vineyards, Virginia in 2011. Dulbecco's Modified Eagle's Medium 
(DMEM), antibiotic/ antimycotic, fetal bovine serum (FBS), and 0.25% trypsin with 
0.9 mM EDTA were purchased from Invitrogen (Carlsbad, CA). 3T3-L1 cell line was 
purchased from the American Type Culture Collection (Rockville, MD). 
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Adipogenesis Assay Kit (Cell-Based), Adiponectin Mouse ELISA kit and Glycerol-
3-Phosphate Dehydrogenase (G3PDH) Colorimetric Assay Kits were purchased from 
Abcam, (Cambridge, MA). 
Sample Preparation and Extractions 
Grape pomace samples were air dried under low pressure. Dried pomace was 
milled to 40 mesh size using a Scienceware Bel Art Micromill, (Pequannock, NJ). 
The milled grape pomace was then extracted with water (1:10 m/v) by shaking for 2 
hours at ambient temperature. Following extraction, the mixture was centrifuged at 
4,000 rpm at 20oC for 30 min. Supernatants were collected and freeze dried in the 
bench top freeze drier (AdVantage 2.0 BenchTop Freeze Dryer / Lyophilizer, SP 
Scientific) to obtain GPE. 
Cell viability assay 
GPE extracted using water was re-dissolved in 10% DMSO. The 10% DMSO 
GPE mixtures were then examined for cytotoxicity on 3T3-L1 cells. Cells are 
propagated in T-75 flasks and maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, 
and 1500 mg/L sodium bicarbonate  (ATCC® 30-2002™) with 10% fetal bovine 
serum and antibiotic/antimycotic. Cells were seeded at 5x104/well in 96-well plate at 
37oC in a humidified atmosphere with 5% CO2 supplied. Cells were treated with GPE 
at 0-4000μg/ml concentrations. Culture medium with 0.1% DMSO was used as 
negative control. Following 24 h exposure, cell viability was determined by the 
ATPlite™ Luminescence Assay System (PerkinElmer, Massachusetts, USA) 
according to the manufacturer’s direction. Absorbance at 570 nm will be directly 
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correlated to live cell number. All measurements were taken in triplicate with 
PerkinElmer VICTOR3 V Multilabel Readers 96-well plate reader (Massachusetts, 
USA).  
Cell culture differentiation 
Adipocyte differentiation of 3T3-L1 cells was measured with a cell-based 
adipogenesis assay kit following manufacture’s instructions. In brief, cells were 
cultured in 12-well plates to 100% confluence for 2 days and then transferred to 
differentiation medium (DM) containing 10 μg/ml insulin (Sigma, St. Louis, MO), 0.5 
μM dexamethasone (Sigma, St. Louis, MO), and 0.8 mM isobutylmethyl xanthine 
(IBMX). GPE were added in differentiation medium at 0, 200, 400, 800μg/ml. After 
a 3-day induction, the medium is changed to DMEM with 10% fetal bovine serum 
containing 10 μg/ml insulin for differentiation and DMEM with 10% fetal bovine 
serum for control group at 37 °C, 95% O2, and 5% CO2 for 4 days. Fresh medium 
was changed every other day. 
Oil Red O staining  
Seven days after adipocyte differentiation, an oil red staining assay was 
conducted. Culture medium was remove from the wells, and 75 μL diluted Lipid 
Droplets Assay Fixative was added to each well and incubate for 15 minutes. Wells 
were washed with 100 μL Wash Solution two times for five minutes each. The plate 
was dried completely and then 75 μL oil Red O Working Solution was added to all 
wells and incubated for 20 minutes. Oil Red O Solution was then removed and the 
cells were washed with distilled water several times until the water contained no 
visible pink color. After Oil Red-O stain, microscope images were taken to visualize 
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pink to red oil droplets staining in differentiated cells. Cells were photographed using 
a phase-contrast microscope (Olympus CKX41, Tokyo, Japan) in combination with a 
digital camera at 100X magnification. Differentiated cells were dried completely and 
400μL of dye extraction solution was added to each well and gently mixed for 15-30 
min. 250μl extraction solution with cells were added to 96-well plate and read the 
absorbance at 490-520 nm with a PerkinElmer VICTOR3 V Multilabel Readers 96-
well plate reader (Massachusetts, USA). 
Colorimetric Glycerol-3-Phosphate Dehydrogenase (G3PDH) Assay  
3T3-L1 adipocyte cells were plated in six-well plates with a density of 2 x 106 
cells per well. Two days after, differentiation medium (DM) was added to the cells. 
GPE was added at various concentrations, and cells were incubated at 37oC with 5% 
humidified CO2 for 3 additional days. Abcam colorimetric Glycerol-3-Phosphate 
Dehydrogenase (G3PDH) Assay was performed following manufacture’s protocol 
(Abcam, Cambridge, MA). In brief, the 3T3-L1 adipocytes were harvested 7 days 
after the initiation of differentiation with various concentrations of GPE. Cells were 
carefully washed twice with ice-cold PBS and collected with a scraper. Cells were 
spun down briefly and suspended in 200μL ice cold GPDH Assay Buffer. 50μL of 
sample and positive control were added to each well and mixed thoroughly with 50μL 
of the Reaction Mix containing 46µL of GPDH Assay Buffer, 2µL of GPDH Substrate 
and 2 µL of GPDH Probe. Reactions were incubated for 20-60 min at 37ºC and 
measured OD at 450 nm. Enzyme activity (%) was expressed as a ratio of the 
experimental condition relative to the control (which was set at 100% activity). 
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RNA isolation and gene expression analysis with quantitative real-time reverse 
transcription-polymerase chain reaction (RT-PCR) 
For gene expression analysis, highly sensitive and reliable real-time RT-
PCR’s were performed.  Total RNA was extracted from 3T3-L1 adipocytes, which 
had been treated with various concentrations of GPE for 7 days, with RNeasy Plus 
Universal Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. The quantity and quality of RNA was determined by measuring 
absorbance in a Nano drop spectrophotometer.  RNA was treated with DNaseI at 
room temperature for 15 min to remove genomic DNA contamination. RT2 First 
Strand Kit from Qiagen (Qiagen, Hilden, Germany) was used to synthesis first strand 
complementary DNA (cDNA).  Gene expression were analyzed by Quantitative real-
time RT-PCR conducted on the Bio-Rad CFX-96 Real-Time PCR System using RT2 
SYBR Green Master mix (Bio-Rad Laboratories, Hercules, CA).  
The Mouse Adipogenesis RT² Profiler™ PCR Array containing 84 genes 
related to the differentiation and maintenance of mature adipocytes was used to 
examine the expression patterns of the selected genes. The marker genes for 
adipogenesis are listed in Table 4-1. Genes encoding adipokines that were tested are 
listed in Table 4-2. Hot-Start DNA Taq Polymerase was activated by heating at 95°C 
for 10 min and real time PCR was conducted for 40 cycles (15 s for 95°C, 1 min for 
60°C). All results were obtained from at least three independent biological repeats. 
Data were analyzed using the ΔΔCT method. The expression of all genes was 




Gene expression analysis at protein levels  
Fully differentiated adipocytes (at 7 days after differentiation induction) were 
treated with the 0, 400 and 800 µg/ml of GPE for 72 h, and adiponectin concentrations 
in cell culture supernatants were determined. A quantitative adiponectin enzyme-linked 
immunosorbent assay (ELISA) was performed using a commercial Mouse adiponectin 
ELISA kit (Abcam, Cambridge, MA) according to the manufacturer’s protocols.  
Animal experiments 
Mouse food preparation:  
Rodent chow and western style high fat diet (HFD) was purchased from 
Research Diets, INC (New Brunswick, NJ). For GPE containing HFD diet, 2.4 grams 
of GPE was mixed with 1 kilogram of HFD by the same company. All mouse food 
was sterilized by irradiation to minimize bacterial contamination. Macronutrient and 
selected micronutrient content in the mouse diet is summarized in Table 4-3. 
Animals:  
6-week male C57BLK/6J mice, were housed in clean cages at 12-hour light 
dark cycle at 20°C to 22°C, with 4 mice/cage. The mice were maintained on rodent 
feed with continuous access to tap water so as to acclimatize to the experimental 
conditions for 1 week prior to being assigned to experimental groups.  
Experimental group assignment:  
Each mouse was assigned to one of the following groups: 1) group-1 mice fed 
with regular rat chow and served as control (n=14); 2) group-2 mice fed with HFD 
(n=14); 3) group-3 mice fed with HFD + GPE (n=14). All mice were fed with the 




Food intake, body weight and fasting glucose measurements during the 
experiment:  
During the 12-week feeding experiment, food intake and body weight were 
recorded every week. Fasting blood glucose levels was also monitored weekly using 
a blood glucometer and the accompanying test strips (ACCU-CHEK Meter®, Roche 
Diagnostics, Kalamazoo, MI). Plasma insulin was monitored monthly at week 0, 4, 8 
and 12. A Mouse insulin ELISA kit from BioRad was used to quantify insulin 
following the manufacturer’s procedure.  
Animal sacrifice and tissue collection:  
Mice were anesthetized with CO2 at the end of feeding study. Blood samples 
were collected and the plasma was separated. Liver, heart, kidney, white adipose 
tissue and pancreas were dissected, weighed and immediately frozen in liquid nitrogen 
and stored in -80oC. The ARC and LHA regions of the hypothalamus were dissected 
under a binocular microscope and immediately frozen in liquid nitrogen.  
Histological analysis of animal adipocytes 
Freshly isolated epididymal WAT sections were fixed in 10% formalin for 24 
hours followed by embedding the tissues in paraffin. The paraffin-embedded samples 
were sectioned and stained with hematoxylin-eosin following the procedures used by 
An et al., 2010.  
 
RNA isolation and real-time RT-PCR in hypothalamus:  
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The ARC and LHA regions of the hypothalamus tissue were subjected to total 
RNA extraction with RNeasy Plus Universal Mini Kit (Qiagen USA). DNase I treated 
RNA samples were used to synthesis first strand complementary DNA (cDNA) using 
RT2 First Strand Kit from Qiagen (Qiagen USA). We used ARC tissue to test the 
NPY, AgRP, POMC, CART, and MC4R, and LHA tissue to test the MCH through 
quantitative real-time RT-PCR (qRT-PCR). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) genes was used as an internal control. All data were 
analyzed using the ∆∆CT method. 
 
4.4. Results 
Effects of GPE on cell viability, adipocyte differentiation and triglyceride 
accumulation 
The ATPlite™ Luminescence Assay was performed to determine the effect of 
GPE on 3T3-L1 cell viability. 3T3-L1 cells were exposed to various concentrations 
of GPE. As shown in Fig 4-1, no significant effect on viability was observed at GPE 
concentrations up to 1000 µg/ml after 72h incubation with GPE.  
To investigate the effect of GPE on attenuation adipocyte differentiation and 
preventing lipid accumulation, 3T3-L1 adipocytes were incubated with differentiation 
medium supplemented with different concentrations of GPE. The total amount of lipid 
accumulation was examined by Oil-Red-O staining. Shown in Fig 4-2A, GPE 
significantly reduced lipid accumulation, as indicated by decreasing Oil Red-O 
staining. Triglyceride content in 3T3-L1 adipocytes was drastically decreased at 400 
µg/ml and 800 µg/ml GPE concentrations (p<0.01) to 79.7% and 68.2% respectively 
as compared to control cells (Fig. 4-2B). 
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Glycerol-3-phosphate dehydrogenase (GPDH) is an enzyme that links 
carbohydrate metabolism and lipid metabolism. GPDH activity was verified to 
determine the effect of GPE on 3T3-L1 pre-adipocytes differentiation. GPDH activity 
in 3T3-L1 adipocytes was significantly decreased by GPE at 400 µg/ml and 800 µg/ml 
to 84.4% (p<0.05) and 79.8% (p<0.01) respectively. In contrast, no significant effect 
on GPDH activity was showed in control treatment (Fig. 4-3). 
 
Effect of GPE on 3T3-L1 adipocyte differentiation and the expression level of 
key adipogenesis genes 
Real-time RT-PCR was performed to examine the effect of GPE on the gene 
expression of adipogenic transcription factors in 3T3 L1 pre-adipocytes. Shown in 
Fig. 4-4, 3T3-L1 pre-adipocyte cells incubated with 800 µg/ml GPE exhibited 
markedly decreased mRNA expression of C/EBPα, C/EBPβ, PPARα, PPARγ, PGC-
1α, and SREBP1 (Fig. 4-4A-F) when compared with control (p<0.01). The expression 
of most these genes did not significantly differ between 400 µg/ml and 800 µg/ml 
GPE treatments.  Only C/EBPβ showed dosage dependent inhibition where 800 µg/ml 
GPE inhibited significantly more expression than that of 400 µg/ml GPE.  
Finally we also investigated the effect of GPE on the expression of adipocyte-
related genes that are known to participate in the adipogenesis. Shown in Fig 4-4. G-
J, LPL and ap2, were significantly decreased by 400 and 800 µg/ml of GPE treatments 
(p<0.05). The expression of the lipase gene was not inhibited until 800ug/ml GPE was 
added. No significant changes were detected on FAS, an important fatty acid 




Effect of GPE on the expression of adipocytokines in 3T3-L1 pre-adipocyte 
Inflammatory cytokines released from adipose tissue are a major cause of 
systemic low-grade inflammation. To understand the molecular mechanism 
underlying the anti-inflammatory effect of GPE, adipocytokines during 3T3-L1 
adipocyte differentiation were investigated. The expression level of the key 
adipokines including angiopoietin, adiponectin, leptin, resistin, PAI1 (Fig. 4-5).  
These were examined by real-time RT-PCR. The expression of angiopoietin, resistin 
and PAI1 was significantly reduced (p<0.05 or p<0.01) after treatment with 800 µg/ml 
GPE (Fig 4-5A, B and E). 400 µg/ml GPE inhibited the expression of resistin 
(p<0.01). No changes were observed on the expression of leptin (Fig. 4-5C). An effect 
of GPE on adiponectin, was also observed. 800 µg/ml GPE significantly increased 
adiponectin expression in the fully differentiated adipocytes with a 1.8-fold increase 
compared to the control treatment. 
Effect of GPE on the secretion of adiponectin during 3T3-L1 adipocyte 
differentiation 
To understand the molecular mechanisms responsible for the GPE-induced 
upregulation of adiponectin expression, fully differentiated adipocytes were treated 
with 0, 200, 400 µg/mL and 800 µg/mL GPE, and the concentrations of adiponectin 
in cell culture supernatants were determined with ELISA kit. Shown in Fig 6, GPE 
significantly increased the secretion of adiponectin in a dose-dependent manner (Fig. 
4-6). Significant differences were observed at GPE concentrations of 400 and 800 




Effect of GPE on body weight, abdominal fat weight and adiposity in HFD 
induced obese mice. 
We also conducted an animal study to evaluate the effect of GPE on fat 
metabolism and its potential capacity of being an anti-obesity treatment. As shown in 
Figure 4-7A, the HFD and HFD+GPE dietary treatments significantly increased body 
weight compared to the normal diet control group. However, significantly decreased 
body weight was shown in animals that were fed an HFD with GPE compared with 
HFD only. A significant difference between the HFD+ GPE group and the HFD group 
started at week 6 (𝑃𝑃 < 0.05), and was constantly maintained until the end of the 
experiment. No difference in food intake was observed between the HFD+ GPE group 
and the HFD group (data not show). To test whether body weight loss was caused by 
decreased adiposity, mice were sacrificed and abdominal white adipose tissue was 
dissected and weighed (Fig. 4-7B). Abdominal white adipose tissue was significantly 
reduced in the HFD+GPE group (p<0.01) with 26.6% less than in the HFD group. 
Abnormalities of epididymal white adipose tissue in the HFD group were observed in 
the histology WAT stained with hematoxylin and eosin (Fig. 4-7C). The size of the 
adipocytes in HFD+GPE group was markedly decreased when compared with that of 
the HFD group. 
 
Effects of GPE on blood glucose and organ weight in HFD induced obese mice. 
Blood glucose and organ weight (heart, liver and pancreas) were measured at 
week-12 and summarized in Table 4-2. A significant increase in blood glucose was 
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observed in the HFD fed group when compared with normal diet (p<0.01). However, 
HFD supplemented with GPE shown no difference in blood glucose after fed for 12 
weeks in comparison to normal diet (p<0.05), but decreased by 23.3% compared with 
HFD alone. No difference in liver and pancreas weights were observed between HFD 
and HFD+GPE. However, HFD increased the weight of the heart compared with 
normal diet and HFD+GPE. 
 
Effect of GPE on neuropeptides produced by the hypothalamic arcuate nucleus 
(ARC) in HFD induced obese mice. 
Neuropeptide Y (NPY)/agouti-related protein (AGRP) neurons, and the pro-
opiomelanocortin (POMC)/ cocaine and amphetamine related transcript (CART) 
neurons in the arcuate nucleus of the hypothalamus play a central role in controlling 
energy homeostasis and feeding behavior. We examined the mRNA expression of 
AGRP, NPY, POMC and CART to determine the effects of GPE on the hypothalamic 
gene expression (Fig. 4-8). No significant difference was observed for NPY among 
mice fed with different diets (Fig. 4-8B). Compared to the normal diet, the high-fat 
diet significantly increased AGRP expression by a factor of 3.5. Animals fed the GPE 
supplemented diet showed a similar increase in AGRP as mice fed a high-fat diet (Fig. 
4-8A). POMC, was up-regulated 92.2% and 74.5% in high-fat diets with or without 
GPE supplementation as compared to normal diet (Fig. 4-8C). CART expression 





Relative expression of genes related to adipogenesis and lipogenesis in HFD 
induced obese mice. 
To determine whether reduced adiposity was associated with reduced 
adipogenesis through the multiple transcription factors, C/EBPs, PPARs and SREBPs 
transcription cascade and the down-stream genes involved in fatty acid metabolism 
were evaluated. As shown in Fig. 4-9, no significant difference was observed for 
SREBP1 between normal diet and HFD diet, as well as between normal diet and 
HFD+GPE. However, 44.7% less expression of SREBP was observed in the HFD+ 
GPE group when compared with the HFD alone group (Fig. 4-9A). In mice fed the 
HFD CEBPα expression in adipose tissue was not different compared with the group 
fed the normal diet, but GPE supplementation reduced adipose CEBPα by 2-fold 
compared with HFD alone (Fig. 4-10B). PPARγ was significantly higher (42.6% 
increased) in mice fed with HFD as compared to mice on the normal diets. GPE 
consumption reduced its expression to 1.6-fold compared to mice fed with HFD only. 
High fat diet fed mice recorded significant increase (p<0.05) in mRNA expression of 
ap2 (p<0.05), and GPE supplementation significantly decreased ap2 gene expression 
by 75% (Fig. 4-9D). However, the expression of FAS, LPL, and lipase were not 
affected by the diet (data not show).  
GPE attenuated the inflammatory cytokines/adipokines expression in adipose 
tissue. 
Inflammatory cytokines/adipokines released from adipose tissue are key 
factors in promoting systematic inflammation, insulin resistance and obesity. To 
investigate the effect of GPE on systematic inflammation, we examined the 
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expression changes on several inflammation cytokines/adipokines in white adipose 
tissue (Fig. 4-10). Real-time RT-PCR showed that dietary supplement of HFD with 
GPE significantly suppressed the expression of inflammation factors PAI-1 (Fig. 4-
10A) by 48.0% comparing with HFD alone (P<0.05). There was no difference 
observed in comparison with a normal diet control. Leptin expression was not affected 
by GPE consumption (Fig. 4-10C). No significant changes on resistin, IFNγ, TNFα, 
and angiopoietin2 were observed (data not show). Adiponectin levels were also 
reduced in association with insulin resistance.  GPE consumption caused a significant 
increase in the adiponectin (~1.6 fold increase, p<0.05) compared to HFD (Fig. 4-
10C).  
4.5. Discussion 
Grape has been reported to have various biological activities and health 
benefits. As a nutraceutical product, its anti-cancer, anti-inflammatory and anti-
diabetes properties have been well documented (Bagchi et al., 2003; Belleville, 2002; 
Sun et al., 2002, Hogan et al., 2010, Zhang et al., 2011). We have reported that GPE 
inhibited post prandial hyperglycemia through inhibition of α-glucosidase activity in 
STZ induced diabetic mice and healthy human subjects (submitted data). 
Additionally, GPE significantly decreased both postprandial and random blood 
glucose levels in mice fed 12 weeks of HFD supplemented with GPE.  GPE regulates 
glucose homeostasis hormones and attenuates low-grade systemic inflammation. 
Nevertheless, the anti-obesity effects of GPE had not been explored. In the present 
study, we investigated the anti-obesity effects of GPE using 3T3-L1 adipocyte cells 
and HFD induced obese mice. This research was designed to elucidate the 
physiological and molecular mechanisms of grape pomace’s roles in preventing 
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obesity using an in vitro cell-based study and high fat induced obese mice model. We 
evaluated GPE for its putative effects on reducing adipocyte differentiation, 
decreasing fatty acid accumulation and G3PDH activity, controlling body weight, 
obesity-related biochemical parameters, and regulating adipose tissue gene expression 
in both 3T3-L1 pre-adipocyte and high-fat diet–induced obese mice. Our data clearly 
demonstrate when treated with GPE, maturation and lipid accumulation in the 3T3-
L1 cells were inhibited; consumption of GPE in high-fat diet induced obese mice 
exhibited noticeable attenuation of weight gain, adiposity and abdominal fat-pad 
weight.  GPE also inhibited transcriptional factors expression and the down-stream 
genes in adipogenesis and fatty acid synthesis and metabolism. The inflammatory 
cytokines such as PAI1 were also decreased. On the contrary, adiponectin, the anti-
inflammatory adipokine, was increased in mice fed with HFD supplemented with 
GPE. These results indicate that GPE exerts anti-obesity effects. 
Our data showed that GPE significantly decreased the mRNA levels of the 
inflammatory adipokines in both 3T3-L1 pre-adipocyte differentiation and high fat 
diet induced obese mice. This was in agreement with previous reported studies. Taey 
et al. reported that PAI-1, plasminogen activator inhibitor-1 plays a key role in obesity, 
diabetes and cardiovascular disease (Taey et al., 2005) and contributes directly to the 
complications of obesity, such as type 2 diabetes, pathogenesis of atherothrombosis 
and cardiovascular diseases. Elevation of PAI-1 can also be attributed to the 
accumulation of visceral fat (Kruithof, 1988; Skurk et al., 2004; Primrose et al., 1992). 
Direct inhibition of PAI-1 shows beneficial effects on obesity and insulin resistance. 
Arçari et al. found that yerba maté extract (Ilex paraguariensis) reduced the expression 
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of PAI-1 in high-fat diet–induced obese mice and exhibited anti-obesity effects 
(Arçari et al., 2009).  
Adiponectin is the most abundantly adipokine secreted by fat tissue. 
Biological functions of adiponectin and its close connection with obesity has been 
reported. Circulating levels of adiponectin are negatively correlated with obesity, 
insulin resistance, and coronary artery disease (CAD).  Plasma adiponectin is relevant 
in the prediction of insulin resistance and metabolic syndrome (Hara et al., 2006; Eglit 
et al., 2013). In addition, the anti-inflammatory capacity of adiponectin has become a 
major focus of research. Adiponectin plays a causal role in protecting against 
inflammation related diseases such as atherosclerosis, CVDs, and insulin resistance 
(Surmi et al., 2008, Villarreal-Molina and Antuna-Puente, 2012; Ouchi et al., 2007). 
Adiponectin targets inflammatory cells to stimulate the expression of the anti-
inflammatory cytokines and suppress the genes involved in inflammatory signaling 
pathway, such as NF-𝜅𝜅B, TNFα (Ouchi and Walsh, 2007; Nigro et al., Shibata et al., 
2004). The present study showed that adiponectin expression in white adipose tissue 
was significantly increased in mice administrated GPE with high fat diet for 12 weeks. 
Similar results were revealed in the 3T3-L1 pre-adipocytes. Both mRNA expression 
and protein secretion in the differentiating 3T3-L1 cells are dramatically increased 
after being treated with GPE. Beneficial effects of grape products on serum 
adiponectin and inflammation were also reported by Tomé-Carneiro et al.,  with a 75 
stable-CAD patients involved triple-blind, randomized, placebo-controlled,  3-arm 
pilot clinical trial, (Tomé-Carneiro et al., 2013). Grape resveratrol extract exhibited 
an increase of the anti-inflammatory serum adiponectin (p = 0.01) and a decrease of 
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the plasminogen activator inhibitor type 1 (PAI-1) (p = 0.05). These results indicated 
that grape and its derivations have potential anti-inflammatory effects and attenuate 
obesity related metabolic syndrome.  
Obesity is caused by the imbalance of energy intake and energy expenditure. 
Irregular adipocyte differentiation, lipogenesis, and excess amount of lipid droplets 
accumulated in the adipocyte all contribute to obesity. In the present study, GPE 
reduced oil droplets in adipocytes, depleted  fat storage and reduced the triglycerol 
content and inhibited the activity of H3PDH activity in in-vitro pre-adipocytes (Fig 4-
2 and 4-3).  GPE also decreased body weight, reduced blood glucose, attenuated 
abdominal fat weight, and affected white adipocyte morphology in high fat induced 
obese mice (Fig 4-7. And Table 4-2). The molecular mechanisms of GPE on the 
regulation of adipocyte differentiation were evaluated. Adipogenesis is a highly 
coordinated multistep process regulated by transcriptional activators synergistically 
interacted with the transcriptional regulators, such as PPARs, SREBPs and C/EBPs. 
They are sequentially activated in adipogenesis transcriptional cascade (Ali et al., 
2013). In the present study the mRNA expression of PPAR-γ was upregulated in 
visceral adipose tissue from mice fed the high-fat diet. The results presented in this 
study show that treatment with GPE recovered PPAR-γ expression to normal levels. 
Furthermore, GPE also decreased CEBPα and SREBF1 expression to attenuate 
adipogenesis in high fat induced mice. 
Our results indicate that GPE has potential anti-obesity effect through 
reduction of adipogenesis and lipogenesis. However, genome-wide studies of how 
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GPE regulate obesity remained to be conducted. Genome-wide transcriptome analysis 
should be conducted to provide insights and answers to many remaining questions. 
 
4.6. Conclusion 
Our primary goal was to investigate the effects of a dietary grape pomace 
extract supplement on the prevention of obesity. This study provides preliminary 
evidence that long-term consumption of GPE can: 1) lower the body weight. 2) down-
regulate the expression of several cytokines involved in chronic low-grade 
inflammation triggered by high fat diet, and 3) attenuate adipogenesis both in vitro and 
in vivo in 3T3-L1 pre-adipocytes and high fat diet induced obese mice. GPE shows 



































Figure 4- 1 Effect of GPE on pre-adipocyte cell 3T3-L1 viability.3T3-L1 pre-
adipocytes were treated with GPE at various concentrations (0, 100, 200, 400, 600, 800, 
1000, 2000, 4000 µg/mL) for 24 h. The results represent mean ± SD (n=4). *:p<0.05, 


























































Figure 4- 2 Effect of GPE on inhibiting 3T3-L1 adipocyte differentiation.3T3-L1 cells 
were differentiated using differentiation media with or without hormones for 3 days 
under different GPE treatments: 0, 100, 200, 400, 800µg/mL. (A) Intracellular lipids 
GPE-0 GPE-100 Non-induced 
GPE-200 GPE-400 GPE-800 
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stained with Oil Red-O. (B) Triglyceride content quantified by measuring absorbance. 
Non, undifferentiated cells; DM, differentiated medium. The results represent mean ± 

















































Figure 4- 3 Effect of GPE on Glycerol-3-phosphate dehydrogenase (GPDH) activity 
during 3T3-L1 adipocyte differentiation.3T3-L1 cells were stimulated with 
differentiation media with hormones for 3 days under different GPE concentrations: 0, 
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Figure 4- 4 Effect of GPE on adipogenesis gene expression. A-J: C/EBPα, C/EBPβ, 
PPARα, PPARγ, PGC-1α, SREBP1, ap2, FAS, and Lipase gene in 3T3-L1 adipocytes 
were investigated using real-time RT-PCR. 3T3-L1 cells were stimulated to 
differentiation with hormones for 3 days in different GPE concentrations: 0, 400, 
800µg/mL. The results represent mean ± SD (n=3). Columns marked with different 
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Figure 4-5 Effect of GPE on adipokines gene expression.A-E: angiotensinogen, 
adiponectin, leptin, resistin, and PAI1 in 3T3-L1 adipocytes were investigated using 
real-time RT-PCR. 3T3-L1 cells were stimulated to differentiation with hormones for 
3 days in different GPE concentrations: 0, 400, 800µg/mL. The results represent mean 
± SEM (n=3). Columns marked with different letters are significantly different from 
each other at p ≤ 0.05.
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Figure 4- 6 Effect of GPE on protein secretion in the cultured media.3T3-L1 cells were 
stimulated to differentiation with hormones for 3 days in different GPE concentrations: 
0, 200, 400, 800µg/mL. The results represent mean ± SEM (n=3). Columns marked 
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Figure 4- 7 GPE reduced body weight, abdominal fat weight and the size of white 
adipocytes in HFD-induced obese mice.8-week-old C57BLK/6J male mice were 
randomly divided into three dietary groups fed on ND (normal diet), HFD (high fat 
diet), HFD+ GPE (high fat diet supplemented with GPE) for 12 weeks (n=14 per 
group). (A) Body weight of the mice during the 12-week treatment. The results 
represent mean ± SEM (n=14). (B) Abdominal weight of the mice at 12th week 
treatment. The results represent mean ± SD (n=14). Columns marked with different 
letters are significantly different from each other at p ≤ 0.05. (C) Histology of white 
adipose tissue in HFD-induced obese mice. Representative epididymal WAT freshly 
isolated from each mouse group was fixed in 4% formalin and embedded in paraffin. 
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Figure 4-8 Expression of several hypothalamic neuropeptide genes in the 
hypothalamus.ARC region of hypothalamus were dissected from mice on different 
diets. Total RNA was extracted and the expression was determined using Real Time 
PCR. A-D: AGRP, NPY, POMC and CART gene. The results represent mean ± SEM 
(n=6). Columns marked with different letters are significantly different from each 
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Figure 4-9 Effects of GPE on adipogenesis related transcription factors. White 
adipocyte tissue were harvested from animals on different diets. A-D: SREBP1, 
C/EBPα, PPARγ and ap2 gene. Results were expressed as relative expression levels 
(mean ± SEM, n = 6) to normal diet. Columns marked with different letters are 
significantly different from each other at p ≤ 0.0.
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Figure 4-10 Effects of GPE on inflammatory cytokine/adipokine in adipose 
tissue.WATs were harvested from animals on different diets. A-C: PAI-1, adiponectin 
and leptin. Results were expressed as relative expression levels (mean ± SEM, n = 6) 
to normal diet. Columns marked with different letters are significantly different from 
each other at p ≤ 0.05. 
  
122  
Table 4-1. The list of genes encoding different peptide hormones related to glucose 
homeostasis.  
Adipogenesis regulation genes: Cebpb, Cebpd 
PPARγ Targets: Adiponectin, Cebpa, FAS, Fabp4, Lipe, Lpl, Pparg, 
Ppargc1α (Pgc-1α), Ppargc1β (Pgc-1β), Srebf1 
 
Table 4-2. The list of genes which are adipokines secreted in adipose tissue  
Anti-inflammation adipokines: adiponectin 





Table 4-3. Macronutrient and selected micronutrient content in the mouse diet. 
Rodent Diet with 60 kcal% Fat and 2.4 g Grape Extract /kg 
Product # D12492 D12492+GPE 
% gm kcal gm kcal 
Protein 26.2 20 26.2 20 
Carbohydrate 26.3 20 26.3 20 
Fat 34.9 60 34.9 60 
Total  100  100 
kcal/gm 5.2
 
 5.24  
     
Ingredient gm kcal gm kcal 
Casein, 80 Mesh 200 800 200 800 
L-Cystine 3 12 3 12 
     
Corn Starch 0 0 0 0 




     
Cellulose, BW200 50 0 50 0 
     
Soybean Oil 25 225 25 225 
Lard 245 2205 245 2205 
     
Mineral Mix S10026 10 0 10 0 
Mineral Mix S10026B 0 0 0 0 
DiCalcium Phosphate 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 
Potassium Citrate, 1 H2O 16.5 0 16.5 0 
     
Vitamin Mix V10001 10 40 10 40 
Choline Bitartrate 2 0 2 0 
     
Grape Extract 0 0 2.4 0 
     
FD&C Yellow Dye #5 0.05 0 0 0 
FD&C Red Dye #40 0 0 0 0 
FD&C Blue Dye #1 0 0 0.05 0 






     





Table 4-4. Effects of GPE on blood glucose, food intake, body weight, organ 
weight on 12th week of treatment. 
 DN HFD HFD+ GPE 
Blood glucose 136.80±3.95a 179.09±4.30b 136.35±1.78a 
Food intake 
(g/day) 
0.41±0.15a 0.31±0.16b 0.30±0.12b 
Heart weight 0.16±0.003a 0.22±0.015b 0.17±0.008a 
Liver weight 1.25±0.045a 1.81±0.15b 1.40±0.056b 
Pancreas 
weight 
0.24±0.022a 0.34±0.037a 0.30±0.041a 
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Chapter 5: Effects of Grape Pomace Extract on preventing 
Western Pattern Diet Induced Obesity Revealed by Hepatic 




Obesity and diabetes are two of the leading risk factors causing health challenges 
worldwide. Western pattern diet (WPD) with its high fat and high sugar content is 
well known to cause obesity and diabetes. Recently, we and others have argued that 
plant-based products could provide a great potential in preventing WPD induced 
obesity and diabetes. Our previous studies and others’ have demonstrated that grape 
pomace extract (GPE) can reduce blood glucose and eliminate inflammation caused 
by high fat diet. In the present study, we investigated the role of GPE in the control of 
body weight.  In particular, we wanted to better characterize the molecular basis of 
how GPE could prevent obesity in mice fed a high fat diet by using an RNA-
sequencing (RNA-seq) approach. GPE marginally, but consistently increased body 
weight gain and significantly reduced circulating leptin. Hepatic transcriptome 
profiling analysis indicated that GPE significantly modulated expression of 181 genes. 
Further analysis indicated that GPE upregulated many genes involved in metabolic 
processes and those associated with energy expenditure and solute carrier transport. 
Additionally, a large number of genes related to immune responses, oxidative stress 
responses and inflammation biomarkers were significantly down regulated by GPE. 
Taken together, our results suggest that GPE can prevent obesity development through 
enhancing metabolism, accelerating energy expenditure, and reducing various stresses 
caused by WPD consumption. This study provides a molecular basis of GPE’s 
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potential as a functional food ingredient to prevent WPD-induced obesity 
development. 
   
5.2. Introduction 
Obesity is one of the leading risk factors for a number of diseases that have 
collectively been referred to as “metabolic syndrome”.  These include heart disease, 
diabetes and hypertension (Pi-Sunyer 2009 (ref27). In 2013, the American Medical 
Association officially classified obesity as a disease (http://www.ama-assn.org). 
According to the World Health Organization’s estimate, globally, more than 39% of 
adults aged 18 years and older are over-weight, and of these, more than half a billion 
are obese (www.who.int). In the United States, newly released statistics by the Centers 
for Disease Control and Prevention (CDC) indicated that 69.0% of Americans aged 
20 and older are over-weight and almost half of them are obese (CDC Statistics 2011-
2012 data).  
Obesity and diabetes are considered to be twin epidemics (Smyth & Heron, 
2006). They are two of the most serious public health challenges in developed 
countries, as well as in developing countries. In addition to genetic factors, the main 
causes for obesity are thought to be related to diet (high fat and high carbohydrate 
consumption) and lifestyle (lack of physical activity). It is believed that prolonged 
consumption of a western pattern diet (WPD), typically a high fat and high 
carbohydrate diet, can lead to obesity and insulin resistance (Newberry et al., 2006; 
Prada et al., 2005). 
Due to its great challenge to human health, molecular mechanisms that 
regulate obesity development are being intensively investigated. Adipose tissue, 
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traditionally considered to merely being used as the body’s energy storage tissues, has 
been re-examined and discovered to play important roles in secreting numerous 
protein hormones and receptors.  These include TNF-alpha, IL-6, leptin and 
adiponectin. These hormones and receptors effectively communicate with the brain 
and peripheral tissues to modulate glucose homeostasis, influence energy metabolism, 
regulate appetite and insulin resistance and control immune function (Matsuzawa et 
al., 1999; Funahashi et al., 1999). It is also well known that PPAR genes, a 
transcription factor family regulating glucose, lipid, and cholesterol metabolism in 
response to fatty acids, are highly expressed in adipose tissue and are key factors 
controlling adipocyte differentiation and adipocyte-specific gene expression (Jeong et 
al., 2012).  In addition, systemic chronic inflammation due to adipogenesis was also 
found as a major factor promoting obesity (Xu et al., 2003; Arkan et al., 2005).  
Long term high fat diet consumption significantly contributes to the 
development of both diabetes and obesity in both humans and rodents (Astrup et al., 
1994; Lin et al., 2000). At the molecular level, high fat diets cause genome-wide gene 
expression changes. Several genes encoding enzymes or signaling components related 
to lipid and glucose metabolism are significantly altered by high fat diet (Murase et 
al., 2001; Yu et al., 2000;  Maquoi et al., 2005; Croce et al., 2007; ). Using C57BL/6J 
mouse as human obesity model, Kim et al. (2004) examined genome-wide hepatic 
gene expression profiles affected by high fat diet by using a microarray analysis. 
Compared to a low fat diet (that was used as the control diet), high fat diet 
consumption significantly altered the expression of 97 hepatic genes involved in 
metabolism, inflammation responses, apoptosis and cell cycle, and transport (Kim et 
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al., 2004). These studies provided important insights on signals and molecules 
involved in the development of high fat diet induced obesity.  
Some forms of obesity are thought to be preventable through diet and lifestyle 
changes (Bray & Popkin, 1998; Leonard et al.,. 2001). In recent years, many 
researchers have focused on the identification of plant-based natural products which 
may play potential roles in preventing or delaying the development of obesity and 
diabetes (Prior et al., 2008; Decorde et al., 2009; Prior et al., 2010). One group of such 
natural products (including polyphenols, flavonoids and resveratrol) are derived from 
grapes and other fruits and vegetables. Flavonoids in grapes play a key role in 
preventing the development of diabetes by acting as multi-target modulators that 
reduce oxidative stress, lower the degree of systematic inflammation (Tsuda et al., 
2012; Chuang et al., 2011), and improve the insulin resistance and other anti-
hyperglycemic effects. In obese mice, grape powder has been shown to acutely 
improve glucose tolerance and chronically reduce inflammation (Chuang et al., 2012). 
Grape pomace from the Norton variety have been reported to contain significant 
amount of antioxidants (Hogan et al., 2010), and consumption of Norton grape 
pomace for 3 months exerted an anti-inflammatory effect in a high fat diet induced 
mouse obesity model (Hogan et al.,  2011). 
Previously we investigated the properties of GPE from a Tinta Cao grape 
variety. GPE had high antioxidant activities, and significantly inhibited the 
proliferation of HT-29 and Caco-2 colon cancer cells through triggering apoptosis 
(Parry et al., 2011). The in vitro action of GPE in reducing postprandial hyperglycemia 
through inhibition of alpha-glucosidase has also been demonstrated (Li et al, 2015a, 
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submitted). In-vivo studies with STZ-induced diabetic mice as well as with healthy 
human subjects have been conducted. GPE’s acute effect on postprandial 
hyperglycemia, acute insulin secretion and lipid metabolism were noted (Li et al., 
2015a Submitted). Furthermore, we examined several long term effects of GPE 
consumption on blood glucose regulation, as well as on several circulating peptide 
hormones. Although GPE did not affect blood glucose in STZ-induced diabetic mice, 
it significantly reduced blood glucose in WPD induced obese mice. In addition, GPE 
consumption significantly altered peptide hormones in circulation, such as insulin, 
GLP-1 and DPP-4. 
The liver is an essential organ for lipid and carbohydrate metabolism (Carey 
et al., 1983). It also plays a critical role in maintaining energy balance. Energy 
imbalance over a prolonged period can cause obesity. Therefore, in the current study, 
we focused on examination of hepatic gene expression profiles affected by long term 
consumption of GPE in a WPD induced obesity mouse model using RNA-seq 
approach. The present study was conducted to provide genome-wide molecular 
insights on how GPE balances the effects of WPD on induction of obesity, and 
prevents and delays the onset of obesity development caused by diets.   
 
5.3. Materials and Methods 
Sample preparation and extractions  
Grape pomace fruits were received from Chrysalis Vineyards, Virginia. GPE water 
extraction was prepared as previously described (Li et al., 2015 submitted). 
Animals and diet preparation 
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Animal husbandry, care, and experimental procedures in this study were 
approved by the Institutional Animal Care and Use Committee at the University of 
Georgia. Twelve-week old male C57BL/6NCr mice (National Cancer Institute, 
Frederick, MD, USA) were housed in clean cages at 12-hour light dark cycle at 20°C 
to 22°C with five mice per cage. After  two-week acclimation in the facility with 
standard rodent chow (8728C Teklad Certified Rodent Diet, Harlan Laboratories, Inc, 
Frederick, MD), twelve mice were randomly assigned to one of two dietary groups 
for a 12-week feeding experiment (n=6). Group 1 was fed with WPD diet (45% fat 
kcal, 35% carbohydrate, 20% protein); while the other group was fed with same WPD 
diet supplemented with GPE at 2.4 g/kg diet. All mice were fed with the respective 
diet for 12 weeks with water available ad libitum. Food intake and body weight were 
recorded every week.  
Tissue collection and sample analysis 
After completion of the experiments, diet was removed 12 h prior to sacrifice. 
Mice were anesthetized with CO2, and blood was collected by cardiac puncture with 
syringes previously rinsed with potassium EDTA solution (15% w/v). The plasma 
was separated by centrifugation at 1,000x g for 15 min at 4°C and transferred the 
serum to a clean polypropylene tube and stored at -80°C until analyzed. Liver tissues 
were collected and immediately frozen in liquid nitrogen and stored in -80°C for 
subsequent analysis.  
For collected serum, plasma leptin and ghrelin were measured using ELISA 
assay kit (Bio-Rad Laboratories, Hercules, CA). All assays were conducted according 
to the manufacturer’s protocols. 
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RNA isolation, library construction and RNA-seq sequencing 
Total RNA was extracted from liver samples using RNeasy Plus Universal 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
RNA integrity was monitored using a Nanodrop 2000 Spectrophotometer and an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only those 
samples with RIN larger than 7.0 were used for RNA-seq library construction. Total 
RNA samples of two randomly chosen mice from each treatment were subject to 
RNA-seq analysis. Messenger RNAs (mRNA) was isolated with oligo (dT) selection 
through Dynal magnetic beads. The pair-end libraries were constructed using the 
TruSeq RNA sample preparation kit (Illumina, San Diego, CA, USA) following the 
manufacture’s instructions. Briefly, the mRNA was fragmented by exposure to 
divalent cations at 94°C and the fragmented mRNA was converted into double 
stranded cDNA. The cDNA ends were polished, the 3′-hydroxls extended with A 
bases, and ligated to Illumina-specific adapter-primers. The adaptor ligated DNA was 
amplified by 15 cycles of PCR followed by purification using  PCR purification kit 
(Qiagen, Hilden, Germany) to obtain the final library for sequencing. The DNA yield 
and fragment insert size distribution of the library was measured using an Agilent Bio-
analyzer. Library quantifications were performed by qPCR assays using the KAPA 
Library Quant Kit™ following the manufacturer's instructions. The constructed 
libraries were loaded on an Illumina flow cell and were sequenced on the HiSeq2000 
sequencing instrument using 101PE pair-ends protocol. Primary data analysis and 
base calling was performed by the Illumina instrument software. 
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Bioinformatics analyses and data mining 
RNA-seq mapping and expression analyses were performed using the Tuxedo 
pipeline (Trapnell et al., 2012), and using iPlant cyberinfrastructure resources as 
described previously (Goff et al., 2011; Mandadi and Scholthof, 2015). Briefly, raw 
RNA-seq reads were subjected to quality-based filtering and trimming using the 
FASTQ-quality trimmer and FASTQ-quality filter programs 
(hannonlab.cshl.edu/fastx_toolkit/index.html). Filtered RNA-seq reads were mapped 
to the mouse reference genome (NCBIm37) using the TopHat2 for paired-end reads 
program. The resulting alignments were used to assemble and quantify transcripts, 
and also were merged with the reference genome using Cufflinks2 and Cuffmerge2 
programs, respectively. Normalization of expression was performed using the 
fragments per kilobase transcript per million mapped fragment (FPKM) metric. 
Differential gene expression analysis was performed using the Cuffdiff2 program 
(Trapnell et al., 2013). Statistically significant changes in gene expression were 
identified after FDR corrections (FDR<0.05). 
Global quality assessment of the RNA-seq data was performed by density plot, 
box plot and scatter plot representation using the CummeRbund program (Trapnell et 
al., 2012). Statistically significant (FDR<0.05) differences in gene expression were 
visualized using volcano plots. Visualization of transcript assemblies in the genomic 
context was performed using the Integrative Genomics Viewer tool (Broad Institute) 
(Robinson et al., 2011).  
Gene ontology (GO)-based functional annotation of the differentially 
expressed genes was performed using Blast2Go PRO software (Conesa and Gotz, 
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2008). The assembled transcript sequences were used to perform BLASTX (E-value: 
1e-5) analysis against the reference mouse genome sequences, followed by mapping 
and annotation of the significant hits, according to the recommended instructions 
(Conesa and Gotz, 2008). Additionally, gene set enrichment analyses (GSEA) and 
directed acyclic graphs (DAG) of the enriched GO terms in biological process, 
molecular function and cellular component were performed using WEBbased GEne 
SeT AnaLysis Toolkit (WebGestalt) (Wang et al., 2013). The Hypergeometric 
statistical method and FDR correction, using the Benjamini & Hochberg (1995) 
method, was used for GSEA analysis (Benjamini and Hochberg, 1995) 
Statistical analysis 
All data were presented as means ±SEM. The differences between two groups 
were analyzed by t-test using Prism 6 (Graphpad). Differences were considered 
significant when the P value was ≤0.05. 
 
5.4. Result 
Effects of GPE on body weight gain and food intake in WPD-induced obesity 
mice 
We monitored body weight and food intake weekly during the feeding 
experiment. Before the start of the feeding program, the average body weight of the 
control group was 29.8g, the treatment group (WPD+GPE) weighed 29.8g. Although 
there was no statistically significant difference between the treatments, the body 
weight for WPD group was always slightly heavier than that of WPD+GPE feeding 
group, and reached 43.00g and 40.98g for WPD and WPD+GPE feeding groups 
respectively at the end of 12-week experiment. Total body weight gain during 12-
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week experiment was 13.2g for WPD group, and 11.2g for WPD+GPE feeding group. 
This difference represented 17.8% less gain on body weight by consumption of GPE.  
Food intake was also measured weekly. As shown in Table 5-1, mice fed GPE 
consumed significantly more food at weeks 5-8 and the 12th week than that fed with 
WPD only. Overall, on average, 246.1g of food was consumed by each mouse in GPE 
feeding group during the 12-week experiment, while only 216.0g was consumed for 
its counterpart in WPD group representing a 14.0% more food consumed by mice 
feeding with GPE.  
Although no statistic difference were detected for both body weight gain and 
food intake, such trends of changes indicated a potential positive role of GPE in 
control of body weight and therefore obesity development. 
 
Effects of GPE on serum peptide hormones related to obesity development  
To further investigate the role of GPE in control of obesity development, we 
examined the changes of two obesity related serum peptide hormones. Ghrelin is 
known as a hunger hormone and plays a significant role in regulating the energy 
distribution and use efficiency (Inui et al., 2004; Burger & Berner, 2014). Blood 
ghrelin level was not significantly altered by GPE consumption when compared to the 
control group (Figure 5-1). However, Leptin, another hormone that regulates energy 
balance (Friedman, 2010), was significantly altered by GPE feeding. As shown in 
Figure 5-1, mice from the GPE feeding group had significantly reduced leptin in the 
blood (95.5 ng/ml in GPE feeding group versus 28,9pg/ml in the control group).  
GPE alters hepatic gene expression profiles 
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We previously studied the effects of GPE on diabetes control and found that 
GPE can significantly reduce blood glucose and GHbA1C. In addition, GPE 
attenuated the expression of several peptide hormones related to glucose homeostasis 
(Li et al., 2015, submitted). Furthermore, we demonstrated in this study that GPE 
reduced body weight gain under western pattern diet condition and significantly 
inhibited the secretion of leptin in the circulating system. These results promoted us 
to further examine the role of GPE on regulating genome-wide transcriptome 
expression profiles. We conducted high throughput RNA sequencing using liver 
tissues from both mice fed with WPD and WPD+GPE. Two randomly chosen 
independent mice from each group were used as biological replicates and subjected to 
RNA-seq. 
After filtering and trimming short prematurely terminated sequences, low 
quality sequences and ambiguous bases, a total of more than 36 million high quality 
reads (left and right ends) from each library (WPD-1, WPD-2, GPE-1 and GPE-2) 
were generated  (Table 5-2). These reads were mapped to the mouse reference 
genome, and transcript assembly and gene expression analysis were conducted, using 
the Tuxedo RNA-seq data analyses pipeline (Trapnell et al., 2010, 2012, 2013; 
Mandadi and Scholthof, 2015) (Figure 5-2A). Approximately 95% reads from each 
library were successfully mapped to the mouse reference genome. Of the mapped 
sequences, 73% to 86% were unique, and mapped only once to a genomic locus in the 
mouse reference genome. Global inspection of the gene expression results was further 
performed using the CummeRbund program (Trapnell et al., 2012). Pairwise scatter 
matrix plots, density and box plots of the gene expressions revealed normal 
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distribution of the data, and no systematic biases (Figures 5-2A, 2B and 2C) (Dillies 
et al., 2013). Volcano matrix plots showed that a significant (FDR<0.05) number of 
transcripts were up- or down-regulated by GPE (Figures 2D). 
In total, we detected 15,759 genes from WPD only group with 1,384 genes 
uniquely expressed, and 15,276 genes from WPD+GPE feeding group with 901 genes 
uniquely expressed (Figure 5-3A). Using FPKM≥1 as cut off, these numbers were 
reduced to 11,168 (with 685 unique genes) and 11,118 (with 635 unique genes) 
respectively (Figure 5-3B). Furthermore, we identified 286 (2.6%) genes from the 
WPD group, and 270 (2.4%) genes from the WPD+GPE feeding group as previously 
unannotated genes that were expressed at FPKM≥1. Fourteen of these genes were 
significantly differently expressed between WPD group and WPD+GPE group at 
FDR value less than 0.05. BLASTX analysis against the publicly available reference 
sequence databases indicated that a few genes were unannotated within any gene 
models or genome annotations. Others had matches to putative orthologs in other 
species. For example, these genes encode endonuclease reverse transcriptase 
(XLOC_027768), NAD-dependent protein deacylase sirtuin (XLOC_033674), GTP-
Rho binding proteins (XLOC_019482 and XLOC_007568) and uncharacterized 
hypothetical proteins (XLOC_023889, XLOC_025814, XLCO_028520, and 
XLOC_030807). 
Differential gene expression analysis between WPD and WPD+GPE groups 
was conducted using Cuffdiff2. At FDR<0.05 correction, we identified a total of 181 
genes that showed significant difference between the two feeding groups. Of these, 
94 genes were significantly down regulated by GPE consumption, and 87 genes were 
137  
significantly upregulated by GPE. The hierarchical clustering (HCL) and the heat-
map analysis clearly showed that samples within the treatment grouped in one cluster 
distinct from control samples (Figure 5-3C).  Moreover, four genes (Cyp2a4, Gsta1, 
Sprr1a and XLOC-033998) were completely suppressed by GPE feeding while 
another 4 genes (Moxd 1, Crybb3, XLOC_006742 and XLOC_021098) were 
uniquely induced by GPE feeding. When using FDR<0.10 as cut off, we identified 
~240 genes with significantly different expressions between the groups. The list of 
these genes with their FPKM values, fold changes and p and FDR-adjusted p values 
(q values) are presented in Table 5-5 (upregulated genes) and Table 5-6 (down 
regulated genes). All the genes with significant changes in expression levels in 
response to GPE treatment at FDR<0.05 level were further analyzed and classified 
according to their functions using Blast2Go PRO software. 
Annotation and classification of differentially expressed genes into functional 
categories 
The Gene Ontology (GO) classification was conducted for all genes exhibiting 
a significant change in transcript levels using Blast2Go PRO software and against the 
reference mouse genome sequences as background. All genes were classified 
according to their biological process and molecular functions. Of the up-regulated 
genes that are classified based on biological functions, approximately 54% were 
involved in metabolic process including lipid and carbohydrate metabolisms and 
small molecule metabolism (Table 5-3). For the molecular function category, 39% 
were dedicated to catalytic activity (Table 5-4). However, in the genes that were 
down-regulated by GPE, 27.7% of genes were involved in negative regulation of 
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biological process, and 26.6% involved in responses to chemical stimulus. A total of 
21.3% of genes were involved in immune responses or innate immune responses 
(Table 5-3). Small amount of genes (3.1%) involved in lipoprotein transport were also 
down regulated by GPE. When categorized by molecular function, 61.7% of these 
genes were involved in binding, and of these, more than half (56.9%) were involved 
in ion binding. Proteins involved in growth factor binding (5.3%) were also down 
regulated by GPE (Table 5-4). 
Genes related to metabolism and energy expenditure were up regulated by GPE 
Several genes upregulated by GPE were involved in metabolism and energy 
expenditure. Many genes controlling metabolism were downregulated by HFD in liver 
when compared to regular diet (Kim et al., 2004). However, in our experiment (using 
diets that were high fat and high sugar) when supplemented with GPE, these genes 
appeared to be upregulated back to the level comparable to that of regular diet 
condition. These genes included Fabp5 with 1.5 fold change, Serpina4-ps1 with 2.9 
fold change, Slc22a7 with 2.8 fold change, 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 (Papss2, with 1.5 fold change), elongation of very long chain fatty acids 
(Elovl3 with 1.1 fold change), cystathionine beta-synthase (Cbs with 1.3 fold change), 
carbamoyl-phosphate synthetase 1 (Cps1 with 2 fold change), Lipin1 with 1 fold 
change and at least 6 cytochrome P450 (with 1 to 1.6 fold changes).  
Interestingly, genes involved in energy expenditure were also upregulated by 
GPE. The expression changes for some of these genes are presented individually as 
FPKM plots (Figure 5-4). Among the GPE altered genes, 6 major urinary proteins 
(Mup1, Mup 9, Mup11, Mup 12, Mup16, and Mup17) were significantly up regulated 
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by GPE with at least 2-fold changes (Figure 5-4). Although MUP proteins were 
originally identified in urine and played key roles in chemical signaling, recent studies 
suggested that circulating MUP proteins regulate glucose and lipid metabolism. Most 
members of this gene family are not yet well studied, however, MUP1 has been 
extensively investigated. It increases energy expenditure and serves as a regulator for 
glucose and lipid metabolism (Hui et al., 2009; Zhou et al., 2009). Additionally, 
ENHO (energy homeostasis associated gene) was also significantly up regulated by 
GPE (Figure 5-4). ENHO encodes a peptide, adropin which is a newly discovered, 
liver-secreted hormone, and is believed to regulate glucose and lipid metabolism 
(Kumar et al., 2008). 
Another gene family that appeared to be significantly upregulated by GPE is 
the solute carriers (SLC), which play important roles in transporting organic 
molecules and inorganic ions in and out of cells through cell membrane. We identified 
six SLC genes that were significantly altered by GPE. Four of them are upregulated 
and include Slc22a7, Slc7a2, Slco1a1 and Slco2a1 (Figure 5-4). Furthermore, four 
serpin peptidase inhibitors (Serpina11, Serpina1e, Serpina4-ps1 and Serpine2) were 
also significantly up regulated by GPE in liver tissues (Figure 5-4).    
Genes related to immune responses and stress responses were down regulated by 
GPE 
In contrast to the GPE up regulated genes, most genes down regulated by GPE 
were involved in immune responses and include biomarker genes for inflammation. 
For example, PPARγ, an important gene in regulating diabetes and obesity, was 
significantly down regulated by GPE, as noted with a 2.7 fold change (Figure 5-5). In 
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HFD induced obese mice, PPARγ was highly expressed. PPARγ promotes 
adipogensis and leads to synthesis and deposit of excess fat tissue. GPE consumption 
significantly reduced PPARγ expression that is induced by HFD suggesting the role 
of GPE in preventing adipogensis and fat tissue formation. Aox1 gene, a potential 
target of PPARα was also significantly down regulated by GPE. CD36 was another 
down regulated gene by GPE. CD36 is responsible for the transport of long chain fatty 
acids into the adipose tissue (Coburn et al., 2000) and induced by HFD (Kim et al., 
2004). Both PPARγ and CD36 are also involved in lipoprotein transport. Another 
lipoprotein transporter identified as being down regulated by GPE was Unc119. 
Additionally, several hepatic genes associated with stress responses were significantly 
down regulated by GPE. These genes include transcription factor myc, heat shock 
protein 1 (Hspb1), glutamate-cysteine ligase (catalytic subunit) (Gclc), 
metallothionein 1 (Mt1), and glutathione S-transferases (GSTs). Many of these genes 
were induced by HFD (Kim et al., 2004). The reduction in expression of these genes 
by GPE suggests that GPE significantly reduced the stress response caused by high 
fat contained diets. 
 
5.5. Discussion 
It is well known that western pattern diet induces obesity and diabetes in both 
mice and humans. We and others have demonstrated that grape and grape derived 
products have the potential to prevent or delay obesity development caused by western 
pattern diet (Décordé et al., 2009). The purpose of this study was to examine hepatic 
gene expression profiles affected by GPE in a WPD induced obese mouse model, and 
to provide molecular mechanisms that drive GPE’s action in prevention of obesity 
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development. After a 12-week feeding experiment, mice fed with WPD supplemented 
with 2.4g/kg GPE, gained 21% less in body weight. Interestingly, food intake analysis 
indicated that mice consuming GPE ate 13% more food than HFD consuming mice. 
The peptide hormone grehlin, a known factor in controlling food intake, did not show 
any difference between two treatments. However, leptin, another peptide hormone 
regulating obesity development, was significantly reduced in circulating system by 
GPE supplementation. Kang et al., (2011) also reported that feeding mice a mixture 
of red grape extract, soy isoflavone and L-carnitine improved high fat diet induced 
obesity through down regulation of plasma leptin. Taken together, our results and 
others strongly suggest that GPE may play positive roles in preventing increased body 
weight and obesity. 
The liver plays an essential role in maintaining energy balance. In general, 
obesity can be caused by energy imbalance over a prolonged time. Previously, the 
effects of HFD on transcriptional changes in liver were investigated in both the early 
stage of HFD intake (Gregorie et al., 2002) and a long term HFD feeding stage using 
microarray technology (Kim et al., 2004, 2005; Gu et al, 2009; Xie et al., 2010). Most 
of these studies identified approximately 100 genes (from 86 to 130 genes) that were 
significantly altered by HFD when compared to standard diet. In our current study, 
using the RNA-seq approach, we examined the role of GPE on regulating hepatic 
transcriptome profiles under high fat and high sugar conditions. We used a more 
stringent high fat diet, with 45% of calories derived from fat when compared to other 
studies with 35% of calories derived from fat (Kim et al, 2004, 2005). In addition, 
another 35% of the calories in our diet were derived from sugar. In total, more than 
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15,000 genes were detected in both WPD-fed and WPD+GPE fed mice. Of these, 
approximately 180 genes were significantly up- or down- regulated by GPE after FDR 
correction (<0.05). Based on our literature review, we found that ~50% of these genes 
were previously identified as either being induced or suppressed by high fat diet or 
were found in obese mice and humans, even though the specific roles for most of these 
genes in obesity development are not yet understood. Surprisingly, expression of 
many of these genes was adjusted by GPE supplementation. Expression levels were 
closer to that under the standard diet condition. Furthermore, about 45% of identified 
genes in the current research were previously unidentified in relation to obesity or 
diabetes.   
GO analysis showed that most of the up regulated genes were involved in 
metabolism. Solute carrier genes and serpin peptidase inhibitors were also upregulated 
by GPE. Interestingly, we also found that several hepatic genes that are involved in 
energy expenditure were significantly upregulated by GPE. These include several 
members of MUP family and ENHO. Upregulation of these genes is related to 
metabolism and energy expenditure by GPE and could enhance the efficient use of 
the excess energy derived from WPD, and in that way could prevent the deposit of 
unused energy into adipose tissue. On the other hand, those that were down regulated 
by GPE were involved in immune and stress responses. Accordingly, many immune 
responsive genes and stress defending genes were up regulated by high fat diet (Kim 
et al., 2004, 2005). Obesity causes systemic chronic inflammation, hence HFD leads 
to significant induction of biomarker genes related to inflammation (Xu et al., 2003; 
Arkan et al., 2005). Supplementation of GPE, along with WPD, significantly 
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downregulated expression of inflammation biomarkers, which are commonly induced 
by HFD. These included PPARγ, cd36, cd74 for immune responses; MTs and GSts 
for stress responses; and postn, gpc1 and saa2 for inflammation. Downregulation of 
these genes by GPE suggests that GPE can reduce stresses caused by WPD and delays 
obesity development under WPD condition. 
  
5.6. Conclusion 
Our hepatic transcriptome analysis has shown that GPE supplementation could 
enhance energy expenditure through upregulation of metabolism related genes and 
genes controlling energy homeostasis. Furthermore, GPE reduces various WPD-
induced stress responses and obesity-induced inflammation. This study provides 
insights at the molecular level into understanding GPE’s actions in preventing and 
delaying the development of obesity by a western pattern diet. Our previous research 
found that, when consumed with white bread, GPE can significantly reduce acute 
blood glucose level (Li et al., 2015). Taken together, our studies indicate that GPE 
may be a potential functional food ingredient that can potentially prevent or delay the 
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Figure 5- 1 Circulated peptide hormone expression in WPD and WPD+GPE treated 
groups.A. Ghrelin expression showed no difference between treatments; B. Leptin 
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Figure 5- 2 Global analysis of gene expression in WPD and WPD+GPE treated mice 
showed normal distribution of the expression data and differentially expressed genes.A. 
Expression scatter matrix, B. Expression density plots, C. Expression box plots, and D. 
Expression fold change volcano matrix 
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Figure 5- 3 Venn diagrams of the expressed genes and hierarchical cluster analysis of 
differentially expressed genes between WPD and WPD+GPE treatments. A. Venn 
diagram showing the distribution of all genes expressed in WPD group and WPD+GPE 
group. B. Venn diagram showing the distribution of genes with FPKM>1 in WPD 
group and WPD+GPE group. C. Cluster analysis of all genes with significant 
differences in their expression between the groups. Control group represents those fed 
with WPD only, treatment group represents mice with WPD+GPE feeding.  
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Figure 5-4 Expression plots of selected upregulated genes in GPE 
supplementation.Levels of expression (FPKM) of each individual gene is plotted to 
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Figure 5-5 Expression plots of selected downregulated genes in GPE 
supplementation.Levels of expression (FPKM) of each individual gene is plotted to 
reveal the difference between WPD fed and WPD+GPE fed mice.  
 
  






































  0 29.82±0.77 29.79±0.72   
  1 33.59±1.14 32.56±1.24 3.74±0.19 3.97±0.2 
  2 34.6±1.59 33.1±1.22 2.59±0.13 2.79±0.06 
  3 36.53±1.59 34.08±1.47 2.83±0.13 2.9±0.14 
  4 35.74±1.64 33.18+1.47 2.53±0.06 2.74±0.10 
  5 37.87±1.71 35.46+1.56 2.51±0.10 2.89±0.13* 
  6 38.28±1.57 36.35+1.48 2.33±0.02 2.71±0.14* 
  7 39.09±1.52 36.58+1.89 2.36±0.09 2.85±0.09** 
  8 39.79±1.59 38.16±2.33 2.45±0.08 3.02±0.12** 
  9 39.68±1.62 38.16±2.28 2.02±0.09 2.28±0.20 
  10 40.58±1.54 38.68±1.98 2.43±0.03 2.78±0.18 
  11 41.97±1.53 39.46±2.17 2.52±0.20 3.22±0.29 
  12 43± 1.49 40.98±2.04 2.54±0.06 3.01±0.18* 
  Total 
weight 
gain (g) 13.18 11.19   
   Total Food 
Consumed(g)  215.95 246.12 
  Difference 







Table 5-2. Statistics of RNA-seq mapping analysis.  
 WPD-1 WPD-2 WPD+GPE-1 WPD+GPE-2 
Trimmed reads     
Left 18,145,626 19,501,734 18,446,697 19,181,364 
Right 18,113,614 19,469,121 18,418,621 19,152,427 
Mapped     
Unique left (%) 14,836,086(81.8) 15,188,107(77.9) 13,997,103(75.9) 14,058,494(73.3) 
Nonunique left (%) 2,517,763(13.9) 3,283,928(16.8) 3,568,483(19.3) 4,256,496(22.2) 
Unique right (%) 14,796,700(81.7) 15,150,906(77.8) 13,965,442(75.8) 14,036,156(73.3) 
Nonunique right (%) 2,504,632(13.8) 3,268,023(16.8) 3,553,152(19.3) 4,242,932(22.2) 
Overall alignment 95.55% 94.65% 95.15% 95.45% 





Table 5-3. GO enrichment analysis of differentially expressed genes in biological process category. 
GO term Description No. in input list No. in Ref P value FDR 
Genes in Group A     
GO:0044281 small molecule metabolic process 23 1821 6.57E-09 4.15E-06 
GO:0006082 organic acid metabolic process 14 731 7.76E-08 2.45E-05 
GO:0019752 carboxylic acid metabolic process 13 675 2.26E-07 4.75E-05 
GO:0043436 oxoacid metabolic process 13 717 4.49E-07 7.08E-05 
GO:1901606 alpha-amino acid catabolic process 5 57 1.14E-06 0.0001 
GO:0009063 cellular amino acid catabolic process 5 67 2.56E-06 0.0003 
GO:0046395 carboxylic acid catabolic process 6 148 8.57E-06 0.0007 
GO:0016054 organic acid catabolic process 6 148 8.57E-06 0.0007 
GO:0008152 metabolic process 47 8894 1.14E-05 0.0008 
GO:0044282 small molecule catabolic process 6 196 4.20E-05 0.0021 
Genes in Group B     
GO:0070887 
cellular response to chemical 
stimulus 21 1053 1.49E-10 1.21E-07 
GO:0042221 response to chemical stimulus 25 2020 3.62E-08 1.47E-05 
GO:0055114 oxidation-reduction process 15 919 1.20E-06 0.0002 
GO:0010035 response to inorganic substance 9 279 9.08E-07 0.0002 
GO:0006950 response to stress 22 2088 4.54E-06 0.0007 
GO:0006955 immune response 12 669 6.15E-06 0.0008 
GO:0048519 
negative regulation of biological 
process 26 2902 9.40E-06 0.0011 
GO:0071229 cellular response to acid 4 38 1.16E-05 0.0012 
GO:0045087 innate immune response 8 299 1.49E-05 0.0013 
GO:0042953 lipoprotein transport 3 14 1.72E-05 0.0014 
• Genes in Group A are upregulated by GPE supplementation; and genes in group B are down regulated by GPE supplementation 
 
 
Table 5-4. GO enrichment analysis of differentially expressed genes in molecular function category 
GO term Description No. in input list No. in Ref P value FDR 
Genes in Group A     
GO:0030170 pyridoxal phosphate binding 5 51 7.22E-07 3.84E-05 
GO:0009055 electron carrier activity 6 108 1.56E-06 3.84E-05 
GO:0008483 transaminase activity 4 24 1.12E-06 3.84E-05 
GO:0016769 
transferase activity, transferring nitrogenous 
groups 4 25 1.33E-06 3.84E-05 
GO:0070279 vitamin B6 binding 5 51 7.22E-07 3.84E-05 
GO:0020037 heme binding 6 114 2.15E-06 4.41E-05 
GO:0031406 carboxylic acid binding 7 189 3.07E-06 4.90E-05 
GO:0046906 tetrapyrrole binding 6 122 3.19E-06 4.90E-05 
GO:0004497 monooxygenase activity 6 143 7.97E-06 0.0001 
GO:0003824 catalytic activity 34 5105 8.72E-06 0.0001 
Genes in Group B     
GO:0050840 extracellular matrix binding 5 38 2.39E-07 3.01E-05 
GO:0005488 binding 58 10781 6.83E-06 0.0004 
GO:0016491 oxidoreductase activity 12 737 1.18E-05 0.0005 
GO:0019838 growth factor binding 5 107 4.17E-05 0.0013 
GO:0043236 laminin binding 3 22 6.51E-05 0.0016 
GO:0004364 glutathione transferase activity 3 26 0.0001 0.0021 
GO:0043167 ion binding 33 5208 0.0003 0.0054 
GO:0046983 protein dimerization activity 11 934 0.0005 0.0063 
GO:0008289 lipid binding 9 648 0.0005 0.0063 
GO:0005518 collagen binding 3 41 0.0004 0.0063 
• Genes in Group A are upregulated by GPE supplementation; and genes in group B are down regulated by GPE supplementation
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change) p_value q_value 
Moxd1 0 36.0572 inf 
5.00E-
05 0.004307 
Crybb3 0 3.9232 inf 
5.00E-
05 0.004307 
XLOC_021098 0 9.05402 inf 0.0001 0.008061 
XLOC_006742 0 98.1434 inf 0.0004 0.023908 
Hsd3b5 3.61628 141.493 5.29008 
5.00E-
05 0.004307 
Cbx8 3.15135 48.0516 3.93054 
5.00E-
05 0.004307 
Mup16 16.359 196.478 3.58621 
5.00E-
05 0.004307 
Serpina1e 194.381 2187.37 3.49224 
5.00E-
05 0.004307 
XLOC_033674 1.06501 11.8183 3.47207 
5.00E-
05 0.004307 
Mup1 37.6937 379.341 3.3311 
5.00E-
05 0.004307 
Enho 1.81 16.6186 3.19874 
5.00E-
05 0.004307 
Scara5 0.463545 3.92739 3.08279 0.0003 0.019818 
Selenbp2 25.056 197.383 2.97777 
5.00E-
05 0.004307 
Serpina4-ps1 8.05187 60.2661 2.90395 
5.00E-
05 0.004307 
Slc22a7 6.6424 47.8653 2.84921 
5.00E-
05 0.004307 
Rabl2 1.66147 11.8461 2.83388 0.0007 0.036608 
Mup12 22.9421 162.792 2.82697 
5.00E-
05 0.004307 
Mup11 186.086 1215.61 2.70764 
5.00E-
05 0.004307 
C8b 30.4408 176.799 2.53803 
5.00E-
05 0.004307 
Slco1a1 21.6119 125.337 2.53592 
5.00E-
05 0.004307 
Mup17 306.03 1731.28 2.50009 
5.00E-
05 0.004307 
Ighm 7.3934 39.6005 2.42121 
5.00E-
05 0.004307 
XLOC_014487 1.50612 7.91347 2.39348 0.0016 0.069249 
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Mup9 35.1333 176.757 2.33086 
5.00E-
05 0.004307 
XLOC_027770 2.0418 9.88298 2.2751 0.00145 0.063699 
Slc43a1 0.89391 4.3248 2.27443 0.00265 0.09824 
Zbtb49 0.901191 4.14683 2.20211 0.0027 0.098843 
Egfr 32.2418 142.533 2.1443 0.0002 0.014286 
Upp2 38.5061 167.763 2.12327 
5.00E-
05 0.004307 
Acmsd 2.57294 10.8568 2.07711 0.0002 0.014286 
Lrrc16a 2.69661 11.2614 2.06217 0.0001 0.008061 
Marco 3.6366 15.1593 2.05954 
5.00E-
05 0.004307 
Cps1 178.254 727.483 2.02898 
5.00E-
05 0.004307 
XLOC_015037 1.74251 7.02461 2.01125 0.00195 0.079318 
Igkc 14.2835 56.6227 1.98703 
5.00E-
05 0.004307 
Acpp 1.62289 6.28508 1.95336 
5.00E-
05 0.004307 
Lifr 11.3699 43.8454 1.9472 
5.00E-
05 0.004307 
Socs2 1.54613 5.45279 1.81834 0.0024 0.093303 
Cadm4 1.24048 4.36957 1.81659 0.00255 0.095338 
Hamp 1274.89 4474.75 1.81143 
5.00E-
05 0.004307 
Avpr1a 1.60847 5.61163 1.80273 0.00085 0.042675 
XLOC_027768 2.43088 8.4263 1.79342 0.0009 0.044175 
Prhoxnb 17.3853 60.2084 1.79209 
5.00E-
05 0.004307 
XLOC_008927 2.03094 6.82999 1.74973 0.00195 0.079318 
Pold3 6.59681 21.5652 1.70886 0.00255 0.095338 
XLOC_026364 1.78265 5.81716 1.70629 0.0024 0.093303 
Igfbp2 75.4467 239.364 1.66568 
5.00E-
05 0.004307 
Susd4 4.71087 14.6646 1.63827 
5.00E-
05 0.004307 
Tat 240.842 747.02 1.63306 0.00015 0.011264 
Cyp2c70 106.006 325.516 1.61858 
5.00E-
05 0.004307 
Cyp7b1 41.6257 126.977 1.60902 
5.00E-
05 0.004307 
Tnrc18 1.37261 4.16457 1.60125 0.00245 0.094411 
Trim14 9.04926 27.148 1.58497 0.00015 0.011264 




Mpv17l 4.89329 14.5088 1.56805 0.0003 0.019818 
Ces3b 68.2837 197.388 1.53142 
5.00E-
05 0.004307 
Cyp1a2 76.905 221.594 1.52677 
5.00E-
05 0.004307 
Emr1 3.51451 10.076 1.51952 
5.00E-
05 0.004307 
Tgm1 1.63912 4.64967 1.5042 0.0013 0.057979 
Serpine2 4.87296 13.8167 1.50355 
5.00E-
05 0.004307 
Cyp2c54 33.0642 93.1461 1.49422 
5.00E-
05 0.004307 
Camkk2 1.35482 3.7647 1.47444 0.0018 0.075669 
Fgl1 207.214 573.246 1.46804 
5.00E-
05 0.004307 
Papss2 23.4493 64.827 1.46705 
5.00E-
05 0.004307 
Eapp 7.75341 20.8587 1.42774 0.00255 0.095337 
Camk1d 6.06286 15.6069 1.36412 
5.00E-
05 0.004307 
Tfdp2 1.83488 4.719 1.36279 0.0005 0.02816 
Cela1 20.7264 52.2742 1.33463 0.00035 0.021809 
Nnmt 86.5215 217.402 1.32923 
5.00E-
05 0.004307 
Rnase4 249.116 623.428 1.32341 
5.00E-
05 0.004307 
Cbs 133.045 328.714 1.30492 0.0002 0.014286 
Cdh1 2.73557 6.74993 1.30303 0.0005 0.02816 
Ablim3 1.5797 3.83855 1.28091 0.00165 0.070717 
Got1 72.0253 173.019 1.26435 
5.00E-
05 0.004307 
Ankrd33b 2.12592 5.10462 1.26372 0.00085 0.042675 
Cyp4f14 49.6096 116.851 1.23598 
5.00E-
05 0.004307 
Agxt 77.9814 183.563 1.23507 
5.00E-
05 0.004307 
Tnfaip2 5.04012 11.8391 1.23204 0.0026 0.096795 
Ccbl1 32.4535 75.9433 1.22655 
5.00E-
05 0.004307 
Anubl1 5.2151 12.0711 1.21079 0.0005 0.02816 
Nudt7 310.368 717.806 1.20961 0.0001 0.008061 
Gabbr2 4.03488 9.23289 1.19426 0.0025 0.095338 
Rdh11 18.9883 43.1703 1.18493 0.0001 0.008061 
Dicer1 2.52702 5.71979 1.17853 0.0017 0.072156 
Pde9a 10.3118 23.3092 1.1766 0.0013 0.057979 
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Setd3 23.9092 53.8866 1.17236 0.00115 0.053744 
Slco2a1 5.17976 11.598 1.16291 
5.00E-
05 0.004307 
XLOC_028520 52.2106 116.183 1.15398 
5.00E-
05 0.004307 
BC029214 10.3873 23.019 1.14801 0.0019 0.078373 
Slc7a2 26.5029 58.6511 1.14601 0.00035 0.021809 
Gprc5c 15.0448 33.2781 1.14531 0.0017 0.072156 
2810007J24Rik 271.66 599.196 1.14122 0.0006 0.032743 
Gpcpd1 14.7812 32.2696 1.12641 0.0001 0.008061 
Elovl3 50.2301 109.576 1.12531 0.00035 0.021809 
Gnat1 16.1289 34.9645 1.11624 0.00125 0.057201 
Casp3 5.11642 11.0782 1.11451 0.002 0.080977 
C6 47.8015 103.33 1.11213 
5.00E-
05 0.004307 
Fam188a 15.4096 33.278 1.11074 0.0027 0.098843 
Eif4ebp2 17.1322 36.5717 1.09401 
5.00E-
05 0.004307 
Cml1 108.524 229.996 1.0836 
5.00E-
05 0.004307 
Prodh 51.4369 108.798 1.08078 0.00125 0.057201 
Nfix 7.8389 16.4177 1.06653 0.0011 0.051682 
Pstpip2 6.94864 14.5424 1.06546 0.0009 0.044175 
Serpina11 31.1668 64.7905 1.05577 0.0003 0.019818 
C9 134.528 279.541 1.05515 0.0022 0.086678 
Cyp2c44 73.232 151.388 1.0477 
5.00E-
05 0.004307 
Pdia5 13.2052 27.1489 1.03979 0.00025 0.017433 
Kcnk5 5.60549 11.4846 1.03479 0.0013 0.057979 
Hes6 69.1855 141.515 1.03242 0.00015 0.011264 
Mafb 7.36383 15.0254 1.02887 0.00045 0.026358 
Il13ra1 5.56609 11.2701 1.01776 0.0008 0.041346 
Lpin1 11.5968 23.1468 0.99708 0.0004 0.023908 
Als2 8.11245 16.0915 0.988088 0.00065 0.034612 
Sdc3 8.2911 16.3595 0.98049 0.001 0.048541 
Slc29a1 62.7708 122.298 0.962232 0.0018 0.075669 
F7 26.5526 50.4188 0.925108 0.0007 0.036608 
Cpn2 35.6567 67.0016 0.910021 0.0005 0.02816 
F11 13.4264 24.9979 0.896728 0.00205 0.081499 
Tmem86b 55.3413 102.926 0.895173 0.00105 0.050412 
Atg9a 11.5721 21.3438 0.883167 0.0011 0.051682 
Cyp4a12b 15.4838 28.503 0.880351 0.00205 0.081499 
Mthfd1 37.7002 69.3482 0.879289 0.0011 0.051682 
Igfals 28.2896 50.3251 0.831005 0.0019 0.078373 
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Aadat 31.6905 56.3069 0.829262 0.00255 0.095338 











(fold_change) p_value q_value 
Cyp2b9 73.0556 3.48953 -4.38789 5.00E-05 0.004307 
Cidec 59.7329 4.15838 -3.84443 5.00E-05 0.004307 
XLOC_030807 11.396 0.806843 -3.8201 0.00035 0.021809 
Slc22a29 6.87116 0.655381 -3.39015 5.00E-05 0.004307 
Plin4 6.27789 0.607294 -3.36981 0.00025 0.017433 
Wdr67 8.40753 0.963578 -3.12521 5.00E-05 0.004307 
Tceal8 36.8431 4.33769 -3.08639 5.00E-05 0.004307 
Ttc39a 3.81451 0.469118 -3.02348 0.00035 0.021809 
Themis 3.01026 0.381673 -2.97948 0.0011 0.051682 
Myc 6.47278 0.855089 -2.92024 0.0002 0.014286 
Pnldc1 23.0335 3.27144 -2.81573 0.0005 0.02816 
Ramp2 11.3924 1.6343 -2.80133 0.00165 0.070717 
Uap1l1 30.3376 4.61341 -2.7172 0.0003 0.019818 
Igfbp1 39.5268 6.10681 -2.69434 5.00E-05 0.004307 
Anxa2 53.3494 8.66955 -2.62144 5.00E-05 0.004307 
Cd36 105.851 18.0294 -2.55362 5.00E-05 0.004307 
Cd63 29.8768 5.10886 -2.54795 0.0003 0.019818 
Lgals1 139.644 24.1011 -2.53458 5.00E-05 0.004307 
Cgref1 10.2737 1.90823 -2.42864 0.00085 0.042675 
Cfd 17.6928 3.40088 -2.37918 0.0007 0.036608 
Gm10680 1948.71 377.857 -2.36661 0.00105 0.050412 
Apoa4 918.231 181.889 -2.3358 5.00E-05 0.004307 
Mt1 50.4376 10.3475 -2.28521 5.00E-05 0.004307 
Cyp3a11 866.007 177.775 -2.28432 5.00E-05 0.004307 
H2-Q1 10.2868 2.13004 -2.27185 5.00E-05 0.004307 
Wfdc2 49.6306 10.6468 -2.22081 5.00E-05 0.004307 
S100a11 61.1705 13.5342 -2.17622 5.00E-05 0.004307 
Gm11419 8.96552 2.015 -2.15361 5.00E-05 0.004307 
Raet1d 16.1388 3.65446 -2.1428 0.0001 0.008061 
Col1a2 5.57628 1.26349 -2.14189 5.00E-05 0.004307 
Unc119 17.4467 3.97793 -2.13286 5.00E-05 0.004307 
Col3a1 14.6281 3.35332 -2.12508 5.00E-05 0.004307 
Postn 9.07662 2.08395 -2.12284 5.00E-05 0.004307 
Tubb2a 108.361 25.1149 -2.10923 5.00E-05 0.004307 
Spon2 10.9116 2.57511 -2.08315 5.00E-05 0.004307 
Limk1 5.16549 1.24166 -2.05664 0.00055 0.030584 
Osbpl3 5.90132 1.43485 -2.04014 0.0003 0.019818 
4-Sep 10.1363 2.51407 -2.01144 5.00E-05 0.004307 
Cyp2c38 30.1022 7.49422 -2.00602 5.00E-05 0.004307 
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Spp1 124.633 33.6478 -1.88911 5.00E-05 0.004307 
XLOC_026575 10.3609 2.91741 -1.82838 5.00E-05 0.004307 
Anxa5 128.165 36.1193 -1.82716 5.00E-05 0.004307 
2010003K11Rik 65.8868 19.2202 -1.77736 5.00E-05 0.004307 
XLOC_023889 17.3503 5.14681 -1.75321 0.0006 0.032743 
St6gal1 42.1959 12.5805 -1.74591 0.00035 0.021809 
Ifi27l2b 28.0596 8.47923 -1.72649 0.00015 0.011264 
Hspb1 54.3618 16.5179 -1.71857 5.00E-05 0.004307 
Ccnd1 17.5741 5.44684 -1.68996 5.00E-05 0.004307 
XLOC_025814 10.3863 3.23401 -1.68329 5.00E-05 0.004307 
S100a10 305.285 97.807 -1.64215 5.00E-05 0.004307 
Gadd45g 15.7716 5.11409 -1.62478 0.0013 0.057979 
Tubb6 7.95814 2.58134 -1.62431 0.00135 0.059905 
Lyve1 5.86838 1.91127 -1.61843 0.00185 0.077034 
Mgst3 27.2076 8.93182 -1.60698 0.00015 0.011264 
Cyp2j9 5.86434 1.93339 -1.60084 0.0027 0.098843 
Fam126a 5.08877 1.69807 -1.58343 0.00065 0.034612 
Gpr98 9.53986 3.26245 -1.54801 0.00055 0.030584 
Aox1 48.3686 17.1363 -1.49701 5.00E-05 0.004307 
Rgs16 62.1802 22.116 -1.49136 5.00E-05 0.004307 
Pcolce 10.8077 3.8482 -1.48981 0.0009 0.044175 
Prss8 15.8814 5.66085 -1.48824 0.00255 0.095338 
Fabp4 41.2702 14.7232 -1.48701 0.0004 0.023908 
XLOC_019482 31.0554 11.1694 -1.47529 5.00E-05 0.004307 
Acnat2 23.7726 8.61251 -1.46479 5.00E-05 0.004307 
Gpc1 13.9353 5.10096 -1.4499 5.00E-05 0.004307 
Tm4sf1 8.1777 2.99996 -1.44675 0.00245 0.094411 
Abcc3 118.257 44.1636 -1.42099 0.00085 0.042675 
Cyp3a59 11.7773 4.41253 -1.41632 0.0004 0.023908 
Nid1 3.36952 1.2712 -1.40636 0.00035 0.021809 
Vnn1 50.0463 19.2761 -1.37645 5.00E-05 0.004307 
Aifm2 12.5959 4.94253 -1.34964 0.00095 0.046371 
Pyroxd2 13.494 5.32754 -1.34078 5.00E-05 0.004307 
Sparc 41.4332 16.5735 -1.32191 5.00E-05 0.004307 
9130409I23Rik 15.3932 6.27387 -1.29486 0.0005 0.02816 
Hsd17b6 58.9736 24.1439 -1.28841 5.00E-05 0.004307 
Pparg 14.4594 5.93214 -1.28538 0.0003 0.019818 
Reep5 6.91942 2.87242 -1.26838 0.0013 0.057979 
Rbp1 6.65631 2.77371 -1.26291 0.0023 0.090213 
Kdsr 6.34172 2.65333 -1.25707 0.00015 0.011264 
Plk3 24.6551 10.319 -1.25658 5.00E-05 0.004307 
Gstm1 1307.3 548.699 -1.2525 0.00015 0.011264 
Chkb 40.8391 17.2272 -1.24526 0.00075 0.038991 
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Abhd2 23.8715 10.1769 -1.22999 5.00E-05 0.004307 
Vcam1 5.56274 2.38051 -1.22453 0.00195 0.079318 
Srxn1 36.6311 15.704 -1.22194 0.0006 0.032743 
Acss3 8.165 3.50868 -1.21853 0.00125 0.057201 
Cxcl9 8.43835 3.72329 -1.18038 0.0015 0.065567 
Kctd2 20.492 9.15258 -1.16281 0.0004 0.023908 
Tpm1 32.5309 14.6819 -1.14777 5.00E-05 0.004307 
Hsd17b13 694.382 313.444 -1.14752 0.00015 0.011264 
Slc16a7 26.8333 12.251 -1.13113 5.00E-05 0.004307 
Rcan1 16.8597 7.81532 -1.1092 0.00045 0.026358 
Gclc 146.543 68.1511 -1.10451 0.0001 0.008061 
Cd9 22.535 10.6991 -1.07468 0.0021 0.083111 
Lcn2 51.7583 24.6078 -1.07267 0.00065 0.034612 
Orm2 73.0595 35.3577 -1.04705 0.00085 0.042675 
Mfge8 13.1544 6.37522 -1.045 0.0025 0.095338 
Gstm2 67.7112 32.8547 -1.04329 0.0002 0.014286 
XLOC_007568 7.8437 3.86274 -1.02191 0.0009 0.044175 
1500017E21Rik 44.6667 22.1219 -1.01372 5.00E-05 0.004307 
Cd74 74.2839 36.9092 -1.00907 0.0002 0.014286 
Krt8 176.855 90.4303 -0.96769 0.00035 0.021809 
Gas6 29.9915 15.3573 -0.96562 0.00125 0.057201 
Saa2 327.926 168.145 -0.96366 0.0004 0.023908 
Hexa 42.0673 21.587 -0.96254 0.00045 0.026358 
Adora1 7.67779 3.94294 -0.96142 0.00205 0.081499 
Mme 9.46745 4.89563 -0.95148 0.00145 0.063699 
Csad 51.2336 26.5667 -0.94747 0.00025 0.017433 
Mapre3 34.781 18.2388 -0.93129 0.00065 0.034612 
Vnn3 30.9468 16.5149 -0.90602 0.0016 0.069249 
Aqp8 261.857 141.749 -0.88544 0.00205 0.081499 
Sprr1a 12.5782 0 inf 5.00E-05 0.004307 
Gsta1 11.0491 0 inf 5.00E-05 0.004307 
Cyp2a4 10.2681 0 inf 5.00E-05 0.004307 









It is promising and essential to investigate grape pomace’s health promoting 
potential as an important value adding products. Our main goal was to investigate 
the effects of a dietary grape pomace extract supplement on the prevention of diabetes 
and obesity. We demonstrated that GPE may prevent metabolic syndrome including 
diabetes and obesity through alternating the expression of genes, on the signaling or 
metabolic pathways that lead to reduction of diabetes and obesity. This current stusy 
was focused on examining such molecular mechanism(s) that support the 
incorporation of GPE as an alternative therapy for controlling postprandial blood 
sugar, regulate insulin resistance and preventing diabetes and obesity.  
Grape pomace can suppress postprandial hyperglycemia through inhibitory 
effects on α-Glucosidase activity in vitro. It also reduces acute blood glucose in vivo 
in induced-diabetic mice. qRT- PCR and ELISA tests confirmed that grape pomace 
extracts affected insulin signaling pathway at both RNA and protein levels. GPE could 
correct insulin resistance, decrease HbA1c and blood glucose levels, and consequently 
prevent type 2 diabetic through the regulation of glucose metabolism as well as 
glucose homeostasis at both transcriptional and translational levels. Also, grape 
pomace extracts translational regulation of the adipokine, cytokine/chemokine, 
inflammatory factors, lower systematic inflammation status, decreased the 
adipogenesis and lowering the fatty acids accumulation. High throughput RNA 
sequencing technology elucidated gene expression profiles at genomics level caused 
by GPE treatment under high fat diet condition. Genes involved in glucose and lipid 
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metabolisms and the related signal transduction pathways were altered. 
 
This project provided scientific evidence for the health beneficial effects of 
the grape pomace extract, and may promote the use of GPE as healthy dietary 




Isolate and identify the active compound(s) of GPE effect in diabetes and 
obesity and GPE effect on microbiome in the GI tract may be investigated in future 
studies. 
 
GPE has been studied for its effect and ability to regulate glucose homeostasis, 
and influence energy balance and control body weight through attenuation of the 
adipogenesis. Additional analyses should be conducted to isolate, purify and identify 
the active compound(s) of GPE to gain more understanding of GPE effects metabolic 
syndrome.      
 
The gut microbiome can be a factor involved in the control of host energy 
metabolism and systematic inflammation status. PGE will be further tested on the gut 
microbiota composition in rat models under high fat diet and its association with 
metabolic biomarkers. Fecal samples and colon sections can be collected from animals 
and determined by PCR-DGGE profiles followed by sequencing of selected bands 
from DGGE gels, the total number and types of microbes in GI tract can be determined. 
The associations between the gut microbiota and appetite-regulating hormones that 
may be important in terms of satiety and host metabolism.  
 
Molecular mechanism of GPE’s anti-diabetes, anti-obesity and anti- 
inflammatory effect and GPE’ long-term effect on metabolic disorder induced by 
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Ph.D in Nutrition and Food Science (2015) University of Maryland,  
College Park. Overall GPA 4.0/4.0 
M.S in Molecular and Environmental Plant Sciences (2002) Texas A&M University, 
College Station. Overall GPA 3.83/4.0 
B.A. in Horticulture, Beijing Agricultural College (1994), Beijing, China 
 
Professional Experience 
Research and Laboratory Specialist II (06/08 – Present) Agricultural Research 
Station, Virginia State University, Petersburg, Virginia 
Projects:  
Prevention property of grape pomace on metabolic syndrome (obesity and diabetes): 
Effects and molecular actions.  
1) The research aims to prevention of metabolic syndrome through basic 
molecular and preclinical studies.  
2) Antioxidant capacity estimation and in vitro cytotoxicity, antiproliferative, 
apoptotic activities study of variety of pro-drugs.  
 
Research Specialist II Department of Anatomy & Neurobiology, Virginia 
Commonwealth University Medical Campus, 2007- 2008. 
Projects:  
Investigating the role of microglia, the resident innate immune cell in the brain, in 
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease 
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1). Define how microglia both initiate neuron damage and fuel progressive 
neurotoxicity 
2). Identify the triggers of deleterious microglial activation towards the development 
of novel therapeutic compounds capable of halting the progression of 
neurodegenerative diseases 
 
Research Associate Department of Biochemistry, Texas A&M University, 2006- 2007 
Projects:  
Characterization of Drosophila Sialyltransferase at molecular and genetic levels to 
dissect the roles of sialylation in Drosophila central nervous system development. 
1). Biochemical and genetic characterization of Sialyltransferase in Drosophila.   
2). Dominant negative phenotype study for sialylation. 
 
Research Associate Department of Entomology, Texas A&M University, 2002-2006 
Projects: 
Molecular study of the symbiotic bacteria from fire ant midgut. 
1). Isolation, biochemical and molecular characterization of bacteria from the red    
imported fire ant midgut. 
2). Genetic modification of the bacteria by Mariner transposon Himar1 mediated gene  
     integration.  
3). Transcriptional profiling and protein localization in the red imported fire ant. 
Graduate Research Assistant Department of Entomology, Texas A&M University, 
        2000-2002 
Projects: 
Identification and biodiversity study of sorghum green bug biotypes. 
1). Identification of molecular marker and biodiversity study of green bug using AFLP  
     technique.  
2). Construction and characterization of Bacterial Artificial Chromosome  
     (BAC) library of green bug. 
Achievements:  
1). Studied the biodiversity relationship of the green bug and separated a sorghum  
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      related green bug group.  
2). Developed a green bug Megabase DNA isolation protocol and constructed a  
     Green bug BAC library.  
3). One paper was published based on master thesis. 
Graduate Research Assistant Department of Forest, Texas A&M University, 1999-
        2000 
Projects: 
Genetic modification of cotton by Agrobacterium-mediated transformation and 
identification of the integrated junction sequence in the plant genome.  
Achievements:  
1). Developed a rapid and high yield miniprep DNA isolation protocol for cotton 
2). Published one paper. 
Research Assistant Institute of Developmental Biology, Chinese Academy of  
                                 Sciences, Beijing, China 1994-1996 
 
Teaching Experience 
Teaching Assistant, Department of Biochemistry, Texas A&M University, 2001-2002 
Molecular genetics laboratory course, trained undergraduate students in biochemistry 
and genetics majors on molecular biology techniques such as cloning, protein 
expression, SDS-PAGE, non-radioactive labeling Southern blotting, PCR and Western 
blots. 
Teaching Assistant, Department of Nutrition and Food Science, University of 
Maryland 2011-2012 
Food chemistry laboratory course, trained undergraduate students in Food and nutrition 
Science major on food chemistry techniques such as HPLC, GC, enzymatic activity, 
water activity, lipid and carbohydrate characterization.  
Teaching Assistant, Department of Nutrition and Food Science, University of 
Maryland 2014-2015 
Food Science and Technology course, trained undergraduate students in Food and 
nutrition Science major on basic concept of Food Science and Technology.  
 
197  
Honors and Awards 
1) Student Research Day of Department of Nutrition and Food Science, poster 
comtetition second place, 2015 
2) Travel grant from Molecular and Environmental Plant Sciences program, 2000     
3) Academic Excellence Scholarship of Molecular and Environmental Plant     
              Sciences program, 2001 
4) Elected Member of The Honor Society of Phi Kappa Phi at TAMU, 2001. 
 
Professional Affiliations  
The American Society of Plant Biologists 2000-2001  
International Food Technologists, 2013-present 
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1. Li, H., Luo, J., Hemphill, K.J., Wamg, J and Gould, J. (2001) A Rapid and high    
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Neurosci. 30(18):6466-76. 
6. Parry J#, Li H#, Liu J, Zhou K, Zhang L and Ren S, (2011) Antioxidant Activity, 
Antiproliferation of Colon Cancer Cells, and Chemical Composition of Grape 
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Pomace," Food and Nutrition Sciences. 2(6): 530-540. #Authors have 
contributed equally to this work. 
7. Li H and Parry J, (2011) Phytochemical Compositions, Antioxidant Properties, and 
Colon Cancer Antiproliferation Effects of Turkish and Oregon Hazelnut," Food 
and Nutrition Sciences, 2 (10): 1142-1149. 
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11. Li X, Li H, Jia L, Li X, Nafis Rahman N. (2015) Oestrogen action and male 
fertility: experimental and clinical findings. Cellular and Molecular Life 
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12. Li H, Guo TL, Parry J, Pao S, Zhou K, Castonguay T. Grape Pomace Aqueous 
Extract Inhibits α-Glucosidase in vitro and Suppresses Postprandial Hyperglycemia 
in vivo. Submmited. 
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Aqueous Extract (GPE) Prevents Western High Fat Diet-induced Diabetes and 
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14. Li H, Tai L. Guo, Parry J, Weeda S, Ren S , Castonguay T.  Effects of Grape 
Pomace Extract (GPE) on preventing Western Pattern Diet (WPD) Induced Obesity 
Revealed by Hepatic RNA-seq Transcriptome Profile. Submitted. 
14. Kim C, Nartea T, Pao S, Li H, Jordan K, Xu Y, Stein R, Sismour E. Microbial 
Quality   
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      of Shiitake Mushrooms (Lentinula edodes) Acquired from Internet and Local Retail     
      Markets. Submitted. 
Book chapter 
Parry J and Li H (2012) Cereals and Pulses: Nutraceutical Properties and Health 
Benefits. John Wiley & Sons, Inc. Chapter 5. 
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1. Luo, J-H., Li, H and Gould, J. 2000. Cotton Transformation for Disease Resistance. 
San Diego, CA. Plant Biology 2000. 
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